ICOBM 2026
International Conference on BioMedicine
第二屆高雄生醫國際研討會

The New Era of Intelligent Healthcare:
AI, Biomedical Translation and Clinical Innovation

智慧醫療新紀元:
人工智慧、生醫轉譯與臨床創新

2026/10/16(fri)-18(sun)

KMU International Convention Center, **KAOHSIUNG, TAIWAN**

Conference Program



Organizer:

Co-organizer:

TEZSPIRE™
(tezepelumab) Subcutaneous injection

跨越複雜性 擊潰所有表現型[1]



Tezspire 不論嚴重氣喘表現型，都能減少急性惡化的生物製劑[1]

無論血中嗜酸性白血球或 FeNO 的基準點濃度如何，接受 TEZSPIRE 的病人急性發作率比接受安慰劑的病人更低

	Tezspire n / Estimate	Placebo n / Estimate	Rate Ratio (92% CI)
Overall	528 / 0.93	531 / 2.10	0.44 (0.37, 0.53)
Eosinophils at baseline (cells/UL)			
<150	138 / 1.04	138 / 1.70	0.61 (0.42, 0.88)
150 - <300	171 / 1.00	171 / 1.75	0.57 (0.41, 0.79)
300 - <450	99 / 0.92	95 / 2.22	0.41 (0.27, 0.64)
>=450	120 / 0.68	127 / 3.00	0.23 (0.15, 0.34)
FeNO at baseline (ppb)			
<25	213 / 1.07	220 / 1.56	0.68 (0.51,0.92)
25 - <50	158 / 0.87	151 / 2.20	0.40 (0.28, 0.56)
>=50	151 / 0.75	156 / 2.83	0.27 (0.19, 0.38)



泰莎樂注射液劑210毫克 TEZSPIRE Solution for Injection 210 mg

【適應症】1. 氣喘: 12歲以上嚴重氣喘病人的附加維持治療 (add-on maintenance therapy)。使用限制：不適用於緩解急性支氣管痙攣或重積性氣喘 (status asthmaticus)。2. 慢性鼻竇炎合併鼻息肉(CRSwNP): 慢性鼻竇炎合併鼻息肉(CRSwNP)且使用鼻腔內皮質類固醇仍控制不良之成人病人的附加維持治療 (add-on maintenance treatment)。【用法用量】 劑量：氣喘 成人及青少年 (12歲以上) 建議劑量為每4週皮下注射210毫克 TEZSPIRE。TEZSPIRE 用於12至17歲青少年的相關資料請見第11節。慢性鼻竇炎合併鼻息肉(CRSwNP) 成人建議劑量為每4週皮下注射210毫克TEZSPIRE。若錯過一劑藥物應盡速注射藥物，之後病人可依平常的用藥日恢復用藥。若下一劑用藥時間已到則按計畫用藥。不可一次注射雙倍劑量。用法：TEZSPIRE以皮下(SC)注射方式給藥。TEZSPIRE應注射到大腿或腹部，但肚臍周圍 2 吋 (5公分) 除外。病人不可自行注射在上臂。TEZSPIRE不可注射在皮膚觸痛、瘀傷、紅斑或變硬的部位。建議每次注射時輪換注射部位。尚未確立TEZSPIRE用於未滿12歲兒童的安全性及療效。65歲以上的老年病人、腎功能或肝功能不全病人無需調整劑量(見第11節)。【禁忌】 TEZSPIRE禁用於對tezepelumab或列於第1.2節之賦形劑過敏的病人。【特殊警告及使用注意事項】 TEZSPIRE不適用於治療急性氣喘症狀或急性發作，請勿使用TEZSPIRE治療急性支氣管痙攣或重積性氣喘。病人開始使用TEZSPIRE治療後，如果氣喘症狀仍控制不良或惡化，必須就醫。【常見不良反應】 在臨床試驗中，嚴重氣喘病人最常見的不良反應為關節痛和咽喉炎。藥物不良反應：鼻咽炎、咽喉炎*、皮疹、關節痛、背痛及注射部位反應。*咽喉炎包括以下細項：咽喉炎、細菌性咽喉炎、鏈球菌性咽喉炎和病毒性咽喉炎。皮疹包括以下細項：皮疹、癢疹、紅斑疹、斑丘疹、斑疹。
【使用前詳閱說明書警語及注意事項，詳細仿單資料備索】 【僅限醫藥專業人員參考；處方藥物請參考衛生福利部核准仿單說明書】

1.Menzies-Gow A,Corren J,Bourdin A, et al.Tezepelumab in adults and adolescents with severe,uncontrolled asthma. *NEngl J Med*.2021;384(19):1800 1809

AstraZeneca
臺灣阿斯特捷利康股份有限公司

ICOBM 2026
International Conference on BioMedicine
The New Era of Intelligent Healthcare: AI, Biomedical Translation and Clinical Innovation


	10/16				10/17				10/18		
08:00~08:30	校慶典禮 (8:00-12:00)				Registration				Registration		
08:30~08:40					Welcome remarks				Welcome remarks		
08:40~09:20 (40分鐘)					Keynote (3) 衛福部 石崇良 部長				Keynote (7) 牛津 Simon Buczacki 教授		
09:20~10:00 (40分鐘)					Keynote (4) 史丹佛 錢湘 教授				Keynote (8) 喬治亞理工學院 李錦輝 教授		
10:00 -10:20					Coffee break				Coffee break		
10:20~12:00 (100分鐘)					A3 高醫-衛采雙年論壇	B3 小港旗津	C3 長期照顧	D3 神經科學 B1自習室	A6 中和-精準醫療	B6 產學及金屬工業中心	C6 醫療科技與政策
12:00~13:10	Registration				高醫-衛采雙年論壇	Lunch seminar 衛星演講 多功能會議室 1	Lunch seminar 衛星演講 多功能會議室 3		頒獎/ Closing remark		
13:10~13:20	Welcome remarks				Welcome remarks				City tour		
13:20~14:00	Keynote (1) 中研院 陳建仁 院長				Keynote (5) MIT 蔡立慧 教授						
14:00-14:40	Keynote (2) Jean Marc Egly 教授				Keynote (6) 烏普薩拉 Sara Mangsbo 教授						
14:50~16:30 (100分鐘)	A1 精準環境醫學	B1 醫學院醫學教育暨人本化教育	C1 USR 那瑪夏	D1 AI人工智慧醫療 B1自習室	A4 圓桌* 會議	B4 新藥開發暨價創	C4 岡山-失智症/甲狀腺	D4 海報競賽 B1自習室			
16:30~16:50	Coffee break				Coffee break						
16:50~18:30 (100分鐘)	A2 精準環境醫學	B2 多體學中心	C2 生命科學院	D2 AI人工智慧醫療 B1自習室	A5 圓桌* 會議	B5 健康科學院/熱帶醫學	C5 中和-智慧醫療與永續轉型實踐	D5 海報競賽 B1自習室			
18:50	Buffet (創新館)				Gala dinner (福客來)						

October 16 Hall A | 14:50–18:30

Environment, Immunity and Respiratory Diseases-Recent Research and Development

A1/A2-精準環境醫學研

Time	Speaker	Moderator
14:50–15:40	Yuan Pu Di 狄元璞	Chih-Hsing Hung 洪志興
15:40–16:30	Hsiao-Chi Chuang 莊校奇	Jin-Shuen Chen 陳金順
16:50–17:40	Kwei-Yan Liu 劉奎延	Shih-Hsien Hsu 許世賢
17:40–18:30	Da-Wei Wu 吳大緯	Pei-Shih Chen 陳培詩



Speaker

Name Yuan Pu Di
Job Title Professor
Department Cellular and Molecular Medicine
Organization Florida International University

A brief biographical sketch

Yuanpu (Peter) Di, PhD, MBA, is Professor of Cellular and Molecular Medicine at the Herbert Wertheim College of Medicine, Florida International University, and a faculty member of the Center for Translational Science. He is also Professor Emeritus at the University of Pittsburgh, where he spent more than two decades developing a nationally recognized research program in pulmonary biology, inhalation toxicology, environmental health, and airway innate immunity.

Dr. Di received a medical certificate from the National Defense Medical University, earned his PhD in Biophysics from the State University of New York at Buffalo through Roswell Park Cancer Institute, and completed an MBA in Innovation and Technology Management at the University of California, Davis. His research examines how environmental exposures, microbial pathogens, airway epithelial cells, and mucosal immune responses interact to shape respiratory health and disease. His major research interests include epithelial host defense, BPIFA1/SPLUNC1 biology, host-pathogen interactions, antimicrobial resistance, pneumonia and sepsis, chronic inflammatory lung diseases, lung cancer, and the development of peptide-based and host-directed therapeutics.

Over nearly three decades, Dr. Di has maintained continuous external research funding and currently directs five NIH-funded programs. He has secured more than $47 million in competitive funding, including more than $22 million as principal investigator, and has authored more than 100 peer-reviewed publications and 19 book chapters or invited reviews, receiving more than 8,800 citations with an h-index of 47. His translational research has generated two issued U.S. patents, issued patents in Canada and China, additional pending U.S. and European patent applications, and three federally funded SBIR Phase I awards.


Dr. Di has delivered 152 invited seminars and keynote lectures, served on more than 40 NIH study sections and numerous national and international review panels, and reviewed manuscripts for more than 100 journals. He currently serves on five editorial boards and as an Associate or Academic Editor for three journals. A committed mentor, he has trained 17 postdoctoral fellows, 5 PhD students, 7 MS students, and more than 35 undergraduate researchers.

Speaking Topic(s)

The Lung as an Adaptive Ecosystem: Linking Environmental Exposures, Mucosal Immunity, and Precision Therapeutics

Session Abstract

The lung is a dynamic, adaptive ecosystem in which environmental exposures continuously reshape epithelial barrier function, mucosal immunity, and microbial behavior. This presentation will examine how disruption of these interconnected systems drives susceptibility to respiratory infection, chronic inflammation, COPD, and lung cancer. Drawing on our studies of environmental exposure and airway epithelial cell-mediated airway defense, bacterial adaptation, and engineered antimicrobial peptides, I will highlight opportunities to translate mechanistic discoveries into new interventions. Finally, I will present a systems-based vision for precision therapeutics guided by each patient's barrier integrity, immune state, and airway microbiome.



Moderator

Name Chih-Hsing Hung
Job Title Director / Superintendent
Department Research Center for Precision Environmental Medicine
Organization Kaohsiung Medical University / Kaohsiung Municipal Siaogang Hospital

A brief biographical sketch

Dr. Chih-Hsing Hung is Professor of Pediatrics at Kaohsiung Medical University (KMU) and Superintendent of Kaohsiung Municipal Siaogang Hospital. He also serves as Director of the Research Center for Precision Environmental Medicine at KMU. His clinical specialties include general pediatrics, pediatric allergy, and immunology.

Dr. Hung received his M.D. from National Defense Medical College and his Ph.D. from the Institute of Medicine at Kaohsiung Medical University. He completed research training at the Johns Hopkins Asthma and Allergy Center, Johns Hopkins University, where he conducted studies in allergic inflammation and respiratory diseases. He subsequently held academic and clinical positions at Kaohsiung Medical University and Kaohsiung Medical University Hospital, advancing to Professor of Pediatrics and leadership positions in pediatric allergy and immunology.

His research interests encompass pediatric allergy and asthma, immunology, dendritic-cell biology, environmental health, and the impact of environmental exposures on allergic and respiratory diseases. His representative research has investigated the molecular mechanisms underlying allergic inflammation, immune regulation, and environmental determinants of asthma, with publications in internationally recognized journals including the Journal of Allergy and Clinical Immunology and Respiratory Research.



Speaker

Name Hsiao-Chi Chuang
Job Title Professor
Department School of Respiratory Therapy
Organization Taipei Medical University

A brief biographical sketch

Dr. Hsiao-Chi Chuang is Professor in the School of Respiratory Therapy, College of Medicine, Taipei Medical University (TMU), Taiwan. He also serves as Vice Director of the TMU Research Center of Thoracic Medicine, Adjunct Investigator at the National Institute of Environmental Health Sciences, National Health Research Institutes, and President of the Taiwan Society for Aerosol in Medicine.

Dr. Chuang's research focuses on how aerosol-derived reactive oxygen species influence cellular signaling, metabolic regulation, and injury responses in the lung. His work examines the mechanisms linking air pollution and other environmental exposures to oxidative stress, inflammation, epithelial dysfunction, and respiratory diseases, particularly chronic obstructive pulmonary disease, asthma, and acute respiratory distress syndrome. His translational research aims to identify therapeutic targets and advance innovative aerosol-based interventions.

He earned his PhD in Pathophysiology and Repair from Cardiff University, United Kingdom, an MSc in Occupational Medicine and Industrial Hygiene from National Taiwan University, and a BSc in Occupational Safety and Health from China Medical University, Taiwan. His international experience includes a visiting professorship at Imperial College London.

Dr. Chuang has received numerous honors for research, teaching, and innovation, including Taiwan's National Innovation Awards, the Malaysia Technology Expo International Innovation Silver Award, and repeated TMU Research Excellence Awards. He has also been recognized among the world's top 2% of scientists. He is an Editor of the Journal of Hazardous Materials and an Associate Editor of Frontiers in Medicine. His current work includes leading the Taiwan component of the Wellcome Trust–supported PREDICT-ASIA program.

Speaking Topic(s)

Air Pollution and Chronic Obstructive Pulmonary Disease

Session Abstract

Air pollution is a major environmental risk factor for chronic obstructive pulmonary disease (COPD), contributing to lung-function decline, emphysema progression, and disease development among never-smokers. This presentation integrates epidemiological, clinical, and experimental evidence to characterize air pollution–associated COPD and its underlying mechanisms. Chronic exposure to $PM_{2.5}$ promotes alveolar epithelial injury and type II alveolar cell apoptosis, while particle-associated microbiomes may further contribute to acute exacerbations. These findings underscore the need for clean-air policies, exposure reduction, and early interventions to mitigate the growing burden of COPD.



Moderator

Name Jin-Shuen Chen
Job Title Superintendent
Department Nephrology
Organization Kaohsiung Veterans General Hospital

A brief biographical sketch

Jin-Shuen Chen, M.D., Ph.D., currently serves as Superintendent of Kaohsiung Veterans General Hospital, one of Taiwan's leading tertiary medical centers, and holds a professorship in the Department of Internal Medicine at National Defense Medical Center. A nationally recognized nephrologist and clinician-scientist, he has served as President of the Taiwan Society of Nephrology since December 2025, where he helps shape national standards of kidney care. Concurrently, he serves as Chairman of the Kaohsiung City Medical Association (since April 2025), extending his influence into regional healthcare policy, physician advocacy, and medical governance.

Dr. Chen earned his Ph.D. from the Graduate Institute of Clinical Medicine at National Defense Medical Center, where he was trained in both laboratory science and evidence-based clinical practice, and he subsequently completed an Executive MBA with a concentration in Accounting and Management. This dual academic foundation bridges clinical scholarship with institutional leadership, allowing him to combine scientific rigor with financial and strategic management in the running of a large public hospital.

Dr. Chen's professional experience spans internal medicine, nephrology, clinical research, medical education, and hospital administration. Before assuming his present role, he served as Deputy Superintendent of Kaohsiung Veterans General Hospital from March 2021 to January 2024, taking on hospital-wide responsibility for clinical services, quality management, and research development. As Superintendent he now leads the institution's operations and long-term strategic planning. He remains actively engaged in professional societies and teaching, with a sustained commitment to advancing nephrology care, strengthening chronic kidney disease programs, and training the next generation of specialists in Taiwan.

Dr. Chen specializes in internal medicine and nephrology, with research focusing on the pathophysiology and translational study of kidney diseases. His laboratory uses animal models to investigate membranous nephropathy and diabetic nephropathy, focusing on the mechanistic roles of plasminogen and the discovery of novel disease biomarkers for earlier diagnosis and risk stratification. He also leads initiatives to establish and analyze

comprehensive biobanks for end-stage renal disease (ESRD), linking clinical, laboratory, and molecular data in order to advance precision nephrology. Also, his career reflects a sustained record of clinical excellence, academic leadership, and institutional innovation.

A committed advocate of Smart Healthcare and ESG-based sustainable governance, he led the hospital in developing the "FHIR Commander" system, recognized by Taiwan's SMART 50 Awards, and in achieving prestigious placements in Newsweek's 2026 rankings—2nd in Taiwan and 116th globally among the World's Best Smart Hospitals, and 13th in Taiwan among the World's Best Hospitals. Throughout his career, Dr. Chen has received numerous honors, including Outstanding Military Physician, Best Teacher at National Defense Medical Center and Tri-Service General Hospital, the National Quality Control Circle Outstanding Award, and Clinical Teaching Excellence Awards, underscoring his dedication to medical talent cultivation and pedagogical innovation.

Moreover, in the past decades, he has published more than 100 articles in nephrology and other areas of medicine, and he continues to mentor younger physicians and researchers, contributing to the international exchange of knowledge in kidney health.



Speaker

Name Kwei-Yan, Liu
Job Title Assistant Investigator
Department National Institute of Environmental Health Sciences
Organization National Health Research Institutes

A brief biographical sketch

I am currently an Assistant Investigator at the National Institute of Environmental Health Sciences, National Health Research Institutes, Taiwan. I received my Ph.D. from the Institute of Molecular Medicine, College of Medicine, National Taiwan University, and completed my postdoctoral training at the National Institute of Environmental Health Sciences, National Health Research Institutes.

My research focuses on environmental health, immunology, and the molecular mechanisms underlying environmentally associated diseases. I am particularly interested in how environmental exposures, including air pollution, affect immune regulation and contribute to chronic disease risk, as well as how environmental factors interact with individual genetic susceptibility. By integrating population-based studies, experimental models, and multi-omics approaches, I aim to better understand the links among environmental exposures, immune responses, and disease development. My long-term goal is to provide scientific evidence to support environmental medicine, precision prevention, public health strategies, and health policy.

Speaking Topic(s)

Gene-environmental interaction in asthma: Discovery of susceptibility gene, functional significance and interaction with exposure to PM2.5 and PAHs

Session Abstract

This presentation will discuss how long-term exposure to PM2.5 and polycyclic aromatic hydrocarbons (PAHs) interacts with genetic susceptibility to influence asthma risk. Integrating population-based genetic analyses with cellular models, we will highlight the role of aryl hydrocarbon receptor (AhR) signaling in linking environmental exposure to immune and molecular changes. Particular emphasis will be placed on the 17q21 asthma susceptibility locus, PAH-responsive lncRNA regulation, and the modulation of type 2 immune responses. These findings provide mechanistic insights into gene–environment interactions in asthma and their implications for precision environmental medicine.



Moderator

Name Shih-Hsien, Hsu
Job Title Professor
Department Graduate Institute of Medicine
Organization KMU

A brief biographical sketch

Over the past decade, the primary objective of our laboratory has been to elucidate the intricate interactions among oncogenic transcriptional regulators, immune remodeling, and therapeutic responses in cancer through integrated molecular biology, cell biology, animal models, and translational clinical investigations. Our major research focus has centered on the oncogenic transcription factor Intestine-Specific Homeobox (ISX), a stress-responsive proto-oncogene induced by inflammatory cytokines (such as IL-6), environmental pollutants, and pathogenic signals. ISX regulates diverse downstream targets involved in metabolism, immune checkpoint regulation, epithelial–mesenchymal transition (EMT), and tumor progression. Our earlier studies established ISX as a critical regulator of oncogenic pathways in liver cancer. Through next-generation transcriptomic analyses and mechanistic validation, we identified multiple ISX downstream targets, including cell cycle regulators (Cyclin D1, E2F1), tryptophan metabolic enzymes (IDO/Kynurenine pathway), immune checkpoint molecules (PD-L1, B7-2), and EMT regulators such as TWIST1 and SNAIL1. These pathways collectively promote tumor growth, immune suppression, metastasis, and poor clinical outcomes in HCC patients.

Speaking Topic(s)

Session Abstract

Environment, Immunity and Respiratory Diseases-Recent Research and Developmen



Speaker

Name Da-Wei Wu
Job Title Attending Physician
Department Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
Organization Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University

A brief biographical sketch

Da-Wei Wu, MD, PhD, is an attending physician in the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, at Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Taiwan. He holds both medical and doctoral degrees and has extensive clinical experience in pulmonary medicine, with a particular focus on chronic obstructive pulmonary disease (COPD), asthma, respiratory care, and environmental and occupational lung diseases.

Dr. Wu's research integrates clinical respiratory medicine, environmental exposure assessment, precision health, and smart healthcare technologies. He leads the Smart COPD Outcome and Precision Evaluation (SCOPE) cohort, a longitudinal clinical cohort designed to investigate COPD phenotypes, disease trajectories, acute exacerbations, lung-function decline, and treatment outcomes. His current research combines clinical data with air-pollution exposure modelling, Geo-AI, urinary metabolites of polycyclic aromatic hydrocarbons and volatile organic compounds, exhaled-breath VOC profiling, medical imaging, and molecular biomarkers.

He has published research on air pollution and chronic respiratory diseases, environmental and occupational exposures, COPD clinical outcomes, and heart-rate-variability biofeedback. He has also promoted an integrated Smart Lung Health Clinic that incorporates digital health tools, individualized environmental-risk assessment, patient education, and longitudinal follow-up into routine respiratory care.

In addition, Dr. Wu is actively engaged in sustainable healthcare and circular-economy initiatives, including the systematic collection, disassembly, analysis, and reuse of polypropylene inhaler packaging. His work aims to connect clinical innovation, environmental health, artificial intelligence, and green healthcare to improve respiratory outcomes while reducing the environmental footprint of medical care.



Moderator

Name Pei-Shih Chen
Job Title Professor
Department Department of Public Health
Organization Kaohsiung Medical University

A brief biographical sketch

Pei-Shih Chen, PhD, is the **Vice President of Institutional Research and Sustainable Development and** Professor in the Department of Public Health at Kaohsiung Medical University, Taiwan. Her research expertise includes the health effects of air pollution, indoor air quality, and bioaerosols, with a particular interest in understanding how environmental exposures affect human health.

A major part of her research has focused on airborne infectious agents, including avian influenza, and the potential role of environmental and airborne transmission pathways. She has also conducted extensive research on indoor air quality, measuring particulate matter, gaseous pollutants, airborne microorganisms, and allergens in indoor air and evaluating their potential health effects. More recently, her research has expanded to practical approaches for improving indoor air quality, including air purification interventions using photocatalytic oxidation and filtration technologies. These studies have evaluated the effectiveness of air cleaners in reducing indoor air pollutants and bioaerosols, as well as their potential to improve health-related outcomes.

October 16 Hall B | 14:50-16:30

Cultivating Medical Ethics and Professionalism in Health Professions Education

B1-醫學教育暨人本化教育中心

Time	Speaker	Moderator
14:50–15:40	Yukiko K Hayashi 林由起子	Yuh-Jyh Jong 鍾育志
15:40–16:30	Shin-Yun Wang 王心運	Po-Liang Lu 盧柏樑



Speaker

Name Yukiko K. Hayashi
Job Title Chair of the Board of Regents
Organization Tokyo Medical University

A brief biographical sketch

EDUCATION

1986	MD: Tokyo Medical University, Tokyo, Japan
1995	PhD: Juntendo University Medical School, Tokyo, Japan

WORKING EXPERIENCE

1986-1988	Resident, Juntendo University Hospital, Tokyo, Japan
1988-1991	Clinical Assistant, Department of Neurology, Juntendo University Hospital, Tokyo, Japan
1991	Instructor, Department of Neurology, Juntendo University Medical School, Tokyo, Japan
1995-1991	Research Fellow, Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, Tokyo, Japan
1995-1999	Research Scientist, Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, Tokyo, Japan
1999-2013	Section Chief, Department of Neuromuscular Research, National Institute of Neuroscience, National Institute of Neurology and Psychiatry (NCNP), Tokyo, Japan
2013-present	Professor and Chairman, Department of Pathophysiology, Tokyo Medical University
2016-present	(Concurrently) Deputy Director General, Genetic clinic center, Tokyo Medical University
2018-2024	(Concurrently) President, Tokyo Medical University
2025-present	(Concurrently) Chair of the Board of Regents

BOARD CERTIFICATION

Board Certified Member of the Japanese Society of Internal Medicine
Instructing doctor of the Japanese Society of Neurology
Instructing doctor of the Japanese Society of Human Genetics
Board member for Asian Oceanian Myology Center
Board member for Japan Muscle Society
Board member for Japanese Society of Physiology
Editorial Board member for Neuromuscular Disorders
Editorial Board member of the Journal of Physiological Sciences

Speaking Topic(s)

Education on Medical Ethics and Professionalism for Medical Students in Japan

Session Abstract

Medical ethics and professionalism are core competencies that all medical students should develop, and they are taught systematically. Professionalism education has two main goals: avoiding unprofessional behavior and always striving to become a better professional. Medical ethics includes bioethics, which is important for clinical practice, and research ethics, which focuses on the responsibilities of medical professionals when conducting research. In this presentation, I will introduce major efforts in medical education in Japan, focusing on medical ethics and professionalism.



Moderator

Name Yuh-Jyh Jong
Job Title Emeritus Professor, 2) Visiting Staff
Department College of Medicine, 2) Department of Pediatrics
Organization Kaohsiung Medical University (KMU), 2) KMUHospital

A brief biographical sketch

Dr. Yuh-Jyh Jong earned his M.D. and M.S. degrees from Kaohsiung Medical University (KMU), Taiwan, and completed clinical training in Pediatrics and Pediatric Neurology at KMU Hospital. From 1985 to 1986, he received advanced training in muscle pathology under Dr. Ikuya Nonaka at the National Center of Neurology and Psychiatry and in neuromuscular diseases (NMDs) under Professor Yukio Fukuyama at Tokyo Women's Medical University, where he subsequently earned his D.M.Sci. degree in 1993.

Dr. Jong became Professor at KMU in 2000 and has held numerous academic and administrative leadership positions, including Superintendent of Kaohsiung Municipal Siaogang Hospital (2002–2003), Vice Superintendent of KMU Hospital (2003–2006), Vice President of KMU (2006–2012), Dean of the College of Biological Science and Technology at National Chiao Tung University (2013–2018), and President of KMU (2018–2021). He is currently Professor Emeritus at KMU and Visiting Staff in the Department of Pediatrics at KMU Hospital.


Professor Jong is a pioneer in pediatric NMDs in Taiwan, with contributions spanning basic research, translational medicine, clinical trials, newborn screening (NBS), multidisciplinary care, and health policy. In collaboration with Hung Li, Jan-Gowth Chang, and colleagues, he contributed to the development of the world's first spinal muscular atrophy (SMA) mouse model (Nature Genetics, 2000). Subsequent therapeutic studies using this model provided early proof-of-concept that SMA, once considered untreatable, could potentially be treated (PNAS, 2001).

Under his leadership, KMU Hospital established Taiwan's first multidisciplinary SMA care team in 2007. The team participated in pivotal and landmark clinical trials of disease-modifying therapies, including nusinersen and risdiplam, from symptomatic to presymptomatic treatment (NEJM, 2017; Neuromuscular Disorders, 2019; Muscle &

Nerve, 2023; NEJM, 2025), as well as the clinical development of intrathecal SMA gene therapy (Nature Medicine, 2026). He also contributed to Taiwan's national consensus on SMA gene therapy (Journal of the Formosan Medical Association, 2026).

Dr. Jong has played a major role in advancing SMA NBS and early treatment in Taiwan. His team demonstrated through large-scale screening and five-year real-world evidence that early diagnosis and disease-modifying treatment substantially improve clinical outcomes (J Neurology Neurosurgery Psychiatry 2021; Orphanet Journal of Rare Diseases, 2025). These efforts helped support the expansion of SMA treatment coverage and the implementation of publicly funded nationwide SMA NBS in Taiwan on July 1, 2026. His collaborative health-economic research further demonstrated that universal NBS combined with presymptomatic treatment is cost-effective from both healthcare-payer and societal perspectives (Value in Health Regional Issues, 2026).

His current research focuses on translational research and precision medicine for SMA and other NMDs, with particular emphasis on international collaborative alliances, NBS, early theranostics, innovative therapies, and holistic care, with the goal of improving long-term outcomes, independence, and quality of life for patients across Taiwan and the Asia-Pacific region.



Speaker

Name Shin-Yun Wang
Job Title Professor
Department Department of Medical Humanities and Education, School of Medicine
Organization Kaohsiung Medical University

A brief biographical sketch

Current Position

2026~ Professor
School of Medicine, Kaohsiung medical University, Kaohsiung, Taiwan, R.O.C.

2021~ Director of Department of Medical Humanities and Education

2014–present Principal Investigator, Clinical studies of allogeneic chondrocyte sheets for osteoarthritis

2010–2018 Leeder, Non-invasive cartilage diagnosis using laser-induced photoacoustic measurement

2004–2018 Principal Investigator, Clinical studies of autologous chondrocyte sheets for joint repair

Educational Background

1998-2005 University of Freiburg, Freiburg, B.W., Germany
Doctor of Philosophy

1992-1995 National Taiwan University, Taipei, Taiwan, R.O.C.
Master of Philosophy

1998-1992 National Taiwan University, Taipei, Taiwan, R.O.C. Bachelor of Chemical Engineering

Professional Experience

2026/8~ Professor
School of Medicine, Kaohsiung medical University, Kaohsiung, Taiwan, R.O.C.

2009/8-2026/7 Associate Professor
School of Medicine, Kaohsiung medical University, Kaohsiung, Taiwan, R.O.C.

2006/2-2009/7 Assistant Professor
School of Medicine, Kaohsiung medical University, Kaohsiung, Taiwan, R.O.C.

Research Interests

Philosophy: Phenomenology, Ethics, Philosophy of Science

Medical Education: medical Humanities

Language: Chinese, English and German

Representative Achievements

2022 University-Level Outstanding Mentor

2023 University-Level Outstanding Mentor

Speaking Topic(s)

Integrating Narrative Thinking into Medical Education: The Parallel Between Differential Diagnosis and Narrative Medicine

Session Abstract

This speaking will show that narrative thinking and differential diagnosis share similar cognitive structures. By recognizing these similarities, medical education can better integrate narrative medicine into clinical training, improve students' diagnostic reasoning, strengthen medical ethics, and promote patient-centered care.



Moderator

Name Po-Liang Lu
Job Title Dean/Professor
Department School of Post-Baccalaureate Medicine, College of Medicine
Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Po-Liang Lu is Professor and Dean of the College of Medicine at Kaohsiung Medical University (KMU), and an Attending Physician in the Division of Infectious Diseases at Kaohsiung Medical University Hospital (KMUH), Kaohsiung, Taiwan. In these dual roles, he leads academic and curricular affairs across the college while maintaining an active clinical practice in infectious diseases.

Dr. Lu received his Doctor of Medicine degree from Kaohsiung Medical University in 1992. He completed residency training in Internal Medicine at KMUH, followed by subspecialty fellowship training in Infectious Diseases at National Taiwan University Hospital, Taipei. In 2011, he earned his Ph.D. from the Graduate Institute of Medicine at KMU, with doctoral research focusing on antimicrobial resistance mechanisms and infectious disease epidemiology.

Over the course of his career, Dr. Lu has held a series of leadership positions at KMU and KMUH, including Director of the Division of Infectious Diseases, Director of the Department of Internal Medicine, Director of the Department of Laboratory Medicine, and Chairman of the Post-Baccalaureate School of Medicine. These roles encompassed oversight of clinical services, laboratory operations, and undergraduate medical education. As Dean of the College of Medicine, he is responsible for strategic planning, faculty development, curriculum reform, and fostering research across multiple departments. He is also an active member of the Infectious Diseases Society of Taiwan, the Infection Control Society of Taiwan, and the Taiwan AIDS Society, contributing to national policy development in infection control and public health.

Dr. Lu's research focuses on antimicrobial resistance, HIV/AIDS, tuberculosis, and healthcare-associated infections. He investigates the clinical and molecular epidemiology of drug-resistant organisms, with particular interest in Extended-Spectrum Beta-Lactamases (ESBLs), carbapenemases, and resistance to fluoroquinolones and fosfomycin. In collaboration with the Health Protection Agency of the United Kingdom, he contributed to the first identification and characterization of the OXA-72 carbapenemase in southern Taiwan, an important finding for regional surveillance of carbapenem

resistance. His research team also developed novel rapid detection kits for tuberculosis diagnosis, facilitating earlier treatment initiation, and has led multi-year epidemiological studies on HIV/AIDS in Taiwan that inform national prevention strategies and care programs for people living with HIV.

Through sustained contributions to clinical medicine, translational research, and medical education, Dr. Lu continues to advance infectious disease care and training both in Taiwan and on the international stage.

October 16 Hall B | 16:50-18:30

Multi-Omics in Biomedical Research

B2-疾病多體學中心

Time	Speaker	Moderator
16:50–17:30	Hyun Goo Woo	Ya-Ling Hsu 許雅玲
17:30–18:00	Mei-Hsuan Lee 李美璇	Chia-Yang Li 李佳陽
18:00–18:30	Chia-Hsin Liu 劉佳鑫	Chia-Yang Li 李佳陽



Speaker

Name Hyun Goo Woo
Job Title Professor
Department Department of Physiology
Organization Ajou University School of Medicine

A brief biographical sketch

Hyun Goo Woo, M.D., Ph.D., is Professor in the Department of Physiology at Ajou University School of Medicine, Chair of the Department of Biomedical Science at the Graduate School of Ajou University, and Director of the Ajou Translational Omics Center. He received his M.D. from Korea University in 1996 and Ph.D. from Ajou University in 2001. He served as a senior researcher at the Korea Research Institute of Bioscience and Biotechnology (2004-2006) and a visiting researcher at the National Cancer Institute, NIH (2006-2010), before joining Ajou University in 2010. He has served as Editor-in-Chief of Genomics & Informatics since 2021. His research includes cancer genomics, multi-omics integration, biomarker discovery, and interpretable artificial intelligence. His recent representative senior-author publications include integrative transcriptomic and genomic analyses of MASLD and hepatocellular cancer progression markers (Hepatology, 2025, 2023), single-cell transcriptome profiling of stepwise progression in head and neck cancer (Nature Communications, 2023), identification of molecular subtypes of dementia using blood-protein interaction-aware graph propagational networks (Briefings in Bioinformatics, 2024). He received the Korean Society for Bioinformatics Onbit Award in 2022 and a commendation from the Ministry of Science and ICT in 2023.

Speaking Topic(s)

New Perspectives on Hospital-Driven Diagnostics and Therapeutics

Session Abstract

This presentation examines how hospitals can connect clinical, imaging, pathology, and multi-omics data to advance precision diagnostics and guide the development of individualized therapeutics. It discusses multimodal AI and emerging virtual-cell, digital-twin, and world-model approaches as tools for linking disease characterization to therapeutic hypotheses that require experimental and clinical validation. Examples include personalized cancer vaccines and cell therapies, alongside our research on AI-assisted peptide and minibinder design. The presentation proposes a hospital-centered development framework that links patient data and specimens with iterative design, experimental validation, manufacturing partnerships, and clinical follow-up, with attention to data governance and the distinction between research tools and clinical applications.



Moderator

Name Ya-Ling Hsu

Job Title Vice President, office of Research & Development, KMUFull Professor

Department Graduate Institute of Medicine

Organization Kaohsiung Medical University

A brief biographical sketch

I currently serve as Vice President of the Office of Research and Development and Director of the Division of Administrative Planning within the Office of Research and Development at Kaohsiung Medical University (KMU). My research expertise spans molecular biology, oncology, and pharmacology, with a particular focus on the tumor microenvironment, cancer metastasis, and therapeutic drug development. I have authored more than 120 peer-reviewed scientific publications and was honored with the prestigious Ta-You Wu Memorial Award in 2015. From 2008 to 2026, I have continuously received Kaohsiung Medical University's Outstanding Research Performance Award in recognition of sustained excellence in research productivity and academic achievement. In addition, I received the Kaohsiung Medical University Outstanding Research Award in 2025. I have also been recognized among the world's Top 2% Scientists. In addition to my academic research, I oversee preclinical research programs and am responsible for the establishment, operation, and strategic development of KMU's Single-Cell Multi-Omics Core Facility. Through these roles, I am committed to advancing translational research, strengthening interdisciplinary collaboration, and facilitating the application of cutting-edge multi-omics technologies in biomedical and precision medicine research.



Speaker

Name Mei-Hsuan Lee
Job Title Distinguished Professor
Department Institute of Clinical Medicine
Organization National Yang Ming Chiao Tung University

A brief biographical sketch

Mei-Hsuan Lee, PhD, is a Distinguished Professor at the Institute of Clinical Medicine and Deputy Dean of Research and Development at National Yang Ming Chiao Tung University, Taiwan. She received her PhD in Epidemiology from the College of Public Health, National Taiwan University, and subsequently completed postdoctoral training at the Genomics Research Center, Academia Sinica. She has also served as a visiting scholar at the University of Tokyo and the U.S. National Cancer Institute. Her research focuses on cancer epidemiology, molecular and genomic epidemiology, risk prediction, and precision prevention, with particular interests in hepatobiliary cancers, metabolic liver disease, host genetic susceptibility, viral infections, and cardiometabolic risk. Her work integrates large-scale population cohorts, biobanks, genomic data, and emerging molecular approaches to better understand disease susceptibility and identify high-risk populations. Dr. Lee has published extensively in the fields of hepatology, cancer epidemiology, and genomic epidemiology, with recent studies appearing in journals including Hepatology, Clinical Gastroenterology and Hepatology, and JHEP Reports. Her research achievements have been recognized by several national and international awards, including the Outstanding Research Award from Taiwan's Ministry of Science and Technology, Tien-Te Lee Award-Youth Medical Technology Award, Ten Outstanding Young Persons Award, and the Young Investigator Award from the Asian Pacific Association for the Study of the Liver.

Speaking Topic(s)

From Multi-Omics to Precision Prevention: Connecting Biological and Population Data to Understand Disease Susceptibility

Session Abstract

This presentation will explore how biological and population-based data can provide complementary insights into disease susceptibility and support precision prevention. Using liver disease and hepatocellular carcinoma as examples, I will discuss the contributions of cardiometabolic risk, genetic susceptibility, polygenic risk, lifestyle factors, and emerging serological profiling. The presentation will highlight how these different sources of information can improve risk stratification and help distinguish inherited from potentially modifiable components of disease risk. Ultimately, the goal is to illustrate how advances in multi-omics and population research may inform more targeted prevention strategies.



Moderator

Name Chia-Yang Li
Job Title Professor
Department Graduate Institute of Medicine
Organization Kaohsiung Medical University

A brief biographical sketch

Chia-Yang Li, Ph.D., is a Professor at the Graduate Institute of Medicine, Kaohsiung Medical University (KMU), Taiwan. He currently serves as Associate Vice President for Research and Development at KMU and Executive Director of the Disease Multi-Omics Research Center, where he promotes interdisciplinary research integrating genomics, multi-omics, cellular metabolism, and translational medicine.

Dr. Li received his Ph.D. from the Department of Biomedical Engineering and Environmental Sciences at National Tsing Hua University, Taiwan. His research expertise encompasses genomics, cellular metabolism, tumor immunology, and molecular mechanisms underlying metabolic and inflammatory diseases. Prior to joining the faculty of KMU, Dr. Li received postdoctoral training at the National Health Research Institutes in Taiwan and the Department of Urology at the University of Texas Southwestern Medical Center in the United States. Since joining KMU, he has progressed from Assistant Professor to Associate Professor and Professor and has held several academic and administrative leadership positions, including Director of the Laboratory Animal Center and Director of the Center for Applied Genomics. He has also served as a Visiting Professor in the Department of Pathology at Duke University School of Medicine.

Dr. Li has contributed extensively to research in cancer biology, inflammation, metabolism, and translational multi-omics. His research focuses on understanding how metabolic reprogramming, mitochondrial dysfunction, inflammatory signaling, and genomic alterations contribute to human diseases, particularly metabolic liver disease and cancer. His laboratory integrates experimental models with transcriptomics and multi-omics approaches to identify disease mechanisms, biomarkers, and potential therapeutic targets.



Speaker

Name Chia-Hsin Liu
Job Title Assistant Professor
Department Graduate Institute of Clinical Medicine, College of Medicine
Organization Kaohsiung Medical University

A brief biographical sketch

Chia-Hsin Liu's research expertise focuses on bioinformatics, multi-omics data analysis, and precision medicine. With a solid background in mathematical and medical statistics, he is dedicated to algorithm development and cancer big data analysis, applying next-generation sequencing (NGS) technologies to the study of major diseases. His research primarily centers on the in-depth integration of cross-omics data—encompassing genomics, transcriptomics, and lipidomics—and focuses on bridging predictive biomarkers with their underlying biological mechanisms. Through the lens of big data analysis and translational medicine, he aims to re-evaluate research objectives from the perspectives of public health and clinical application, accurately interpreting data implications to advance the development of precision medicine.

Speaking Topic(s)

DriverDBv5: a multi-omics database for evaluating the prognostic impact of cancer driver genes

Session Abstract

Cancer is driven by alterations distributed across multiple molecular layers, but whether the drivers identified by multi-omics integration carry prognostic weight has received far less systematic attention, and inconsistent sample identifiers across repositories prevent omics layers from being assigned reliably to the same patient. We present DriverDBv5 (https://driverdb.bioinfomics.org/), which extends DriverDB from driver identification to prognostic evaluation. The database has been expanded to 187 cohorts, 43,920 patients and 130,454 samples, of which 154 cohorts originate outside TCGA. Cox and cure models are provided for single features, the Customized Analysis module has been expanded from 5 to 11 tools, and an organ-level human body map provides an anatomical entry point. A generalized barcode system reconciles identifiers across sources and enables patient-level multi-omics intersection, which in turn makes possible two new analysis families: multi-omics survival modelling through LASSO, l-Boost and random forest, and trans-omics synergistic effect analysis across all six pairwise combinations of somatic mutation, RNA expression, copy-number variation and DNA methylation. In summary, DriverDBv5 allows researchers to ask not only which alterations drive a tumour, but which of them relate to how patients fare.

October 16 | **B2 Conference Room** | **14:50-16:30**

Kipahpah ima: From Clapping Together to Global Co-creation- Advancing Health Sustainability from USR to ESG

C1-USR 那瑪夏

Time	Speaker	Moderator
14:50–15:25	Yueh-Chiao Yeh 葉月嬌	Sodio C. N. Hsu 許智能
15:25–15:45	Shih-Fen Hsiao 蕭世芬	Pamela Berilyn So 蘇穎穎
15:45–16:05	Mae A. Responte	Pamela Berilyn So 蘇穎穎
16:05–16:30	Reginald G. Ugaddan	Pamela Berilyn So 蘇穎穎



Speaker

Name Yueh-Chiao Yeh
Job Title Distinguished Professor & Vice President
Department Natural Biotechnology
Organization Nanhua University

A brief biographical sketch

Professor Yueh-Chiao (Stella) Yeh is Vice President of Nanhua University, Taiwan, and a Distinguished Professor in the Department of Natural Biotechnology and Master's Program in Natural Healing Sciences. She also serves as Chief Executive Officer of the university's Higher Education Sprout Project and University Social Responsibility (USR) initiatives, Chief Consultant to the Cittaslow Taiwan Alliance, and Executive Secretary and General Coordinator of the Slow Food Community–Yunlin Earth Market.

Her interdisciplinary research interests encompass cardiovascular and endothelial dysfunction, oxidative stress, pharmacology and toxicology, allergy and asthma, complementary and integrative health, emotional well-being, healthy aging, and community health promotion. Her peer-reviewed work has appeared in international journals including the British Journal of Pharmacology, Cardiovascular Research, Toxicology and Applied Pharmacology, and Complementary Therapies in Medicine.

For more than a decade, Professor Yeh has translated the Slow Food principles of "Good, Clean, and Fair" into sustained university social responsibility and place-based sustainable development. Her work regards food not merely as a commodity, but as an important pathway connecting public health, environmental stewardship, cultural preservation, local economic resilience, and community well-being. Through multi-year USR projects supported by Taiwan's Ministry of Education, she has built cross-sector partnerships among universities, local governments, small-scale farmers, social enterprises, food artisans, educators, students, and community residents. These collaborations have promoted producer capacity-building, food and agricultural education, local product development, community storytelling, responsible consumption, and intergenerational learning.

One of her representative achievements is helping establish the Slow Food Community–Yunlin Earth Market as a living platform for farmers' markets, educational workshops, producer–consumer dialogue, cultural exchange, and community empowerment. She has also advanced Cittaslow initiatives in Dalin, Zhutian, Chishang, Dongyin, and Majia, applying Cittaslow values to local governance, cultural heritage,

ecological conservation, sustainable tourism, community health, and quality of life. Internationally, she represented Taiwan at the 2023 Cittaslow International Assembly in Parma and the Yunlin Slow Food Community at Terra Madre 2024 in Turin, where she shared Taiwan's community-based practices and strengthened international partnerships. Her books, Slow Food and Slow Life Kitchen (2022) and Cittaslow Taiwan Guide (2025), further translate her field experience into accessible resources for education and public engagement. Through this local-to-global approach, Professor Yeh demonstrates how USR can create lasting social value and evolve into ESG-oriented action grounded in shared governance, environmental responsibility, community inclusion, and global co-creation. She has received multiple awards recognizing her contributions to teaching, research, student mentoring, and community service.

Speaking Topic(s)

From Slow Food to Cittaslow: Co-Creating Healthy and Sustainable Communities from USR to ESG

Session Abstract

This presentation will explore how Nanhua University has translated the Slow Food principles of "Good, Clean, and Fair" into long-term University Social Responsibility initiatives that promote community health, environmental stewardship, cultural preservation, and local resilience. It will highlight the Slow Food Community–Yunlin Earth Market as a living platform connecting small-scale farmers, educators, students, consumers, local governments, and social enterprises. The presentation will then explain how these food-based practices have expanded into Cittaslow development and can be institutionalized through an ESG framework. Finally, it will share lessons from international partnerships and propose a local-to-global co-creation model for building healthier, more inclusive, and sustainable communities.



Moderator

Name Sodio C. N. Hsu
Job Title Professor/Dean
Department Department of Medicinal and Applied Chemistry/ College of Life Sciences
Organization Kaohsiung Show Chwan Memorial Hospital

A brief biographical sketch

Professor Sodio C. N. Hsu (許智能) currently serves as Dean of the College of Life Sciences at Kaohsiung Medical University (KMU) and is a Professor in the Department of Medicinal and Applied Chemistry. He has been a faculty member at KMU since 2002 and was promoted to full professor in 2013. In addition to his academic leadership, he has held several important administrative positions at KMU, including Vice President for General Affairs, Director of Environmental Protection and Occupational Safety and Health, and Chair of the Department of Medicinal and Applied Chemistry.

Professor Hsu received his B.S. in Chemistry from Tamkang University (1992) and both his M.S. (1994) and Ph.D. (1998) in Chemistry from National Sun Yat-sen University, Taiwan. Following the completion of his doctoral studies, he conducted postdoctoral research at the Institute of Chemistry, Academia Sinica, and subsequently at the University of Illinois at Urbana-Champaign, USA, where he further developed his expertise in inorganic and organometallic chemistry.

His research focuses on bioinorganic chemistry, coordination chemistry, organometallic chemistry, and supramolecular chemistry. Professor Hsu's laboratory is particularly interested in the design and synthesis of bioinspired metal complexes, metalloprotein active-site models, nanoscale metallo-supramolecular architectures, molecular recognition systems, and transition-metal organometallic compounds. His work seeks to elucidate the role of metals in biological systems and to develop novel functional materials and therapeutic agents with applications in medicine and catalysis.

Over the course of his career, Professor Hsu has established an internationally recognized research program, publishing extensively in leading chemistry journals and mentoring numerous graduate students and young researchers. His representative achievements include significant contributions to the understanding of metal-mediated biological processes, development of bioinspired coordination complexes, advancement of supramolecular molecular-recognition systems, and exploration of metal-based anticancer and nitric oxide-releasing agents. His scholarly impact is reflected in a substantial publication record and an h-index exceeding 20.

Professor Hsu has received numerous honors, including the Taiwan Biological Inorganic Chemical Society (TBICS) Young Investigator Award (2019), KMU Excellent Paper Awards, Research Project Excellence Awards, and recognition from Taiwan's Ministry of Science and Technology for outstanding research performance. Through his research, teaching, and academic leadership, he has made significant contributions to the advancement of chemical and life sciences in Taiwan and internationally.



Speaker

Name Shih-Fen Hsiao
Job Title Assistant Professor
Department Depart of Physical Therapy
Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Shih-Fen Hsiao is an Assistant Professor in the Department of Physical Therapy, College of Health Sciences, and the Master's Program of Long-Term Care in Aging at the College of Nursing, Kaohsiung Medical University (KMU). She also serves as Vice President and Executive Director of the Board of Directors of the Taiwan Physical Therapy Association (TPTA) since 2020.

Dr Hsiao earned her BSc in Physical Therapy from Kaohsiung Medical College and a PhD in Physiotherapy from King's College London, UK. Her professional experience includes academic appointments in Taiwan and the UK, as well as clinical practice as a Senior Neurological Physical Therapist at the KMU affiliated Hospital. Dr. Hsiao's research focuses on neurological rehabilitation, musculoskeletal function, aging, dementia and frailty, sarcopenia, and long-term care. Her recent research focuses on the effect of chronic kidney disease and dialysis on muscles, and advocates regular screening of handgrip strength as an indicator of sarcopenia.

For more than 25 years, Dr Hsiao have worked for TPTS in the international related affairs or task forces, and served as secretary general or committee members of international organisations. Her representative achievements include coordinating international projects with World Physiotherapy, Rotary International, Vietnamese PT Association and TPTA to level up the physical therapy quality in Vietnam (RI Vocational Team Training Project - GG2125902). This collaboration fostered further engagement of iUSR Project of Namahsia of KMU in Vietnam, and the support is still ongoing for improving the ability of PT in northern Vietnam to meet the goal of Rehabilitation 2030.

Speaking Topic(s)

Teamed up with KMU iUSR, Move Together for Rehabilitation 2030

Session Abstract

Strengthen and expand the rehabilitation workforce through training, planning, and sustainable support, is a key to achieve the goal of Rehabilitation 2030. In Vietnam, an important partner of Taiwan's New Southbound Policy, primarily relies on two-year junior college programs for physical therapy training and very low workforce, highlighting an urgent need to elevate the standard of professional physical therapy education. The KMU iUSR Project incorporate online and face-to-face teaching methods with various resources to support the needs in northern Vietnam.



Moderator

Name Pamela Berilyn So
Job Title Assistant Professor
Department Department of Fragrance and Cosmetic Science
Organization Kaohsiung Medical University

A brief biographical sketch

Pamela Berilyn So (蘇穎穎) is an Assistant Professor in the Department of Fragrance & Cosmetic Science at Kaohsiung Medical University, Taiwan, where she has served since 2023. Her work focuses on porous materials and porous material composites, particularly metal-organic frameworks (MOFs) and related materials for drug delivery and volatile organic compound adsorption.

She earned her Ph.D. in Chemistry from Chung Yuan Christian University in 2021 under a Taiwan Ministry of Science and Technology scholarship. Her dissertation examined the sustainable synthesis of MOFs for drug delivery and acetic acid capture, as well as the transformation of amorphous to crystalline MOFs. She also holds an M.S. in Pharmacy and a B.S. in Pharmacy from the University of Santo Tomas, both earned magna cum laude. She is also a licensed pharmacist in the Philippines.

Before joining KMU, Dr. So was a Postdoctoral Research Fellow in the Department of Chemistry at National Taiwan Normal University from 2021 to 2023. She also taught pharmacy courses at the University of Santo Tomas and Centro Escolar University in the Philippines.

Her research interests include biocompatible MOFs for drug delivery, VOC adsorption materials, and functional porous composites. Among her representative achievements are multiple Best Poster awards in Taiwan, a St. Antoninus Best Published Paper Award, several research grants from the National Science and Technology Council and Kaohsiung Medical University, and publications in journals such as Microporous and Mesoporous Materials, Materials Advances, and Chemistry – A European Journal.



Speaker

Name Mae A. Responte
Job Title Associate Professor
Department Department of Biological Sciences and Environmental Studies
Organization UP Mindanao

A brief biographical sketch

Associate Professor Mae A. Responte completed her PhD in the Graduate Institute of Medicine, Kaohsiung Medical University Taiwan in June 2025. She has a broad range of scholarly interests, which include in ecology, evolution, phylogeography, arachnology and insects.

Assoc. Prof. Responte has been a recipient of multiple scholarships and research grants both in the Philippines and Taiwan. She authored various research studies in the areas of arachnology, population genetics and evolution. Moreover, she has shared her research findings in different conferences and fora, like the European Society for Evolutionary Biology (ESEB) conference held in Czech Republic. She also achieved several awards for oral and poster presentation which include the Young Systematic Biologist Forum (Graduate Category) at the Association of Systematics Biologists of the Philippines 39th Symposium and Annual Meeting. Currently, her research is focused on the phylogeography of spiders, insects as well as the population dynamics of mosquitoes.

Speaking Topic(s)

A Sense of Beelongingness: Research and cultural enlightenment from Namasia, Taiwan to the Philippines

Session Abstract

The Namasiology course in KMU has been an eye-opening experience for me, particularly in learning about Indigenous peoples' cultures, traditions, and knowledge systems. The collaborative efforts between Aboriginal communities in Namasia and researchers from KMU have inspired me to pursue similar initiatives in the Philippines. In my own capacity, I started to lead projects in the Philippines that foster environmental protection, promote sustainability, and collaborate with Indigenous Peoples in addressing environmental challenges.



Speaker

Name Reginald G. Ugaddan
Job Title Associate Professor and Director
Department Center for Local and Regional Governance
Organization University of the Philippines Diliman

A brief biographical sketch

Reginald G. Ugaddan, Ph.D., is an Associate Professor at the University of the Philippines – National College of Public Administration and Governance (UP NCPAG), the country's premier institution for studying and practicing public administration. He currently serves as the Director of the Center for Local and Regional Governance (CLRG) and the Program Director of the Governance Futures Lab (GFL), where he leads nationwide research, policy advisory, and capacity-building initiatives that support institutional reform, local governance development, and futures-oriented strategic planning. A specialist in public management, decentralization, disaster governance, and futures thinking, Dr. Ugaddan integrates evidence-based analysis with cutting-edge foresight methodologies to help organizations navigate uncertainty, emerging challenges, and complex governance environments. His work focuses on strengthening institutional capabilities, enhancing public sector leadership, and introducing innovative approaches to policy design, performance management, and long-term planning. He earned his master's and doctoral degrees in Public Administration from the Graduate School of Governance at Sungkyunkwan University (SKKU) in South Korea, specializing in comparative governance and public sector reform. His scholarly contributions and applied research span governance innovation, anticipatory governance, digital transformation, local autonomy, disaster risk management, and strategic public sector leadership. With an extensive portfolio in research, teaching, and extension, Dr. Ugaddan continues to support Philippine public institutions in building future-ready governance systems and cultivating capacities that respond effectively to the fast-changing demands of the 21st century.

Speaking Topic(s)

Who Sustains the Partnership? What Local Governments Can Do to Anchor University Social Responsibility in Community Health

Session Abstract

This presentation examines how hospitals can connect clinical, imaging, pathology, and multi-omics data to advance precision diagnostics and guide the development of individualized therapeutics. It discusses multimodal AI and emerging virtual-cell, digital-twin, and world-model approaches as tools for linking disease characterization to therapeutic hypotheses that require experimental and clinical validation. Examples include personalized cancer vaccines and cell therapies, alongside our research on AI-assisted peptide and minibinder design. The presentation proposes a hospital-centered development framework that links patient data and specimens with iterative design, experimental validation, manufacturing partnerships, and clinical follow-up, with attention to data governance and the distinction between research tools and clinical applications.

October 16 B2 Conference Room 16:50-18:30

Frontier Areas in Advanced Chemistry

C2-生命科學院

Time	Speaker	Moderator
16:50–17:30	Sunwoo Lee	Wei-Yu Lin 林韋佑
17:30–18:00	Winai leawsuwan	Chien-Hung Li 李建宏
18:00–18:30	Chia-Hsiang Chen 陳嘉祥	Wei-Yu Lin 林韋佑



Speaker

Name Sunwoo Lee
Job Title Professor
Department Chemistry
Organization Chonnam National University

A brief biographical sketch

POSTECH (Ph.D, 1999, Prof. Jaiwook Park). Yale University (Postdoc, 1999-2001, Prof. John F. Hartwig) LG Chem (Senior Researcher, 2001-2004) Chonnam National University (Assistant & Associate & Full Professor, 2004-present), President, Korean Society of Organic Synthesis (2026-present)
[Field of Research] Cross coupling reaction, Transamidation. Photo-electrochemical reaction, Synthesis of amides

Speaking Topic(s)

Reappraising Dichloromethane: An Unconventional Coupling Reagent for Direct Amide Bond Construction

Session Abstract

Amide bonds are indispensable structural motifs in pharmaceuticals, agrochemicals, and functional materials, yet their direct formation from carboxylic acids and amines generally requires stoichiometric activating agents. This presentation will highlight an unconventional synthetic strategy in which dichloromethane, traditionally regarded as an inert solvent, functions as a coupling reagent to activate carboxylic acids and promote direct amide bond formation. Mechanistic investigations reveal that carboxylate substitution on dichloromethane generates reactive chloromethyl ester and methylene diester intermediates, which subsequently transfer acyl groups to amine nucleophiles. The reaction scope, mechanistic features, and synthetic significance of this methodology will be discussed, together with its broader implications for uncovering latent reactivity in commonly used organic solvents.



Moderator

Name Wei-Yu Lin
Job Title Chair/Professor
Department Department of Medicinal and Applied Chemistry
Organization Kaohsiung Medical University

A brief biographical sketch

Wei-Yu Lin, Ph.D., is Professor and Chairman of the Department of Medicinal and Applied Chemistry at Kaohsiung Medical University (KMU), Taiwan. He received his B.S. degree in Chemistry from National Cheng Kung University (1998) and his M.S. (2001) and Ph.D. (2006) degrees in Chemistry from National Taiwan University.

From 2006 to 2011, he conducted research in the Department of Molecular and Medical Pharmacology at UCLA, USA, first as a Postdoctoral Fellow and later as a Staff Research Associate. He joined KMU as an Assistant Professor in 2012, was promoted to Associate Professor in 2019 and Professor in 2022, and has served as Department Chairman since 2024.

His research focuses on **continuous-flow chemistry, green and sustainable organic synthesis, photochemistry, mechanochemistry, heterocyclic synthesis, and selective C–N bond activation.** His group develops innovative synthetic methodologies using flow microreactors and other enabling technologies to achieve efficient and selective chemical transformations. His earlier work at UCLA also involved bioorthogonal chemistry and PET imaging.

His honors include the **Everlight Chemical Green Chemistry Award (2023), Asian Core Program Lectureship Awards** in Japan (2023) and Korea (2024), and KMU's **Outstanding Research Award (2016–2026).**



Speaker

Name Winai leawsuwan
Job Title Dr.
Department Laboratory of Medicinal Chemistry
Organization Chulabhorn Research Institute

A brief biographical sketch

Dr. Winai leawsuwan earned his B.Sc. in Chemistry from Silpakorn University, Thailand, in 2001, followed by an M.Sc. in Organic Chemistry from Mahidol University, Thailand, in 2004 under the supervision of Prof. Dr. Manat Pohmakotr. He then pursued his doctoral studies at Goethe University Frankfurt am Main, Germany, obtaining his Dr. phil. nat. in Organic Chemistry in 2009 under the guidance of Prof. Dr. Magnus Rueping. From 2009 to 2010, he was a postdoctoral fellow at the Université catholique de Louvain (Louvain-la-Neuve, Belgium), working with Prof. Dr. István E. Markó. Since 2011, he has served as a researcher at the Chulabhorn Research Institute, Thailand, focusing on advancing organic chemistry research and alkaloid synthesis methodologies.

Speaking Topic(s)


Novel Synthetic Approaches toward the Assembly of Tetrahydroisoquinoline-Fused Heterocycles and Their Synthetic Applications

Session Abstract

The tetrahydroisoquinoline (THIQ) scaffold can be classified as a privileged structure that crosses over into multiple therapeutic indications. As a core framework frequently found in numerous clinically approved drugs and bioactive natural products, this scaffold plays a pivotal role in medicinal chemistry. Some of these THIQ derivatives exhibit important biological activities, including anticancer and anti-inflammatory activities; therefore, developing efficient strategies to access the THIQ core remains a highly desirable synthetic target for pharmaceutical research.

Our research program focuses on the synthesis of THIQ fused with other heterocycles, such as oxazol-2(3*H*)-one and hydantoin moieties, which may enhance or potentially lead to new biological activities. The synthesis of THIQ-fused oxazol-2(3*H*)-ones (THIQ-O) could be achieved either via hypervalent iodine (III)-mediated domino cyclization of *N*-Boc protected ynamides or *via* cyclization of *exo*-cyclic *ene*-carbamates under acidic conditions to provide the corresponding THIQ-O products in good yields. These valuable THIQ-O products serve as precursor for the preparation of phthalideisoquinoline natural products, such as Corlumine. Moreover, an efficient synthesis of the novel THIQ-hydantoin (THIQ-H) derivatives from the simple 3,4-dihydroisoquinoline adducts and commercially available iso(thio/seleno)cyanates via a one-pot

sequential aerobic oxidation/1,3-dipolar cycloaddition/α-iminol rearrangement has been developed. This synthetic approach provided the corresponding THIQ-H products in high yields while demonstrating good functional group tolerance and compatibility, thereby enabling future structure–activity relationships (SARs) studies for further biological investigations. Interestingly, in some cases, the novel THIQ-fused hydantoin-oxazolidine (THIQ-H-O) derivatives could also be obtained in high yields. The selectivity between the formation of THIQ-H and THIQ-H-O derivatives is governed by the electronic properties of the substituents on the isocyanate, isothiocyanate, or isoselenocyanate reactants.






Moderator Information

Name Chien-Hung Li
Job Title Assistant Professor
Department Department of Medicinal and Applied Chemistry
Organization Kaohsiung Medical University

A brief biographical sketch

Chien-Hung (Henry) Li was born in Taipei, Taiwan. He earned a B.S. degree in Chemistry from National Dong Hwa University in 2008. After completing one year of military service, he joined Prof. T. Randall Lee's group as a Ph.D. student at the University of Houston and received his Ph.D. in 2015. His doctoral research focused on the synthesis, functionalization, and photonic applications of plasmonic nanoshells. In 2016, he moved to Canada and joined Prof. Cathleen M. Crudden's group as a postdoctoral fellow at Queen’s University, where his research focused on the functionalization of gold surfaces and nanoparticles with N-heterocyclic carbenes (NHCs).

Currently, he is an Assistant Professor in the Department of Medicinal and Applied Chemistry. He recently received a university-wide Excellence in Teaching award. His research group focuses on the development of NHC-modified materials, ranging from fluorescent molecules and metal complexes to nanomaterials and surfaces. His group aims to leverage the versatility of NHCs to enhance material properties, introduce new functionalities, and expand their potential for practical applications.



Speaker

Name Chia-Hsiang Chen
Job Title Associate Professor
Department Department of Medicinal and Applied Chemistry
Organization Kaohsiung Medical University

A brief biographical sketch

Chia-Hsiang Chen received his Ph.D. degree from National Sun Yat-Sen University in 2012 under the supervision of Professor Wen-Yann Yeh. He then worked as a postdoctoral fellow with Professor Luis Echegoyen at the University of Texas at El Paso from 2013 to 2015 and with Dr. Alexey A. Popov at the Leibniz Institute for Solid State and Materials Research from 2015 to 2018. In 2018, he joined Kaohsiung Medical University as an assistant professor and was promoted to associate professor in 2024. His current research interests include the coordination chemistry of nanographenes, fullerenes, and endohedral metallofullerenes.

Speaking Topic(s)

Rhenium Coordination-Induced Conformational Modulation in Nitrogen-Doped Nanographene

Session Abstract

The conformation of nanographene plays a crucial role in determining its electronic, optical, and mechanical properties, making structural analysis essential for advanced material applications. Here, we investigated the effects of metal coordination on nanographene conformation using a series of nitrogen-doped nanographenes (**2**, **3**, and **4**) and their corresponding rhenium complexes (**2Re**, **3Re**, and **4Re**), which differ by one C–C bond. Spectroscopic and comparative X-ray crystallographic analyses revealed that Re coordination induces distinct conformational changes in the nanographene frameworks. Moreover, the nanographene–Re complexes exhibited promising HER activity, generating hydrogen at a low overpotential of 133 mV in the presence of 1.5 mM acetic acid.

October 16 B1 Study room 14:50-18:30

AI Developments for Healthcare and Education

D1/D2-人工智慧生醫研究院

Time	Speaker	Moderator
14:50–15:15	Chih-Hung Chang 張志宏	Henry Horng-Shing Lu 盧鴻興
15:15–15:40	Kim Fang Yuh Chiang	Henry Horng-Shing Lu 盧鴻興
15:40–16:05	Kevin Kai Chih Chang	I-Chen Wu 吳宜珍
16:05–16:30	Ming Ju Tsai 蔡明儒	I-Chen Wu 吳宜珍
16:50–17:15	Besa H. Bauta	Fan-Hao Chou 周汎澔
17:15–17:40	Keng Yen Huang 黃耿妍	Fan-Hao Chou 周汎澔
17:40–18:05	Janet Nakigudde	Henry Horng-Shing Lu 盧鴻興
18:05–18:30	I-Chin Huang 黃怡靜	Henry Horng-Shing Lu 盧鴻興



Speaker

Name Chih-Hung Chang
Job Title Washington University in St. Louis
Department
Organization

A brief biographical sketch

Dr. Chih-Hung Chang is Professor of Occupational Therapy, Medicine, Orthopedic Surgery, and Public Health at Washington University in St. Louis. Before joining Washington University, he was Professor of Physical Medicine and Rehabilitation and Professor of Physical Therapy and Human Movement Sciences at Northwestern University Feinberg School of Medicine. He also served as Director of Clinical Outcomes and Infometrics at the Shirley Ryan AbilityLab, which was then known as the Rehabilitation Institute of Chicago.

Dr. Chang is a psychometrician and health services researcher with training in research methodology and quantitative psychology. His research integrates advanced methodology and technology to improve clinical outcomes assessment, health professions education, and care delivery across the continuum of care. He has extensive expertise in patient-centered outcomes measurement, item response theory (IRT), computerized adaptive testing (CAT), and advanced quantitative methods for precision assessment.

Dr. Chang developed the field of **Clinical Infometrics**, which synthesizes measurement science, data science analytics, evidence-based medicine, and health informatics to support real-time clinical decision-making and improve symptom and disease management over time.

More recently, Dr. Chang has extended this work to medical and health professions education, applying psychometric, data science, and artificial intelligence methods to learner assessment, competency-based education, clinical reasoning evaluation, and precision education. This work aims to support individualized feedback, evidence-based educational decision-making, and continuous improvement in healthcare professional preparation.

Dr. Chang earned his bachelor's degree in psychology from National Chengchi University in Taipei, Taiwan, in 1987 and his PhD from the Committee on Research Methodology and Quantitative Psychology in the Department of Psychology at the University of Chicago in 1995. He has authored or co-authored more than 100 journal articles and book chapters and served as Co-Editor-in-Chief of the *Journal of Patient-Reported Outcomes*.

Speaking Topic(s)

From Data to Decisions: Clinical Infometrics in the Age of Artificial Intelligence

Session Abstract

Healthcare is producing more data than ever before—from electronic health records and patient-reported outcomes to imaging, wearable sensors, digital behavior, and natural language. Having more data, however, does not necessarily result in better care, stronger evidence, or more effective learning. The more important question is whether these data can be transformed into information that is meaningful, trustworthy, and useful for decision-making.

This presentation introduces Clinical Infometrics as a measurement science that brings together measurement, health informatics, and artificial intelligence (AI)/data science. Its focus is not simply on collecting or analyzing data, but on the full pathway from real-world observations to information and, ultimately, decisions. Measurement provides the foundation by asking what should be measured and how well. Informatics makes it possible to collect, integrate, and represent information from different sources. AI can then help identify patterns, make predictions, and support personalization. The usefulness of AI therefore depends in large part on the quality of the measurement beneath it.

The presentation considers this framework across clinical care, research, and education. In clinical care, multimodal patient information can inform assessment, risk stratification, treatment selection, monitoring, and shared decision-making. In research, combining sound measurement with real-world data can improve phenotyping, predictive modeling, pragmatic studies, and evidence for implementation. In education, learner data can help identify strengths and gaps, guide adaptive learning, provide timely feedback, and support competency-based progression.

These activities are not separate. Together, they can contribute to a learning health system in which care generates data, research turns those data into knowledge, education prepares people to use that knowledge, and subsequent outcomes inform the next cycle of measurement and learning. AI can strengthen this cycle, but it does not replace human judgment, context, or values.

The central argument is straightforward: **better AI begins with better measurement**. Clinical Infometrics provides a framework for turning increasingly complex data into information that clinicians, researchers, educators, and learners can understand, trust, and use.

Keywords: Clinical Infometrics; Artificial Intelligence; Measurement Science; Learning Health Systems; Precision Healthcare



Moderator

Name Henry Horng-Shing Lu
Job Title Dean
Department Biomedical Artificial Intelligence Academy
Organization Kaohsiung Medical University

A brief biographical sketch

Henry Horng-Shing Lu is the Dean of Biomedical Artificial Intelligence Academy, Kaohsiung Medical University(KMU), the Director of Department of Artificial Intelligence in Medicine, KMU, the Deputy Superintendent in Kaohsiung Medical University Chung-Ho Memorial Hospital(KMUH), the Distinguished Professor in the Institute of Statistics, Institute of Data Science and Engineering, Institute of Artificial Intelligence Innovation at National Yang Ming Chiao Tung University (NYCU) that has been formed by the merge of National Yang Ming University (NYMU) and National Chiao Tung University (NCTU), Taiwan. He is also the Adjunct Professor in the Department of Statistics and Data Science, Cornell University, Ithaca, NY.

He is the elected member of International Statistical Institute (ISI), Principal Fellow of Higher Education Academy (PFHEA) and IEEE Senior Member. He has received the Outstanding Research Award from the Ministry of Science and Technology, Taiwan. He has served as the Dean for College of Science and Vice President of Academic Affairs in National Chiao Tung University.

He received his Ph.D. degree in Statistics from Cornell University in 1994, and his B.S. degree in Electrical Engineering from National Taiwan University in 1986.

His research interests include statistics, image science, bioinformatics, data science, machine learning and artificial intelligence. He analyzes different types of data by developing statistical methodologies for machine learning with the power of statistical inference and computation algorithms. The research results have been published in a wide spectrum of journals and conferences.

He co-edited the Handbook of Statistical Bioinformatics and Handbook of Big Data Analytics published by Springer in 2011, 2022 and 2018. More details are on his webpage (https://misg.stat.nycu.edu.tw/).



Speaker

Name Kim Fang Yuh Chiang
Job Title Clinical Associate Professor of Medicine
Department Division of Primary Care and Population Health
Department of Medicine
Organization Stanford University School of Medicine

A brief biographical sketch

Dr. Kim F. Chiang is a Clinical Associate Professor in the Division of Primary Care and Population Health (PCPH) at Stanford University School of Medicine. She serves as Medical Director of the Stanford Internal Medicine Clinic, where she oversees clinical operations for a high-volume academic primary care practice. Dr. Chiang is also Core Faculty for the Stanford Internal Medicine Residency Program and Director of Graduate Medical Education for the Division of PCPH.

In these roles, she serves on multiple task forces and working groups that help steer the implementation of AI tools into frontline clinical practice, and shapes how both resident and faculty physicians are trained to use AI responsibly and effectively in clinical care. Dr. Chiang has a particular interest in integrating emerging tools and standards into the residency curriculum and faculty development efforts.


A graduate of Northwestern University's Honors Program in Medical Education (BS, MD) and Boston University (Internal Medicine residency), Dr. Chiang is board-certified in Internal Medicine and previously served as President of the Northern California Taiwanese Medical Association (2022–2023).

Speaking Topic(s)

Artificial Intelligence as a Cognitive Partner in Clinical Practice

Session Abstract

Artificial intelligence (AI) is rapidly transforming clinical practice, offering opportunities to enhance decision-making, streamline workflows, and improve patient care. This session provides a practical overview of AI tools used in clinical medicine, with a focus on real-world applications at Stanford Internal Medicine and how AI can support documentation, differential diagnosis, and personalized care while reducing administrative burden. Participants will see AI described as a cognitive partner that augments, rather than replaces, clinical judgment, while also addressing limitations and risks such as hallucinations, bias, data privacy, and over-reliance, with emphasis on critical appraisal of AI outputs. We will discuss implementation considerations in Taiwan, including leveraging national health data infrastructure, language-specific AI tools, and regulatory aspects, and attendees will leave with a practical framework and actionable strategies to enhance efficiency and patient care.



Speaker

Name Kevin Kai Chih Chang
Job Title Clinical Assistant Professor
Department Medicine
Organization Stanford University School of Medicine

A brief biographical sketch

Dr. Kevin Chang is a clinical assistant professor of medicine in the Division of Primary Care and Population Health at Stanford University School of Medicine. He received his medical education at New York University School of Medicine and completed his Internal Medicine internship and residency at Stanford University School of Medicine. He is currently a core faculty member for the Stanford Internal Medicine residency program as well as the co-medical director for the Stanford Internal Medicine East clinic – the primary continuity clinic training site for internal medicine resident physicians. His academic interests include graduate medical education, care delivery models, and Asian health.

Speaking Topic(s)

Artificial intelligence tools in healthcare, medical education

Session Abstract

In this session, we will explore how artificial intelligence tools can support clinical care and enhance medical education. Through concrete examples, participants will gain a practical framework on integrating artificial intelligence tools while understanding key limitations and potential pitfalls.



Moderator

Name I-Chen Wu
Job Title Associate Dean for Research
Department College of Medicine
Organization Kaohsiung Medical University

A brief biographical sketch

I-Chen Wu, MD, PhD, is a Professor and Associate Dean of the College of Medicine at Kaohsiung Medical University, and an Attending Physician in the Division of Gastroenterology at Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. She serves as a Supervisor on the Councils of the Digestive Endoscopy Society of Taiwan, the Taiwan Gastric Cancer Society, and the Taiwan Esophageal Society. Her research focuses on translational and clinical studies of upper gastrointestinal cancers, particularly esophageal and gastric malignancies. Dr. Wu's work emphasizes novel endoscopic techniques, biomarker discovery, and optimization of immunotherapy outcomes. She actively participates in many multicenter clinical trials and collaborates with international research consortia to advance cancer treatment and improve patient care.



Speaker

Name Ming Ju Tsai
Job Title Director
Department Medical AI Innovation and Application Center, Kaohsiung Medical University Chung-Ho Memorial Hospital
Organization Ajou University School of Medicine

A brief biographical sketch

Prof. Ming-Ju Tsai is a pulmonologist and intensivist, Professor of Medicine, and Associate Dean of College of Medicine in Kaohsiung Medical University. He also serves in leadership roles at Kaohsiung Medical University Hospital, including medical education and medical AI innovation an application. His work focuses on AI-driven critical care, clinical decision support, digital health transformation, and responsible AI governance. He has led the development and implementation of Smart ICU systems and clinical AI applications, with particular interests in translating predictive models into real-world clinical workflows, improving patient safety, and integrating AI literacy into medical education.

Session Abstract

Artificial intelligence (AI) is being rapidly adopted in hospitals, but local validation, post-deployment monitoring, and clear accountability often lag behind. Emerging frameworks, including Taiwan's AI Basic Act, the national guideline on generative AI in healthcare, and international accreditation guidance, converge on shared requirements: clear ownership, risk-based review, transparency, continuous monitoring, and education. At Kaohsiung Medical University Hospital, these principles have been translated into a hospital-wide governance model comprising a multidisciplinary committee, risk-tiered review, transparency indicators, and lifecycle monitoring with formal decommissioning, applied to in-house tools that reduce clinical workload. Governance of generative AI and AI agents, together with AI literacy for medical students, remains an evolving challenge for teaching hospitals.



Speaker

Name **Besa H. Bauta**

Job Title

Department

Organization

A brief biographical sketch

Dr. Bauta is currently the Chief Executive Officer of Rosetta Labs, a novel DataOps startup focused on fundamentally reshaping the modern enterprise data operations by empowering engineering teams to capture, translate, and automate database structures across complex multi-cloud and on-premises estates. She is also an Adjunct Assistant Professor at New York University - Silver and has taught both public health and social work at graduate and doctoral levels. In addition to her academic background, Dr. Bauta is an experienced technology executive that has actualized large-scale digital transformation projects and brought in novel technology solutions that enabled effective decision-making in healthcare, private and government sectors. She can bring innovative technologies to address business problems and is able to communicate complex technical concepts in a clear and concise manner, including engaging stakeholders across various business sectors to map out issues and provide technical and operational solutions.

In her technology roles she served as the Chief Information Officer (CIO) as well as Chief Information Security Officer (CISO) at the Jewish Boards Information Technology Services (ITS) Division, where she focused on enterprise-wide infrastructure modernization projects, such as migration to cloud computing, enhancing cybersecurity, and implementing emerging technologies with the goal increasing efficiency, reducing costs, and enhancing client experiences and outcomes. She managed technology assets, including budgeting and vendor selection and management for a 250-million-dollar behavioral health organization. During her tenure there she created a Health Informatics division and digitized treatment by implementing Telehealth and remote support technologies including piloting and testing Ambient AI and scribe notetaking with Microsoft and Suki.AI, as well as recording and analyzing provider-client interactions. A key project was building out an AI-Based contact center and communication system with telecommunication partners T-Mobile and Dialpad, with the goal of providing faster response time for crisis calls and therapy appointments. This approach was recognized as an Innovative Employee Enablement technological intervention and won 2nd place for T-Mobile for Business 2025 Innovate Awards.

Prior to her CIO position, Dr. Bauta was the Chief Data and Analytics Officer/CDAO for the Texas Department of Family and Protective Services, Office of Data and System Improvement (ODSI), where she managed analytics, data science, and digital

transformation initiatives, and data assets for a 2.6-billion-dollar state division. In August 2022 the ODSI team (100 plus professionals) under her guidance won the TASSCC Project Excellence Award for Data Sharing by implementing data visualization and analytic tools to support state decision making and integrating over 24 thousand data streams in less than 6 months. In addition, her team of IT and Data professionals developed a Machine Learning/ML model to assess potential operational and staffing risks. The algorithm allowed the state division to identify organizations at risk and intervene early by scoring agencies on multiple parameters. Dr. Bauta also served as a primary liaison between DFPS and other state agencies and was the State DFPS representative to the Texas Department of Information Resources (DIR) Data Management Advisory (DMAC) committee. Her work led to development of Master Data Management (MDM) and Governance Processes for Texas State Data and provide citizens with access to DFPS monthly data on key measures in order to improve transparency and allow stakeholders and the public access to trends and data across many years via the DFPS Data Book.

Her expertise in data/technology also includes experience as a Chief Data Officer (CDO), Chief Compliance Officer (CPO), and Information Privacy Officer (IPO) at MercyFirst, an organization that provides health and mental health services for clients in NYC and Long Island. As the divisional lead for the Research, Evaluation, Analytics, and Compliance for Health (REACH) at MercyFirst, she oversaw data integration technology, infrastructure development, research, evaluation, and analytics. At MercyFirst she developed an analytics team (REACH) that provided daily operational support to staff and key data and metrics with the goal of reducing compliance risks. Dr. Bauta's research experience includes being the Research Director for United States Agency for International Development (USAID) community-based education project in Afghanistan and the Senior Director of Research and Evaluation at the Center for Evidence-Based Implementation and Research (CEBIR) at Catholic Guardian Services working on R01 and other federally funded (AHRQ and SAMHSA) research initiatives.

Dr. Bauta also has experience as a consultant and startup advisor for new and emerging ventures in Technology, Biomedical, Pharma, and Healthcare. In her role as a consultant, she served as the Chief Analytics Officer (CAO) for Precision Human Services where she provided consultation support to healthcare organizations in their digital transformation initiatives. This included developing practical roadmaps to implement and scale technologies at large. As an entrepreneur and startup founder, Dr. Bauta was one of the founders of the Social Impact AI Lab (SIAIL), whose goal was to support the digital transformation of the human service sector. SIAIL won the national Social Determinants of Health Innovation Challenge sponsored by the Robert Wood Jonson Foundation in 2020 and was a finalist in the NYU Berkley Center for Entrepreneurship 2021 challenge. This

venture led to the founding of Augintel which provides NLP based insights to the behavioral health sector. She continued post-competition as a coach and sponsor to graduate and doctoral students at NYU Stern for the past 5 years and under her guidance and mentorship the three teams that she coached won the 300K innovation challenge in healthcare including recently CaroRhythm (2024) (non-invasive medical device that provides point-of-care carotid artery monitoring for strokes) and Vitalis Regenerative Materials (2025) (extended release growth factor to support faster orthopedic wound healing).

She holds a Ph.D. from NYU with training in Health Services and Implementation Science, an MPH in Health Promotion and Disease Prevention from NYU College of Global Public Health, and an MSW in Clinical Social Work with Evidence Based Training from NYU Silver School of Social Work. Dr. Bauta has Psychoanalytic training from the Institute of Psychoanalytic Education, NYU Langone School of Medicine, Division of Psychiatry, and a BA from Rutgers University with training in Evolutionary Anthropology, and studied Biomedical Engineering at Rutgers University School of Engineering. She served as the Associate Editor for the journal of Administration and Policy in Mental Health and Mental Health Services Research, for AI in Mental Health from 2019-2022, Telehealth and Medicine Today, 2022-2025. She is the current Editorial Board Member of CDO Magazine, Business of Data Global Advisory Board judge, and one of the founders and members of World Leaders in Data and AI.

Dr. Bauta was selected as an Ambassador for the AI Time Journal (8/22) and was invited to present on October 2022 at the University of Florida, College of Medicine, Department of Psychiatry's, Bioethics Week on ethical considerations of implementing AI applications in healthcare. She also served as a mentor for the 2024 Biomedical Data Science Innovation Lab (BDSIL) an NIH funded project at the University of Virginia School of Data Science, that was a hybrid academic program held in June 2024 in San Diego, California, focusing on Building Partnerships for Generative AI Training in Biomedical and Clinical Research, and involved 31 junior faculty and researchers alongside 5 senior investigators as mentors. She provided the keynote for the Alliance for Data Science and AI at the 2023 ADSA Annual Meeting held at the University of Texas San Antonio – College of AI, Cyber and Computing. She co-presented with NYU colleagues at Kaohsiung Medical University in Taiwan on September 11th, 2025, on "Harnessing AI for Worldwide Health Solutions: Case examples for Behavioral Health and Mental Health" as part of a conference focusing on "AI and mental health: interdisciplinary perspectives and integrated solutions- from behavior, neuroscience, gender, and education perspectives." Dr. Bauta was invited to provide a guest lecture at the University of Oklahoma – Anne and Henry Zarrow School of Social Work (December 2025), on the topic "The Next Frontier of AI-Driven Client/Customer Experience" and how AI-based technologies will augment health and mental health

provision. And was accepted to the prestigious Summer Institute in Computational Social Science at Florida Atlantic University (SICSS-FAU 2026) to intensive training on AI, ML, data science, and advanced computational methods (June 1–5, 2026).

She has provided thought leadership in the area of AI and healthcare and has been invited to present on various podcasts such as Women in Data – AI Across Spheres, Data Bytes Podcasts (2025), looking at the challenges and opportunities with augmented and AI technologies, Microsoft AI Skills on How to Build a Culture of Skilling: Making Space to Develop Your Nonprofit Team (Jun 2, 2025), Human Centered Design, Episode 056-How Design Helps Drive Adoption of Data Products Used for Social Work (January 12, 2021), The Business of Data Podcast – Spotify: Healthcare Data leaders Must Work Together in the World Post-COVID-19 (Aug 24, 2020).

Dr. Bauta has extensive expertise in information systems, data/analytics, healthcare services, translational research, evaluation, and global public health. She has participated in various global health initiatives and was asked to be part the Global Albanian Health Professionals COVID-19 Response Team by the Germin Foundation, to assist in building the public health infrastructure for Southeast Europe during the COVID pandemic. That work led to supporting local ministries of health in building infectious disease response policies and teams to address future epidemics. She has been recognized throughout her career for her information systems and technology work, such as the T-Mobile Innovate Awards 2025 [Oct 21, 2025] for Employee Enablement by utilizing AI technology to modernize call center functions for the Jewish Board. Was recognized as the City and State of NY, 2024 Above and Beyond Power List of Women who are leading innovation in the state. She was a Changemaker in the Field of Data Finalist (Oct. 2022), recognized as the Top 25 Women in AI: US Healthcare & Pharma (Sept. 2022), and was selected as a Global Data Power Woman and key influencer in shaping the landscape of business and pioneering the field of data and analytics by CDO magazine for three consecutive years (2022, 2021, and 2020). In addition, she was also selected as the top 100 Data and Analytics professionals in 2021, 2024 and 2025, and by DATAx as New York's top 21 CDOs, advancing the fields Data, Analytics, and AI.

Dr. Bauta is a published author who has written about technology, global health, non-communicable diseases, and improving health and mental health systems. She has worked both domestically and internationally on building information technology and advanced analytic systems, implementing health/mental health projects. Her current research focuses on optimizing processes to improve health outcomes, protection of patient health information, including ethical practices in implementing Artificial/Augmented Intelligence technologies in human services and healthcare and understanding Algorithmic biases, hallucinations and system errors.



Moderator

Name Fan-Hao Chou
Job Title Distinguished Professor & Vice President
Department School of Nursing
Organization Kaohsiung Medical University

A brief biographical sketch

Professor Fan-Hao Chou is currently a Distinguished Professor in the School of Nursing and Vice President of Kaohsiung Medical University. She has devoted her career to nursing education and research. She joined the School of Nursing at Kaohsiung Medical University in 1989 and received her Ph.D. in Nursing from the School of Nursing at the University of Texas at Austin in 2001. Her research and professional interests include nursing education, women's health, maternal nursing, artificial intelligence (AI), and social emotional learning (SEL). She has published extensively in international journals, demonstrating significant scholarly contributions to nursing education and research. Professor Chou has been actively involved in professional nursing organizations and higher education initiatives. She currently serves as Supervisor of the Taiwan Union of Nurse Association (TUNA), Supervisor of the Taiwan Association of Nursing Education (TANE), Supervisor of the Asian and Pacific Alliance for Nursing Education (APANE), and Executive Supervisor of the Kaohsiung Nurses Association. She also serves as Deputy Convener of the Medical and Health Sciences Division of the Ministry of Education's Teaching Practice Research Program, a Core Committee Member of the Ministry of Education's University Social Responsibility Promotion Center. Through these roles, she has made significant contributions to the advancement of nursing education and the nursing profession. Professor Chou has received numerous prestigious professional and academic honors, including the Professional Contribution Award for Outstanding Nurses in Taiwan, and the National Excellent Teacher Award. In 2020, she was inducted as a Fellow of the American Academy of Nursing (FAAN). She was also selected as a Distinguished Alumna of the School of Nursing at the University of Texas at Austin in 2025. These achievements reflect her outstanding contributions to nursing education, research, and professional development.



Speaker

Name Keng Yen Huang
Job Title Professor
Department Department of Population Health and Department of Child and Adolescent Psychiatry
Organization Stanford University School of Medicine

A brief biographical sketch

Please provide a brief biographical sketch (maximum 500 words) including your current position, educational background, professional experience, research interests, and representative achievements.

Keng-Yen Huang, PhD, MPH, CPH is Professor of Population Health and Child and Adolescent Psychiatry at the NYU Grossman School of Medicine and Affiliate Professor of Global Public Health at NYU. Her work focuses on improving mental health and behavioral health outcomes across the lifespan by combining prevention science, implementation science, digital health, and artificial intelligence.

Dr. Huang's research aims to bridge the gap between scientific innovation and real-world care. She studies how evidence-based behavioral health interventions can be adapted, personalized, and scaled in practical, equitable, and sustainable ways across health care, school, and community settings in the United States and globally. Her work includes developing digital and AI-enabled tools to support early identification of mental health risk, strengthen prevention efforts, and expand access to care for children, adolescents, families, and frontline providers.

She has led or contributed to more than twenty federally funded studies over the past two decades, with projects spanning the U.S., Uganda, Kenya, Ghana, Nepal, and Europe. Her research has included personalized mobile health toolkits, digital behavioral health screening and intervention platforms, and implementation strategies to support workforce training and delivery of behavioral health services in low-resource and diverse settings. She also applies machine learning and AI-based approaches to identify risk patterns, guide personalized prevention, and improve the efficiency of behavioral health systems.

Dr. Huang's work is especially relevant to current efforts to translate AI into responsible, human-centered, and scalable solutions for public health and clinical practice. Her presentation highlights how AI can be used not only to personalize behavioral health promotion and mental health prevention, but also to augment workforce training and support broader dissemination of high-quality behavioral health care.

Her scholarship reflects a strong commitment to interdisciplinary collaboration, health equity, and implementation strategies that ensure scientific advances can benefit diverse populations in real-world settings.

Dr. Huang received her BS in Clinical Psychology from Kaohsiung Medical University, her MA in Counseling Psychology from West Texas A&M University, her PhD in Applied Developmental Psychology from the University of Maryland, Baltimore County, and her MPH in Global Public Health from New York University. She also completed advanced training in implementation science, prevention science, and quantitative methods through Washington University in St. Louis and NYU Grossman School of Medicine.

Speaking Topic(s)

Translating AI into real-world personalized behavioral health promotion and mental health prevention

Session Abstract

This talk translates the multi-agent model into two deployed programs: mSELY, targeting adolescent behavioral health, and mWEL, supporting adult workforce and caregiver wellbeing. Comparing these programs across adolescents, caregivers, and working adults highlights what generalizes in AI-enabled prevention design and what must be adapted—engagement strategies, risk sensitivity, implementation pathways, and cultural context. The talk also addresses implementation across global health settings, highlighting how precision prevention models can be adapted for populations and infrastructures beyond high-resource settings.



Speaker

Name Janet Nakigudde
Job Title Senior Research Scientist
Department School Mental Health
Organization Global Health Uganda and Makerere University

A brief biographical sketch

IJanet Nakigudde is a Senior Research Scientist and academic with more than 30 years of experience in university teaching, research, mentorship, and engagement with policy and practice. Her work sits at the intersection of mental health, implementation science, education, and public health, with a particular focus on strengthening systems to improve the mental health and psychosocial well-being of children, adolescents, teachers, and school communities.

Over the course of her career, she has combined academic scholarship with applied research aimed at addressing complex health and social challenges in low-resource settings. Her research interests include implementation science, school mental health promotion, mental health literacy, early identification and support for common mental health conditions, and the translation of research evidence into policy and practice. She has particular expertise in developing and evaluating approaches that can be integrated within existing education and health systems and sustained at scale.

A significant component of her work involves collaboration with policymakers, government ministries, universities, researchers, educators, and other stakeholders. She has worked closely with Uganda's education and health sectors to strengthen the integration of mental health promotion within schools and to support evidence-informed decision-making. Her work emphasizes cross-sectoral partnerships and the development of practical strategies that bridge the gap between research evidence, policy, and implementation.

She is actively involved in school mental health research and programming, including the development and implementation of the Mental Wellness and Empowering Lives in the School Community (mWEL) program. This work seeks to strengthen mental health literacy, promote social and emotional well-being, support teachers and school communities, and facilitate early identification and appropriate support for students experiencing mental health challenges.

As an experienced educator and mentor, she has taught and supervised students and emerging researchers at university level and supported capacity building in research and implementation science. She is particularly committed to nurturing the next generation of researchers and strengthening local capacity to conduct rigorous, contextually relevant research.

Her career reflects a sustained commitment to using research to inform policy, strengthen health and education systems, and improve the well-being of children, adolescents, families, and communities. Her current work continues to focus on building partnerships between researchers, policymakers, and practitioners to ensure that evidence is translated into effective, equitable, and sustainable mental health interventions.

Speaking Topic(s)

AI-augmented workforce training for scaling up behavioral health care

Session Abstract

The role of AI in developing, supporting and upskilling professionals and community health workers through AI-driven simulations, real-time feedback, and automated performance insights to strengthen clinicl skill and reduce administrative burden



Speaker

Name I-Chin Huang
Job Title Assistant Research Fellow
Department Biomedical Artificial Intelligence Academy
Organization Kaohsiung Medical University

A brief biographical sketch

I-Chin Huang, PhD, is an Assistant Researcher at the Biomedical Artificial Intelligence Academy, Kaohsiung Medical University (KMU), Taiwan. She received her PhD in Nursing from KMU and her Master's degree in Nursing from National Taiwan University. She was also a visiting scholar at the School of Nursing, University of California, San Francisco (UCSF), where she completed doctoral-level coursework.

Dr. Huang has a multidisciplinary professional background spanning clinical nursing, nursing education, community care, and healthcare research. Her clinical experience includes oncology and medical-surgical nursing, followed by extensive teaching and clinical education experience in nursing programs. Prior to her current position, she served as an Assistant Professor in nursing at Shu-Zen Junior College of Medicine and Management (SZMC).

Her research interests focus on digital health, nursing informatics, smart healthcare technologies, technology-enhanced nursing and patient education, cancer care, osteoporosis care, and community health. Her recent work particularly explores the integration of artificial intelligence, virtual reality (VR), and Social Emotional Learning (SEL) into healthcare and nursing education. She has participated in research and educational projects supported by Taiwan's Ministry of Education, Ministry of Science and Technology, and Kaohsiung Medical University Hospital.

Her scholarly work has been published in international peer-reviewed journals, including *Journal of Nursing Scholarship*, *Worldviews on Evidence-Based Nursing*, and *Journal of the Formosan Medical Association*.

Speaking Topic(s)

AI-enabled Precision Behavioral Health: Clinical Evidence, Implementation, and Future Perspectives.

Session Abstract

This presentation explores how AI can advance precision behavioral health through an AI-enabled multi-agent ecosystem for personalized and preventive care. It highlights the use of AI in education and professional training to strengthen behavioral health competencies, with selected integration of Social and Emotional Learning (SEL) concepts. AI-augmented learning and workforce development can support interprofessional collaboration and the scalable delivery of behavioral health services. Finally, the presentation discusses current clinical and educational evidence, implementation challenges, future opportunities, and the importance of human–AI collaboration and ethical governance.

October 16 Hall B | 10:20-12:00

Chewing and Swallowing in Long-Term Care

B3-小港+旗津

Time	Speaker	Moderator
10:20–11:00	Ly Minh Dang	Chih-Hsing Hung 洪志興
11:00–11:30	Jen-der Lue 呂建德	Ya-Wen Chiu 邱亞文
11:30–12:00	Ching-Min Chen 陳靜敏	Yi-Chun Tsai 蔡宜純



Speaker

Name Ly Minh Dang
Job Title Neurologist; Deputy Head of the Swallowing Disorders Unit
Department Laboratory of Medicinal Chemistry
Organization Chulabhorn Research Institute

A brief biographical sketch


Dr. Winai leawsuwan earned his B.Sc. in Chemistry from Silpakorn University, Thailand, in 2001, followed by an M.Sc. in Organic Chemistry from Mahidol University, Thailand, in 2004 under the supervision of Prof. Dr. Manat Pohmakotr. He then pursued his doctoral studies at Goethe University Frankfurt am Main, Germany, obtaining his Dr. phil. nat. in Organic Chemistry in 2009 under the guidance of Prof. Dr. Magnus Rueping. From 2009 to 2010, he was a postdoctoral fellow at the Université catholique de Louvain (Louvain-la-Neuve, Belgium), working with Prof. Dr. István E. Markó. Since 2011, he has served as a researcher at the Chulabhorn Research Institute, Thailand, focusing on advancing organic chemistry research and alkaloid synthesis methodologies.

Speaking Topic(s)

Developing a Multidisciplinary Approach to Dysphagia Care at Military Hospital 175, Vietnam

Session Abstract

This presentation will describe the development of a multidisciplinary model for the screening, assessment, treatment, and follow-up of neurogenic dysphagia in neurological practice at Military Hospital 175 in Vietnam. Drawing on clinical learning and experience from Kaohsiung Municipal Siaogang Hospital in Taiwan, the presentation will highlight how multidisciplinary dysphagia care—including bedside screening and assessment, instrumental evaluation, individualized swallowing rehabilitation, and cross-disciplinary coordination—has been adapted to the local clinical setting in Vietnam. It will discuss the practical challenges and lessons learned in establishing a dedicated dysphagia service within a resource-conscious hospital environment.



Moderator

Name Chih-Hsing Hung
Job Title Director / Superintendent
Department Research Center for Precision Environmental Medicine
Organization Kaohsiung Medical University / Kaohsiung Municipal Siaogang Hospital

A brief biographical sketch

Dr. Chih-Hsing Hung is Professor of Pediatrics at Kaohsiung Medical University (KMU) and Superintendent of Kaohsiung Municipal Siaogang Hospital. He also serves as Director of the Research Center for Precision Environmental Medicine at KMU. His clinical specialties include general pediatrics, pediatric allergy, and immunology.

Dr. Hung received his M.D. from National Defense Medical College and his Ph.D. from the Institute of Medicine at Kaohsiung Medical University. He completed research training at the Johns Hopkins Asthma and Allergy Center, Johns Hopkins University, where he conducted studies in allergic inflammation and respiratory diseases. He subsequently held academic and clinical positions at Kaohsiung Medical University and Kaohsiung Medical University Hospital, advancing to Professor of Pediatrics and leadership positions in pediatric allergy and immunology.

His research interests encompass pediatric allergy and asthma, immunology, dendritic-cell biology, environmental health, and the impact of environmental exposures on allergic and respiratory diseases. His representative research has investigated the molecular mechanisms underlying allergic inflammation, immune regulation, and environmental determinants of asthma, with publications in internationally recognized journals including the Journal of Allergy and Clinical Immunology and Respiratory Research.



Speaker

Name Chien-Te Lu
Job Title Political Deputy Minister
Department Natural Biotechnology
Organization Ministry of Health and Welfare, Taiwan

A brief biographical sketch

Current Position

Deputy Minister, Ministry of Health and Welfare(2024.05~)

Education

Ph. D in Social Science, University Bielefeld, Germany (1994.06-1999.05)

Master of Arts(M.A) in Graduate Institute of Political Science, National Chengchi University (1988.09-1990.07)

Department of Political Sclence, National Chengchi University (1984.09-1988.06)

Professional Experience

Political Deputy Minister of Civil Service Protection and Training Commission, Examination Yuan (2020.09~2024.05)

Director, Taiwan Thinktank (2022.06~)

Convener, The Sustainable Democracy Research Center - Warm Power and Social Cohesion Research Platform, Foundation for Future Generations, Taiwan (2021.03~2024.05)

Chairman, Taiwan Social Welfare Association (2020.09~2022.05)

Professor and Director, Department and Graduate Institute of Social Welfare, National Chung-Cheng University (2019.08~2020.09)

Committee member, Ministry of Finance Public Welfare Lottery Supervision Committee (2019.07~2020.09)

Convener, Ministry of Education University Social Responsibility Counselling Group (2019.06~2020.09)

Committee member, Ministry of Transportation and Communications Accessible Transportation Environment Promotion Group (2019.06~2020.09)

Committee member, Executive Yuan Social Welfare Promotion Committee (2019.03~2020.09)

Committee member, Ministry of Health and Welfare Health Care and Social Welfare Policy Promotion Advisory Group (2019.03~2020.09)

Office of the President's Pension Reform Committee (2016.06~)

Director, Social Affairs Bureau, Taichung City Government (2014.12~2018.11)

Convener, Employment and Social Security Group of Taiwan Think Tank (2010.10~2012.08)

Visiting Scholar in Max-Planck Institute for the Studies of Societies (MPIfG), Cologne, Germany (2004.07~2004.09)

Member, Health System Advisory Committee of the Health Care Reform Foundation, Taiwan (2002.04~2003.08)

Member, Task Force for National Health Insurance Reform, Ministry of Health, Taiwan (2001.09~2002.02)

Speaking Topic(s)

Long-Term Care 3.0: Policy Reforms and Prospects

Session Abstract

Provide 3~4 complete sentences that effectively describe what your presentation intends to cover.



Moderator

Name Ya-Wen Chiu
Job Title Deputy Director & Principal Investigator
Department Institute of Population Health Sciences
Organization National Health Research Institutes, Taiwan

A brief biographical sketch

Dr. Betty Ya-Wen CHIU received her M.E.M. from Yale University (1993) and Ph.D. from the University of California, Berkeley (2000). She has held research positions in Taiwan's public sector, including the Environmental Protection Agency, the Ministry of Health and Welfare, and the National Health Research Institutes (NHRI). From 2015 to January 2022, she directed the Master's Program in Global Health and Development at Taipei Medical University and, in 2018, established Asia's first Ph.D. Program in Global Health and Health Security. Between 2022 and 2024, she founded the Centre for Global Health and Security at Kaohsiung Medical University. She rejoined NHRI in August 2024 as a Principal Investigator at Institute of Population Health Sciences (IPHS), was appointed as Deputy Director in March 2025, and became Executive Director of the Health Policy Research Center in May 2025.

Her research interests include global health, health policy, international organizations, medical aid, health security, and evidence-based practice (EBP). Her primary expertise focuses on humanitarian health aid strategies and the dissemination of EBP. She has published extensively on the effectiveness of Taiwan's medical missions and the adoption of EBP among healthcare professionals through nationwide surveys. Her EBP questionnaires have been widely cited and adopted by many international researchers. Her book, published in 2008, The World Health Organization (WHO): Its Structure, Functions and Development, is the first Chinese-language monograph on the WHO. Her research has been supported by numerous national agencies.

She currently serves as Vice-President Finance and Taiwan Regional Director of the Asia-Pacific Academic Consortium for Public Health (APACPH), CEO and founding member of Asia-Pacific Academic Consortium for Public Health Collaborating Centres for Health Promotion (APACPH CCHP), Secretary General of Taiwan Association for Global Health Initiative (TAGHI) and has delivered over 67 presentations on COVID-19. Dr. CHIU has published more than 10 book/book chapters and 60 peer-reviewed articles.



Speaker / Moderator

Name Ching-Min Chen
Job Title Distinguished professor and Dean
Department College of Nursing
Organization Kaohsiung Medical University

A brief biographical sketch

Please provide a brief biographical sketch (maximum 500 words) including your current position, educational background, professional experience, research interests, and representative achievements.

Dr. Ching-Min Chen is a Distinguished Professor at Kaohsiung Medical University and serves as Dean of the College of Nursing. She is currently Vice President of the Taiwan Nurses Association and represents the Western Pacific Region as a Board Member of the International Council of Nurses. Dr. Chen earned her Doctor of Nursing Science degree from Indiana University in 1995, with a specialization in Health Policy and Community Health.

Dr. Chen has made significant contributions to public service, having served as a member of Taiwan's Legislative Yuan from 2018 to 2020 and again from 2022 to 2024. During her tenure, she actively advocated for improved working conditions, fair compensation, and enhanced professional recognition for nurses, while also promoting the critical importance of community health and long-term care.

Her professional interests include healthy community development, gerontology, and long-term care. Internationally, Dr. Chen served as a Board Member of the American Academy of Nursing from 2022 to 2024, becoming the first board member based in Asia. She also holds the distinction of being the first Taiwanese recipient of a Fellowship from the Royal College of Surgeons in Ireland (RCSI).

Speaking Topic(s)

AI-Driven Nursing Innovations in Long-Term Care: Advancing Chewing and Swallowing Care in a Super-Aged Era

Session Abstract

Provide 3~4 complete sentences that effectively describe what your presentation intends to cover.

This presentation explores AI-driven nursing innovations in long-term care, focusing on chewing and swallowing care in a super-aged society. It highlights Taiwan's LTC 3.0, smart care technologies, and AI applications that enhance safety, efficiency, and functional recovery, demonstrating opportunities for nurses to lead technology-enabled, person-centered elder care.



Moderator

Name Yi Chun Tsai
Job Title Superintendent
Department
Organization Kaohsiung Municipal CiJin Hospital

A brief biographical sketch

Professor Yi-Chun Tsai is the Superintendent of Kaohsiung Municipal Cijin Hospital and a Professor of Internal Medicine at Kaohsiung Medical University, Taiwan. She is also a nephrologist at Kaohsiung Medical University Hospital. Her research focuses on chronic kidney disease, diabetic kidney disease, environmental nephrotoxins, precision medicine, and multi-omics approaches to kidney and metabolic disorders. She has led clinical and community-based studies integrating biomarkers, genomics, metabolomics, and digital health technologies to improve risk assessment and disease management. Her recent work also explores artificial intelligence, mobile health, and integrated care models for chronic disease prevention and healthy aging. In addition to her academic activities, Professor Tsai actively contributes to national kidney disease prevention strategies, healthcare policy development, and multidisciplinary community care. She is also engaged in international collaborations in diabetic nephropathy, multi-omics, and precision health research.

October 17 | **B2 Conference Room** | **10:20-12:00**

Towards a Resilient Asia-Pacific: Strategic Collaboration in Active Ageing and Transnational Long-Term Care Policies

C3-長期照顧

Time	Speaker	Moderator
10:20–10:50	Pei-Shan Yang 楊培珊	Ching-Min Chen 陳靜敏
10:50–11:30	Donghee Han 韓東希	Pei-Shan Yang 楊培珊
11:30–12:00	Tzu-Yu Lin 林子郁	Chia-Chi Yang 楊家琪



Speaker / Moderator

Name Pei-Shan Yang
Job Title Professor
Department Department of Social Work
Organization National Taiwan University

A brief biographical sketch

Dr. Peishan Yang is a professor in the Department of Social Work at the National Taiwan University. She has served as the Director of the Research Ethics Center at NTU since 2021, and previously served as the Editor-in-Chief of the NTU Social Work Review from 2022 to January 2026.

She received her BA degree from the Department of Foreign Languages and Literature at NTU, and then got both her MSW and Ph.D. degrees at Columbia University, School of Social Work. Before she returned to Taiwan and started teaching at NTUSW in 1997, Dr. Yang had worked for over seven years as a Certified Social Worker at Jewish Home and Hospital for the Aged in the Bronx, whose current name is the New Jewish Home. Dr. Yang contributed heavily to NTUSW's initial international practicum by building connections and practicum infrastructures with the renowned Geriatric organization in New York, USA.

Dr. Yang has specialized in gerontology since her early days in social work. Her research topics include digital aging, productive aging, care and work, dementia care, Taiwan Centenarian Study, long term care, and integrated body-mind-spirit health. She also sits in many government committees on senior social welfare or long term care. Dr. Yang has been known for her many innovations for the elderly welfare and services. She co-led a multi-disciplinary research team funded by the National Science and Technology Council, which later became a spin-off company named JUBO in 2018.

Speaking Topic(s)

Generational Resilience in Active Ageing: A Developmental and Intersectional Perspective

Session Abstract

Resilience plays an important role in active ageing, but its meaning and expression may differ across generations. Over the past century, two World Wars, regional conflicts, economic development, political transitions, technological innovations, and social transformations have profoundly shaped people's lives. These experiences influence how generations develop resilience and respond to challenges.

Taiwan offers a valuable perspective on generational resilience. Lessons from my Taiwanese Centenarians Studies highlight perseverance, adaptability, meaningful relationships, and finding purpose in life. These lessons suggest that resilience develops throughout life and is sustained through relationships across generations. Intergenerational exchange, mutual learning, and reciprocity can help translate these experiences into shared capacities for responding to change. As societies prepare for lives beyond 100 years, policy must give greater attention to intergenerational resilience, creating opportunities for older and younger people to contribute to one another's well-being.

Gender is a critical dimension of generational resilience. Men generally have shorter life expectancy and may face greater challenges in maintaining social connections and participation in later life. Women, despite their longevity advantage, often experience greater economic insecurity and caregiving burdens. These differences reflect intersecting gender roles, socioeconomic conditions, and generational experiences, highlighting the need for gender-responsive active ageing strategies.

Across the Asia-Pacific, generational resilience takes different forms and follows different historical timelines, yet societies share many similar challenges and aspirations. Regional collaboration should move beyond policy and professional exchanges to promote older adults' agency, self-determination, and active participation in cross-national cooperation. Intergenerational exchange and reciprocity can strengthen shared resilience, enabling older and younger generations to learn from and support one another. Such collaboration can contribute to more inclusive, sustainable, and resilient ageing societies.



Speaker / Moderator

Name Ching-Min Chen
Job Title Distinguished professor and Dean
Department College of Nursing
Organization Kaohsiung Medical University

A brief biographical sketch

Please provide a brief biographical sketch (maximum 500 words) including your current position, educational background, professional experience, research interests, and representative achievements.

Dr. Ching-Min Chen is a Distinguished Professor at Kaohsiung Medical University and serves as Dean of the College of Nursing. She is currently Vice President of the Taiwan Nurses Association and represents the Western Pacific Region as a Board Member of the International Council of Nurses. Dr. Chen earned her Doctor of Nursing Science degree from Indiana University in 1995, with a specialization in Health Policy and Community Health.

Dr. Chen has made significant contributions to public service, having served as a member of Taiwan's Legislative Yuan from 2018 to 2020 and again from 2022 to 2024. During her tenure, she actively advocated for improved working conditions, fair compensation, and enhanced professional recognition for nurses, while also promoting the critical importance of community health and long-term care.

Her professional interests include healthy community development, gerontology, and long-term care. Internationally, Dr. Chen served as a Board Member of the American Academy of Nursing from 2022 to 2024, becoming the first board member based in Asia. She also holds the distinction of being the first Taiwanese recipient of a Fellowship from the Royal College of Surgeons in Ireland (RCSI).

Speaking Topic(s)

AI-Driven Nursing Innovations in Long-Term Care: Advancing Chewing and Swallowing Care in a Super-Aged Era

Session Abstract

Provide 3~4 complete sentences that effectively describe what your presentation intends to cover.

This presentation explores AI-driven nursing innovations in long-term care, focusing on chewing and swallowing care in a super-aged society. It highlights Taiwan's LTC 3.0, smart care technologies, and AI applications that enhance safety, efficiency, and functional recovery, demonstrating opportunities for nurses to lead technology-enabled, person-centered elder care.



Speaker

Name Donghee Han
Job Title Director
Department Research, Development and Education
Organization Research Institute of Science for the Better Living of the Elderly

A brief biographical sketch


Dr. Donghee Han is a leading Korean gerontologist and co founder of the Research Institute of Science for the Better Living of the Elderly (RISBLE), which she has led for nearly three decades. She has pioneered programs in elder abuse prevention, elder care, digital aging, and active aging. She lectured on gerontology at universities in Busan and Daegu. She has advised major government bodies—including the National Pension System and Busan Metropolitan City—and served as Chairperson of the Commission on Elderly Policy (2021–2025). Internationally, she contributes to organizations such as the *Active Aging Consortium in Asia Pacific, ACAI, IAGG ASIO e TRIGGER, and the Healthy Aging Prize for Asian Innovation*. Recognized with multiple national awards, she has developed innovative ICT initiatives like *Cyber Family and the CEP Programs*, trained over 800 Wellageing Narrative Teaching Aid Trainers, and introduced new models of community care in Busan. She also writes widely on aging issues as a columnist for Korean media.

Speaking Topic(s)

Building an Age-Friendly Future: Korean Long-Term Care Insurance and Active Ageing Strategy

Session Abstract

Korea is one of the fastest aging countries in the world. Caring for the elderly, supporting their participation in society, and ensuring safe environments are now vital tasks. Since the 2008 Long Term Care Insurance Act, Korea has moved toward community based care. At the same time, active ageing programs focus on health, participation, and seeing older adults as valuable contributors. This presentation shows how these two approaches—long term care and active ageing—work together to build sustainable, age friendly communities.



Speaker

Name Tzu-Yu Lin
Job Title Associate professor
Department Master Program of Long-Term Care in Aging
Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Tzu-Yu Lin earned her Ph.D. from Waseda University in Japan and is currently an Associate Professor in the Master Program of Long-Term Care in Aging at Kaohsiung Medical University (KMU). Since 2024, she has also served as Deputy Director of the KMU Long-Term Care Research Center. Her academic interests include aging in place, healthy aging, and community care. In the past five years, her research has focused on developing a healthy aging ecosystem to improve older adults' physical and cognitive function. She has studied the impact of environmental factors on healthy aging to inform policy and broaden impact. Following the World Health Organization's (2020) guidelines, she has worked to clarify and empirically validate a comprehensive ecosystem model for healthy aging. For the latest updates on her publications, please visit: (https://orcid.org/0000-0002-6960-6196).


In addition to her research, Dr. Lin is dedicated to teaching and received the "Distinguished Teaching Award, KMU" for the 2023 academic year. She has built a strong international network of gerontology scholars in Asia, especially in Japan and South Korea, leading to joint research with the Tokyo Metropolitan Institute for Geriatrics and Gerontology, Kagoshima University, and Dong-A University. Her international standing is demonstrated by her invited presentation at the 2025 Active Aging Consortium Asia Pacific Webinar and her role as a reviewer for international SCIE/SSCI journals. Furthermore, she serves as a committee member for the local government's aging-in-place and age-friendly city project. Through ongoing engagement at both local and international levels, Dr. Lin seeks to apply her expertise to advance a healthy aging society in Taiwan and beyond.

Speaking Topic(s)

Rethinking Active Aging: Strategic Interventions for Multiple Intelligences among Older Adults.

Session Abstract

Current cognitive assessments are narrow and primarily assess academic intelligence, and little research examines multiple dimensions of intelligence among older adults. The topic showed not only the measurement of multiple intelligences (MI) among older adults, but also a comprehensive perspective for researchers and practitioners rethinking cognitive health in a non-disease or non-dysfunction approach. Moreover, the findings suggest designing an MI-oriented, tailored intervention program based on the diverse intellectual capacity profiles of older adults.



Moderator

Name Chia-Chi Yang
Job Title Associate Professor & Director
Department The Master Program of Long-Term Care in Aging
Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Chia-Chi Yang currently serves as the Director and Associate Professor in the Master Program of Long-Term Care in Aging at Kaohsiung Medical University, Taiwan. He received his Bachelor's degree from the Department of Sports Medicine at Kaohsiung Medical University in 2008, a Master's degree from the Department of Physical Therapy and Assistive Technology at National Yang-Ming University in 2010, and a Ph.D. from the Institute of Biomedical Engineering at National Cheng Kung University in 2014.

Regarding his professional experience, Dr. Yang joined Kaohsiung Medical University's Master Program of Long-Term Care in Aging in 2019 as an Assistant Professor, advanced to Associate Professor, and became the Director in August 2025.

His main research interests focus on applied electrophysiology, biomedical signal and image processing, medical device and assistive technology, human motion analysis, rehabilitation engineering, and geriatric health promotion.

October 17 | B1 Study room | 10:20-12:00

Innovation in Neuroscience

D3-神經科學研究中心

Time	Speaker	Moderator
10:20–10:45	Fei-Yang Huang 黃飛揚	Po-Hao Huang 黃博浩
10:45–11:10	Po-Hao Huang 黃博浩	Chih-Lung Lin 林志隆
11:10–11:35	Chou-Ping Song 周秉松	Chung-Yao Hsu 徐崇堯
11:35–12:00	Yuan-Han Yang 楊淵韓	Jing-Yuan Huang 黃靖媛



Speaker

Name Fei-Yang Huang
Job Title Wellcome Trust Early Career Research Fellow
Department Department of Experimental Psychology
Organization University of Oxford

A brief biographical sketch

Dr Fei-Yang Huang (黃飛揚) is a **Wellcome Trust Early Career Research Fellow** in the Department of Experimental Psychology at the University of Oxford and a Junior Research Fellow at Wolfson College, Oxford. He received his MD, with a minor degree in Economics, from National Taiwan University, and completed his PhD in Neurophysiology at the University of Cambridge.

His research studies how the brain integrates sensory and physiological signals to shape learning and decision-making. A central focus of his work is understanding how the brain represents nutrient rewards, such as fat and sugar, to encode subjective value and guide choices between competing options. By combining computer-based behavioral tasks, single-neuron recordings in behaving nonhuman primates, machine-learning methods, and targeted brain stimulation, Dr Huang investigates how distinct reward features are represented in the brain and how their neural organization shapes computation and choice behavior. His research advances understanding of how the brain flexibly adapts behavior to reflect physiological needs, with implications for disorders affecting human motivation, decision-making, and metabolic health.


Dr Huang's research has received international recognition, including the **2025 European Brain and Behaviour Society (EBBS) Young Investigator Award** and the **2025 IBRO/Society for Neuroscience International Travel Fellowship**. He serves on the **Journal of Neuroscience Early Career Researcher Advisory Board** and co-leads the **Behavioural and Cognitive Neuroscience (BEACON) Seminar** at the University of Oxford. Supported by the **Wellcome Early-Career Award**, Dr Huang is extending his research to intracranial recordings in neurosurgical patients through collaborations with Caltech and Cedars-Sinai Medical Center. By bridging nonhuman primate neurophysiology with transcranial ultrasound neuromodulation and direct recordings from the human brain, his research aims to identify neural mechanisms of adaptive decision-making, which may provide new targets for neuromodulation in conditions involving maladaptive reward processing, including obesity, eating disorders, and addiction.

Speaking Topic(s)

Rethinking how the brain makes decisions: from nutrient needs to neural computation

Session Abstract

This presentation will examine how advances in behavioral theory, neural-recording techniques, and machine-learning computation are reshaping our understanding of decision-making mechanisms in the brain. At the conceptual level, economic decision models and principles from nutrient ecology provide a framework for understanding how internal needs and sensory inputs shape learning and choice. At the neural level, large-scale recordings of single-neuron activity in awake nonhuman primates and humans provide access to neural activity associated with cognitive computations at both single-neuron and population levels. At the computational level, machine-learning approaches reveal latent structure in complex neural activity often missed by conventional analyses. Together, these convergent innovations enable new ways of linking behavior, neural activity, and computation to uncover the mechanisms underlying complex decision-making in primates.



Speaker / Moderator

Name Po-Hao Huang
Job Title Attending Neurosurgeon
Department Neurosurgeon
Organization National Taiwan University Hospital

A brief biographical sketch

I am a Clinical Associate Professor at National Taiwan University College of Medicine, an attending neurosurgeon at National Taiwan University Hospital (NTUH), and the Chief Executive Officer of the NTUH International Medical Service Center. He specializes in minimally invasive neurosurgery, with particular expertise in intracerebral hemorrhage, brain tumors, skull base tumors, cerebrovascular disorders, traumatic brain injury, and endoscopic neurosurgery.

I received his medical degree and PhD training from National Taiwan University. He has pursued advanced research and international training at the University of California, San Francisco (UCSF), Harvard Medical School and Brigham and Women's Hospital, as well as the Stanford Biodesign program. These experiences have shaped his multidisciplinary approach to integrating clinical medicine, biomedical engineering, medical devices, and translational research.

My major academic interests focus on developing innovative, minimally invasive approaches to brain surgery. I have been actively involved in the development and clinical application of minimally invasive techniques for intracerebral hemorrhage and other complex neurosurgical conditions, aiming to reduce surgical trauma, improve hematoma evacuation, preserve neurological function, and accelerate patient recovery. His research has been published in international peer-reviewed journals, and he has contributed to the advancement of novel neuroendoscopic technologies and medical

devices.

Beyond clinical practice and research, I am actively engaged in medical innovation, clinical trials, biomedical engineering, and international collaboration. In his role at NTUH International Medical Service Center, he is also committed to advancing international healthcare, facilitating cross-border medical collaboration, and promoting the global exchange of medical expertise and innovative healthcare technologies.

With a strong combination of clinical expertise, academic research, medical innovation, and international experience, I am dedicated to advancing the next generation of minimally invasive neurosurgery and building stronger global partnerships in healthcare.

Speaking Topic(s)

Sometimes an entrepreneur, always a doctor: a biodesign journey in tackling intracerebral hemorrhage.

Session Abstract

Drawing from the personal and clinical journey of an academic neurosurgeon, this presentation explores how unmet clinical needs in intracerebral hemorrhage (ICH) can be transformed into viable medical technologies through the Stanford Biodesign process and entrepreneurial incubation. It details the development, fundraising, and clinical validation of micro-invasive surgical tools and biomaterials, highlighting real-world milestones from Y Combinator backing to FDA clearance and early multi-center clinical trials. Furthermore, it addresses the translation of novel therapies to the bedside—including anti-inflammatory hydrogels, advanced neuroendoscopy, and emerging neurotechnologies such as brain computer interface. Ultimately, the talk examines the delicate balance between practicing clinical medicine and leading entrepreneurial ventures, offering practical insights on cross-disciplinary collaboration, regulatory navigation, and the core physician mission to improve patient outcomes at scale.



Moderator

Name Chih-Lung Lin

Job Title Senior Vice President, KMU
Professor, Department of Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital

Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Chih-Lung Lin is the Vice President of Kaohsiung Medical University, Professor of Surgery, and Attending Neurosurgeon at Kaohsiung Medical University Chung-Ho Memorial Hospital. He is a Past President of the Taiwan Neurosurgical Spine Society and the Founding President of the Taiwan Osteoporosis Care Association. Dr. Lin has previously served as Chair of the School of Medicine, Dean of Academic Affairs, and Secretary-General at Kaohsiung Medical University, as well as Chief of Neurosurgery, Director of the Department of Surgery, and Deputy Superintendent at KMU Chung-Ho Memorial Hospital.

He received his M.D. from Kaohsiung Medical University, followed by a Master's degree in Healthcare Administration and a Ph.D. in Medical Sciences. He completed neurosurgical training at the University of Virginia, USA. His clinical expertise includes robotic spine surgery, customized 3D-printed guiding templates for upper cervical spine fixation, cervical spine surgery, osteoporosis prevention and treatment, spinal tumors, and cerebral aneurysms.

In recent years, he has pioneered the clinical application of customized 3D-printed guiding templates for upper cervical pedicle screw fixation, significantly improving surgical precision and patient safety, while also advancing osteoporosis care and smart healthcare innovations.



Speaker

Name Chou, Ping-Song
Job Title Associate Professor
Department Neurology
Organization Kaohsiung Medical University Hospital

A brief biographical sketch

I am currently the Director of the Department of Neurology at Kaohsiung Medical University Gangshan Hospital, an Attending Staff Neurologist at Kaohsiung Medical University Hospital, and an Associate Professor at the School of Medicine, Kaohsiung Medical University.

I have more than 15 years of clinical experience in neurology and have served as an attending neurologist since 2011. From 2019 to 2023, I served as Director of the Stroke Center at Kaohsiung Medical University Hospital. I have also been actively involved in medical education, serving as an Assistant Professor from 2018 to 2025 and as an Associate Professor since 2025.

My research interests focus on cerebrovascular disease, Alzheimer's disease and cognitive impairment, and clinical neurophysiology. My research has investigated biomarkers and risk factors associated with stroke outcomes, cerebral small vessel disease, Alzheimer's disease progression, and treatment response. I am also interested in applying advanced analytical approaches to investigate the relationships between electrophysiological signals and cognitive function.


I have published extensively in peer-reviewed international journals. My representative research achievements include studies on electronegative low-density lipoprotein L5 and cognitive decline, gut microbiota and outcomes after stroke recanalization therapy, plasma metabolic biomarkers in acute ischemic stroke, pharmacogenetic factors affecting response to donepezil, and longitudinal progression of Alzheimer's disease.

Speaking Topic(s)

Comprehensive Community-Based Dementia Survey: From Early Screening to Advanced Dementia Care

Session Abstract

For community-dwelling older adults, specifically for those requiring advanced care interventions, utilizing a novel functional assessment scale focused on instrumental activities of daily living (IADLs) is critical for the effective screening and early identification of dementia. Furthermore, identifying risk factors related to sleep disorders and the use of sedative-hypnotic medications is essential, as these elements often exacerbate behavioral and psychological symptoms of dementia (BPSD) and significantly complicate daily caregiving efforts. Consequently, understanding the risk factors that drive acute medical resource utilization among these patients highlights an urgent need for healthcare policy adjustments, particularly the enhancement of community-based support systems to prevent unnecessary hospital admissions and improve overall care quality.



Moderator

Name Chung-Yao Hsu
Job Title Professor; Chief
Department Department of Neurology; Sleep Medicine Center
Organization Kaohsiung Medical University and Kaohsiung Medical University Hospital

A brief biographical sketch

Prof. Hsu received his M.D. from Kaohsiung Medical University in Kaohsiung, Taiwan, and his Ph.D. from the University of Edinburgh in the United Kingdom. From 1999 to 2004, he served as a research fellow at the Department of Sleep Medicine, Royal Infirmary of Edinburgh, and the Department of Clinical Neuroscience, Western General Hospital, Edinburgh, UK. He returned to Taiwan in 2004 and began his academic career as an assistant professor and attending physician in the Department of Neurology at Kaohsiung Medical University and Hospital. He currently holds multiple appointments as a professor, director of the Sleep Medicine Center, and chief of the Department of Neurology at the same institution.

Prof. Hsu has held several key positions in professional societies, including President of the Taiwan Society of Sleep Medicine (2016–2018), executive member of the Taiwan Neurological Society, and Vice Secretary-General of the Taiwan Society of Clinical Neurophysiology. He is currently an executive member of both the Taiwan Society of Sleep Medicine and the Taiwan Epilepsy Society.

Under Prof. Hsu's leadership, the Sleep Medicine Center at KMU has evolved into a multidisciplinary hub that combines basic and clinical research in sleep neuroscience. The center has prioritized REM Sleep Behavior Disorder (RBD) as a central research theme. The center incorporates a small-animal sleep laboratory, AI-driven EEG analysis, wearable medical devices, and non-invasive brain stimulation, forming an interdisciplinary translational research team that spans institutions and specialties. With a strong focus on artificial intelligence and industry-academic collaboration, the center has developed into a highly professional and integrated team in the field of sleep medicine.

Throughout his career, Prof. Hsu has published over 100 SCI-indexed papers, including over 50 as first or corresponding author. His recent research emphasizes key findings in sleep architecture alterations in epilepsy and RBD, the efficacy of orexin receptor antagonists in sleep-disordered breathing, and ferritin-associated augmentation in restless legs syndrome.

In recognition of his contributions, Prof. Hsu has received several national honors, including the Symbol of National Quality (SNQ) for translational sleep neuroscience (2024, 2017–2020), the National Innovation Award (2022) for wireless EEG-guided phototherapy, and the National Healthcare Quality Award (HQIC) for smart sleep healthcare (2017). He has also mentored numerous graduate and doctoral students, many of whom have earned national recognition, such as the “Outstanding Epilepsy Research Award” and invitations for oral presentations at leading academic conferences.

Through his innovative integration of neuroscience, artificial intelligence, and translational clinical research, Prof. Hsu continues to lead the advancement of sleep medicine and neurology in Taiwan.



Speaker

Name Yuan-Han, Yang
Job Title Director
Department Neuroscience Research Center
Organization Kaohsiung Medical University

A brief biographical sketch

Professor Yuan-Han Yang, MD, MS, PhD, is a distinguished neurologist, neuroscientist, and internationally engaged researcher in the field of Alzheimer's disease, dementia, and brain health. He currently serves as Professor of Neurology at Kaohsiung Medical University (KMU), Director of the Neuroscience Research Center at KMU, Head: Research Committee, Asian Society Against Dementia, and Distinguish Research: Industrial Technology Research Institute.

Professor Yang received his MD from Kaohsiung Medical College, followed by an MS in Behavioral Neuroscience and a PhD in Medicine from Kaohsiung Medical University. He further broadened his international research experience as a research scholar at the Alzheimer's Disease Research Center, Washington University in St. Louis, USA, one of the leading centers for Alzheimer's disease research.

Throughout his academic and clinical career, Professor Yang has pursued an interdisciplinary approach integrating behavioral neurology, neuropsychology, neuroscience, geriatric neurology, and dementia prevention. His research has evolved from the clinical characterization and early detection of dementia toward a broader vision of precision brain health, incorporating biomarkers, cerebral network function, digital medicine, artificial intelligence, virtual reality, wearable technologies, and personalized risk prediction.

His representative research contributions, more than 200 manuscripts and 5 books, include investigations of very early cognitive impairment and dementia screening, motor-cognitive interactions, cerebral coordination and clinical outcomes in Alzheimer's disease, and technology-enhanced cognitive and behavioral interventions. His work has also explored innovative applications of virtual reality, digital biomarkers, artificial intelligence, and smart wearable technologies to improve early detection, monitoring, prediction, and personalized management of dementia.



Moderator

Name Jing-Yuan Huang
Job Title Chief Executive Officer
Department Operations Center
Organization Show Chwan Healthcare System

A brief biographical sketch

Dr. Ching-Yuan Huang
Chief Executive Officer, Show Chwan Healthcare System

Dr. Ching-Yuan Huang serves as Chief Executive Officer (CEO) of Show Chwan Healthcare System. With a background spanning dentistry, business management, and healthcare administration, she is committed to advancing medical innovation, smart healthcare, healthcare digitalization, and international medical collaboration.

She earned her Doctor of Dental Surgery (DDS) degree from the University of Southern California and a master's degree from the Graduate Institute of Civil Engineering at National Taiwan University in 2015. Her professional experience encompasses clinical dentistry, leadership in the information administration at Show Chwan Healthcare System, giving her a multidisciplinary perspective on healthcare innovation and

In 2016, Dr. Huang founded MedicalTek to advance the development of a 2D-to-3D endoscopic imaging system and promote innovative applications of medical technology. She was also one of the early driving forces behind the Central Taiwan Hospital Information e-Alliance, which facilitates knowledge exchange, information sharing, and resource collaboration among regional hospitals.


Show Chwan Healthcare System has maintained a longstanding international partnership with Tulane University School of Medicine since 2003 through the Tulane Asia Elite Leadership (TAEL) program, which promotes healthcare leadership development and international exchange. Dr. Huang is committed to advancing medical innovation and cultivating healthcare leaders with a global perspective. In recognition of her achievements in medical innovation and entrepreneurship, she received recognition as a model entrepreneur at the **44th ROC Entrepreneurship Model Awards**.

October 17 Hall B | 14:50-16:30

Translational Strategies and Clinical Innovation of Small Molecules and Biologics

B4 新藥開發暨價創研究中心

Time	Speaker	Moderator
14:50–15:20	Yun-Chi Lu 呂韻綺	Wan-Chi Tsai 蔡婉琪
15:20–16:00	Shey-Cherng Tzou 鄒協成	Wan-Chi Tsai 蔡婉琪
16:00–16:30	Chin-Chung Wu 吳志中	Wan-Chi Tsai 蔡婉琪



Speaker

Name Yun-Chi Lu
Job Title CEO
Department Operations Department
Organization Preciesmab Biotech Co., Ltd.

A brief biographical sketch

Yun-Chi Lu, Ph.D., is the CEO and Co-Founder of PrecisemAb Biotech and a co-inventor of the company's Universal Antibody Lock™ technology. She received her Ph.D. from the Graduate Institute of Medicine at Kaohsiung Medical University (KMU), Taiwan, where she subsequently conducted postdoctoral research in Professor Tian-Lu Cheng's laboratory. Her research has focused on antibody engineering and disease-directed activation of antibody therapeutics, with particular interest in translating innovative biologics from academic discoveries into drug development.

Dr. Lu has contributed to the development of Antibody Lock technology from its early academic research through translational development and commercialization. Her research on selectively activated antibodies and antibody engineering has been published in journals including PLOS Biology, Chemical Science, and Journal of Biomedical Science. She received the **2021 Postdoctoral Researcher Academic Research Award** from Taiwan's Ministry of Science and Technology (MOST) in recognition of her academic research achievements.

At PrecisemAb, Dr. Lu leads the development and commercialization of Antibody Lock™ as a platform for next-generation antibody therapeutics. Under her leadership, PrecisemAb was selected as a **Hi-Po Star** by Taiwan's Small and Medium Enterprise and Startup Administration, Ministry of Economic Affairs. Her career spans academic research, translational drug development, and biotechnology entrepreneurship, reflecting her commitment to transforming scientific discoveries into therapeutic innovations.

Speaking Topic(s)

Disease-Directed Antibody Lock™: A Safety Sheath for Powerful Antibody Therapeutics

Unlocking therapeutic activity selectively at the disease site

Session Abstract

Antibody therapeutics have transformed the treatment of cancer and other diseases, yet their activity in healthy tissues can cause on-target toxicity and limit the therapeutic window. This presentation will introduce **Universal Antibody Lock™**, a disease-directed strategy that uses an antibody-derived structure as a reversible "safety sheath," designed to reduce antibody activity in normal tissues and restore therapeutic function in protease-rich disease environments. Preclinical evidence from multiple antibody programs will illustrate how the platform seeks to balance **effective masking, efficient activation, and preserved therapeutic activity,** followed by the translation of these principles into **PSM101, a tumor-activated anti-EGFR antibody.** The presentation will conclude with perspectives on extending the Antibody Lock concept beyond conventional monoclonal antibodies to next-generation antibody therapeutics.



Moderator

Name Wan-Chi Tsai
Job Title Associate Professor
Department Medical Laboratory Science and Biotechnology
Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Wan-Chi Tsai is an Associate Professor in the Department of Medical Laboratory Science and Biotechnology at Kaohsiung Medical University, Taiwan, and currently serves as President of the Taiwan Genomics Medicine and Biomarker Society. Her research focuses on cancer biology, tumor signaling, and the development of novel anticancer strategies, with particular interests in pancreatic and oral cancers and bioactive compounds derived from natural products. She received her postdoctoral training at The Ohio State University College of Pharmacy and has extensive experience in international academic collaboration. She previously served as Associate Vice President for Global Affairs at Kaohsiung Medical University and has been actively involved in promoting interdisciplinary and international collaboration in biomedical sciences.



Speaker

Name Shey-Cherng Tzou
Job Title Associate Professor
Department Institute of Molecular Medicine and Bioengineering
Organization National Yang Ming Chiao Tung University

A brief biographical sketch

I currently serve as an Associate Professor within the Institute of Molecular Medicine and Bioengineering at National Yang Ming Chiao Tung University (NYCU) in Hsinchu, Taiwan. I earned my Ph.D. degree from the Johns Hopkins University School of Medicine in the United States, specializing in immunology and the pathogenesis of autoimmune diseases. During my doctoral training, I successfully established a valid mouse model of autoimmune hypophysitis and identified its autoantigen. Since joining NYCU, my laboratory has focused on two primary areas of investigation: the development of novel therapeutic proteins for the treatment of inflammatory diseases and oncology, and the study of the pathogenesis and therapeutic interventions for metabolic dysfunction-associated steatotic liver disease.

Speaking Topic(s)

Elucidating the Pathway of Nuclear Translocation of PD-1Ig in Cancer Cells and Its Translational Applications

Session Abstract

We unexpectedly found that a novel immune checkpoint inhibitor PD-1Ig translocated into the nuclei of several cancer cell lines. We identified PD-1Ig-interacting proteins by co-immunoprecipitation and LC-MS/MS; many of which are enriched in nucleocytoplasmic transport and ER stress/unfolded protein responses/ERAD pathways. The induction of ER stress significantly increased, whereas the knockdown of KPNA1 or SEC61A/B expressions significantly decreased PD-1Ig nuclear accumulation. A protease granzyme B (GZMB) genetically fused to the C-terminus of PD-1Ig showed a better anti-tumor activity.



Speaker

Name Chin-Chung Wu
Job Title Professor
Department Graduate Institute of Natural Products, College of Pharmacy
Organization Kaohsiung Medical University

A brief biographical sketch

Professor Chin-Chung Wu received his Ph.D. in pharmacology from National Taiwan University in 1997 and has been a full professor in Graduate Institute of Natural Products at Kaohsiung Medical University (KMU) since 2007. He served as the director of Graduate Institute of Natural Products of KMU (2012-2018) and the associated vice president of research and development of KMU (2018-2021). Prof. Wu's specialist is cardiovascular pharmacology. He has been involved in research of the first soluble guanylate cyclase activator, YC-1, and the first protease-activated receptor 4 (PAR4) antagonist, YD-3; these studies have contributed to the development of new therapeutic strategies for cardiovascular disease. His current work focuses on the molecular targets that are involved in platelet aggregation and arterial thrombus formation, including PAR4 and protein disulfide isomerase. Prof. Wu has published over 130 ESCI papers and owns over 10 international patents. He is listed among the world's top 2% of scientists by Stanford University and has received the Excellent Research Award from Natural Medicine Society of Taiwan. He also served as Associate Editor-in-Chief of the Journal of Food and Drug Analysis (2018-2025) and has established international collaborations with institutions such as University of Szeged and the French National Research Agency.

Speaking Topic(s)

Multiple Strategies for Targeting Thrombin Receptor PAR4 in Cardiovascular Diseases

Session Abstract

Despite standard antiplatelet treatments, patients with cardiovascular disease face residual thrombotic risks due to thrombin activating platelets via alternative pathways. Targeting protease-activated receptor 4 (PAR4) is emerging as a promising solution, as it drives late-stage thrombosis and vascular inflammation without severely impairing normal hemostasis. Innovative PAR4-directed strategies, including small-molecule antagonists, PAR4 expression inhibitors, and heparin analogs that disrupt thrombin-PAR4 interactions, will be presented in this talk.

October 17 | **B2 Conference Room** | **14:50-16:30**

Dementia Care Policy and Precision Thyroid Therapy

C4-岡山 失智症照護政策與發展個人化甲狀腺腫瘤治療

Time	Speaker	Moderator
14:50–15:40	Takeshi Iwatsubo 岩坪威	Yuan-Han Yang 楊淵韓
14:50–15:40	Hsi-Wen Wu 吳希文	Yuan-Han Yang 楊淵韓
15:40–16:30	Young Jun Chai	Chih-Jen Huang 黃志仁
15:40–16:30	Tzu-Yen Huang 黃子晏	Chih-Jen Huang 黃志仁



Speaker

Name Takeshi Iwatsubo
Job Title Director General, Professor
Department National Institute of Neuroscience
Organization National Center of Neurology and Psychiatry

A brief biographical sketch

Takeshi Iwatsubo is director of the National Institute of Neuroscience, National Center of Neurology and Psychiatry, Project Professor of the University of Tokyo, and chairman of the Japan Society for Dementia Research. Trained as a neurologist and neuropathologist, Iwatsubo has contributed to the study of human neurodegenerative diseases, particularly Alzheimer's and Parkinson's, using multidisciplinary approaches. He demonstrated that Aβ42 is the initial species deposited in senile plaque amyloid, elucidated the process of γ-secretase complex formation, and identified phosphorylated α-synuclein as a component of Lewy bodies. He was the Principal Investigator of the Japanese AD Neuroimaging Initiative (J-ADNI) and the Japanese Trial Ready Cohort for Prevention of Alzheimer's Disease (J-TRC), and currently is the PI of the Japanese Resitry for AD-DMT. He is the recipient of the MetLife Award for Medical Research (2008), AAIC Lifetime Achievement Award (2010), the Potamkin Prize (2012), the Medal with Purple Ribbon from the Japanese government (2024), and CTAD Lifetime Achievement Award (2025).

Speaking Topic(s)

Alzheimer’s disease: from molecular pathology to therapeutics

Session Abstract

Disease-modifying therapies (DMT) targeting early Alzheimer’s disease (AD), especially those for anti-amyloid β (Aβ) antibody drugs lecanemab and donanemab, have been successfully implemented in clinical practice, opening up a new era for AD therapies. Notably, these positive outcomes of AD DMT trials have largely depended on molecular imaging and fluid biomarkers, underscoring the needs of markers that surrogate the clinical and pathophysiological progression of AD, as well as the efficacy of DMTs. Furthermore, DMT trials in the asymptomatic stage of AD (preclinical AD) are underway. To make these preclinical AD trials successful, trial ready cohorts (TRC) of preclinical and prodromal AD, are being established in the US and Japan. J-TRC launched in 2019 is comprised of a webstudy followed by an on-site study, so far having recruited ~16000 and ~900 participants, respectively. Biomarker studies in J-TRC have shown that combinations of plasma Aβ 42-related biomarkers and p-tau217 are potent in the prediction of Aβ-PET positivity and may be instrumental in the prescreening for clinical trials of DMTs for preclinical and prodromal AD. These clinical activities will pave the way toward the development of AD therapies targeting its very early stages.



Moderator

Name Yuan-Han, Yang
Job Title Director
Department Neuroscience Research Center
Organization Kaohsiung Medical University

A brief biographical sketch

Professor Yuan-Han Yang, MD, MS, PhD, is a distinguished neurologist, neuroscientist, and internationally engaged researcher in the field of Alzheimer's disease, dementia, and brain health. He currently serves as Professor of Neurology at Kaohsiung Medical University (KMU), Director of the Neuroscience Research Center at KMU, Head: Research Committee, Asian Society Against Dementia, and Distinguish Research: Industrial Technology Research Institute.

Professor Yang received his MD from Kaohsiung Medical College, followed by an MS in Behavioral Neuroscience and a PhD in Medicine from Kaohsiung Medical University. He further broadened his international research experience as a research scholar at the Alzheimer's Disease Research Center, Washington University in St. Louis, USA, one of the leading centers for Alzheimer's disease research.

Throughout his academic and clinical career, Professor Yang has pursued an interdisciplinary approach integrating behavioral neurology, neuropsychology, neuroscience, geriatric neurology, and dementia prevention. His research has evolved from the clinical characterization and early detection of dementia toward a broader vision of precision brain health, incorporating biomarkers, cerebral network function, digital medicine, artificial intelligence, virtual reality, wearable technologies, and personalized risk prediction.

His representative research contributions, more than 200 manuscripts and 5 books, include investigations of very early cognitive impairment and dementia screening, motor-cognitive interactions, cerebral coordination and clinical outcomes in Alzheimer's disease, and technology-enhanced cognitive and behavioral interventions. His work has also explored innovative applications of virtual reality, digital biomarkers, artificial intelligence, and smart wearable technologies to improve early detection, monitoring, prediction, and personalized management of dementia.

Professor Yang has contributed to the advancement of dementia medicine through academic publication, interdisciplinary collaboration, education, and scientific leadership.



Speaker

Name Hsi-Wen Wu
Job Title Deputy Director-General
Department Department of Long-Term Care
Organization Ministry of Health and Welfare

A brief biographical sketch

Current Position:

2022 Deputy Director-General, Department of Long-Term Care, MOHW

Educational Background:

2011 PhD, Institute of Health Policy and Management, National Taiwan University
2004 MS, School of Occupational Therapy, National Taiwan University
2001 BS, School of Occupational Therapy, National Taiwan University

Professional Experiences:

2018-2022 Senior Technical Specialist, Department of Long-Term Care, MOHW
2016-2018 Section Chief/Technical Specialist, Food Safety Division, TFDA, MOHW
2009-2016 Section Chief/Technical Specialist, Department of Public Health, Taoyuan
2006-2009 Section Chief/Technical Specialist, Department of Public Health, Taoyuan
2007-2008 Adjunct Lecturer, Department of Occupational Therapy, I-Shou University
2002-2006 Section Chief/Occupational Therapist, Department of Occupational Therapy, Yu-Li Hospital, MOHW

Research Interests:

Long-term Care Policy, Health Policy, Occupational Therapy

Representative Achievements:

2024 The Executive Yuan Model Civil Servant Award
2024 The Ministry of Health and Welfare Model Civil Servant Award

Speaking Topic(s)

Landscape and National Policy Framework for Dementia in Taiwan

Session Abstract

This session focuses on the latest implementation roadmap of Taiwan's dementia prevention and care policy. With the promotion of the 'Dementia Prevention and Care Policy Framework and Action Plan 3.0,' the nation has entered a brand-new strategic transformation across dementia-friendliness, preventive intervention, and care systems. This session will analyze the core objectives, policy pillars, and key cross-ministerial focus areas of Action Plan 3.0, exploring its critical breakthroughs in advancing the rights of people with dementia, strengthening family support networks, and implementing community-based care.



Speaker

Name Young Jun Chai
Job Title Professor
Department Surgery
Organization Seoul National University Boramae Medical Center

A brief biographical sketch

EDUCATION

Young Jun Chai, MD, PhD, MBA, is a Professor in the Department of Surgery at Seoul National University (SNU) Boramae Medical Center and SNU College of Medicine, where he serves as the Associate Dean for Planning Affairs.

Educational Background & Professional Experience

Dr. Chai earned his MD (2003), MS (2014), and PhD (2017) from SNU College of Medicine, and an MBA from Nanyang Technological University (2023). He joined the faculty at SNU Boramae Medical Center in 2014 and was appointed Full Professor in 2024.

Research Interests & Representative Achievements

A pioneer in endocrine surgery, Dr. Chai specializes in scarless Transoral Robotic Thyroidectomy (TORT), intraoperative neural monitoring, and integrating digital health technologies—including AI and augmented reality—into surgical practice. He co-developed the 3-port TORT approach, published over 160 SCIE-indexed papers.. He serves on key executive committees and editorial boards for leading international surgical societies.

Speaking Topic(s)

Remote access thyroid surgery

Session Abstract

This presentation explores the full spectrum of remote-access thyroid surgery, with a focus on Transoral Robotic Thyroidectomy (TORT) as the most rapidly growing and widely discussed surgical approach. Drawing from extensive clinical experience, I will discuss key procedural refinements and safety strategies—including intraoperative neural monitoring and the 3-port TORT method—to optimize surgical precision and nerve preservation.



Moderator Information

Name Chih-Jen Huang
Job Title Vice Superintendent
Department Department of Radiation Oncology
Organization Kaohsiung Medical University Gangshan Hospital

A brief biographical sketch

Ph.D. Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
Professor, Kaohsiung Medical University, Taiwan.
Visiting scholar, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.



Speaker

Name Tzu-Yen Huang
Job Title Director
Department Department of Otolaryngology–Head and Neck Surgery
Organization Kaohsiung Medical University Gangshan Hospital

A brief biographical sketch

TZU-YEN HUANG received his M.D. degree from National Taiwan University, Taipei, Taiwan, in 2009, and his Ph.D. degree in Biological Science and Technology from National Yang Ming Chiao Tung University, Hsinchu, Taiwan, in 2022. He is currently the Director of the Department of Otorhinolaryngology at Kaohsiung Medical University Gangshan Hospital and an Associate Professor at Kaohsiung Medical University, Kaohsiung, Taiwan. His clinical and research interests focus on thyroid and parathyroid diseases, with particular expertise in thyroid surgery, ultrasound-guided thyroid ablation, intraoperative neuromonitoring, and voice preservation. His research focuses on improving the safety and functional outcomes of thyroid interventions, including both surgical and minimally invasive ablative approaches.

Speaking Topic(s)

Ablation Therapy for Thyroid Disease

Session Abstract

This presentation will provide an overview of personalized management for thyroid disease and discuss the evolving role of ablation therapy as a minimally invasive treatment option. The current indications, principles, and clinical roles of thermal and chemical ablation will be reviewed, together with translational evidence from our animal studies investigating thermal- and ethanol-related nerve injury using continuous intraoperative neuromonitoring and thermography. Clinical experience and research findings will also be presented, with particular emphasis on voice outcomes, procedural techniques, and practical considerations for improving the safety and effectiveness of thyroid ablation. Finally, the application of animal models to resident education and procedural training will be highlighted, bridging experimental research, clinical practice, and surgical education.

October 17 Hall B | 16:50-18:30

Global Health and Tropical Medicine

B5-熱帶醫學中心暨傳染病研究中心健康科學院

Time	Speaker	Moderator
16:50–17:30	Hazreen Abdul Majid	Ping-Yen Liu 劉秉彥
17:30–18:00	Che-Mai Chang 張哲邁	Chun-Yu Lin 林俊祐
18:00–18:30	Yu-Te Tsai 蔡毓德	Tzong-Shiann Ho 何宗憲



Speaker

Name Hazreen Abdul Majid

Job Title Prof and School of Health and Rehabilitation Sciences Ethics Lead

Department Dietetics

Organization Health Sciences University, United Kingdom

A brief biographical sketch

Professor Dr Hazreen Majid obtained his PhD from King's College London and subsequently completed a fellowship attachment at the Harvard T.H. Chan School of Public Health, where he worked under the supervision of Professor Walter Willett's research team. He has extensive experience as a specialist dietitian, having practised in tertiary acute care hospitals in both Kuala Lumpur and London, as well as in community healthcare settings in Liverpool. This diverse clinical and academic background has shaped his expertise in clinical nutrition, dietetics, public health, and translational research.

Professor Dr Majid is actively involved in both clinical and population health research. He currently runs a student led clinic that applies dietary approach in the management of patients with irritable bowel syndrome (IBS) and few other medical conditions. His research activities span clinical, epidemiological, and community-based studies, supported through collaborations with stakeholders at local, state, national, and international levels. Over the years, he has successfully established multidisciplinary partnerships and secured funding from a range of national and international agencies.

He serves as the Principal Investigator of the Malaysian Health and Adolescents Longitudinal Research Team Study (MyHeARTs), a major cohort study examining cardiovascular risk factors and health behaviours among Malaysian adolescents. Findings from this research have demonstrated that rural adolescents with unhealthy dietary patterns, particularly girls, experienced greater increases in body weight and body fat over time compared with boys. The MyHeARTs project has facilitated collaborations with numerous organisations, including the Ministry of Health Malaysia, UNICEF Kuala Lumpur, and the University of Bristol. Through support from the Newton Fund (MRC–ASM), his research team has conducted metabolomic analyses related to cardiovascular disease risk and developed MyHeART-BeAT, a school-based intervention targeting canteen operators to promote healthier food environments in Malaysian secondary schools.

Beyond adolescent health research, Professor Dr Majid has contributed significantly to studies investigating sodium intake and excretion among low-income urban populations, as well as the design and evaluation of lifestyle interventions for individuals at risk of non-communicable diseases. He completed research focused on population-level salt reduction strategies and serves as a co-investigator in studies exploring dietary intake and nutritional status among breast cancer survivors in Malaysia. His clinical nutrition research also remains highly active, particularly in critical care nutrition, with a growing focus on the nutritional rehabilitation and long-term recovery of intensive care unit (ICU) survivors.

An accomplished academic, Professor Dr Majid has authored two books, contributed to several book chapters, and published more than 150 articles in Web of Science-indexed journals. He has successfully supervised over 30 PhD students, reflecting his strong commitment to research training and capacity building. In recognition of his contributions to the profession, he was appointed a Fellow of the Malaysian Dietitians' Association in 2022. He currently serves as Ethics Lead for the School of Health and Rehabilitation Sciences at Health Sciences University, while continuing to advance research in post-ICU nutritional rehabilitation. In addition, he holds an Honorary Professorship at the University of Malaya, further strengthening his engagement in international research and academic collaboration.

Speaking Topic(s)

Level Up Your Health: Insights from the MyHeARTs Adolescent-to-Adult Cohort

Session Abstract

- Malaysian Health and Adolescents Longitudinal Research Team Study (MyHeARTs) followed 13-year-old adolescents longitudinally to examine how early lifestyle factors influence cardiovascular, pulmonary, and bone health in adulthood.
- Smoking, inadequate sleep, and higher adiposity were key predictors of NAFLD, while snacking frequency and physical activity showed no significant association.
- Obese rural adolescents consumed more energy and sugar, while physical activity declined across all groups, especially among rural girls.
- Continued follow-up into adulthood provides valuable evidence on how adolescent exposures influence long-term health, informing national policies for non-communicable disease prevention.



Moderator

Name Ping-Yen Liu
Job Title Superintendent
Department
Organization KUO General Hospital

A brief biographical sketch

Prof. Ping-Yen Liu, M.D., Ph.D., currently serves as Superintendent of Kuo General Hospital in Tainan, Taiwan, and is Professor at the Institute of Clinical Medicine, College of Medicine, National Cheng Kung University. He also serves as President of the Taiwan Society of Lipids & Atherosclerosis.

Prof. Liu received his M.D. from Kaohsiung Medical University and his Ph.D. from the Institute of Clinical Medicine at National Cheng Kung University. He subsequently completed postdoctoral research training in the Division of Cardiology at Brigham and Women's Hospital in the United States.

Throughout his career, Prof. Liu has held numerous academic and administrative leadership positions, including Director of Internal Medicine at National Cheng Kung University Hospital, Director of Cardiology, Director of the Institute of Clinical Medicine, and Director of the Clinical Medicine Research Center at National Cheng Kung University Hospital.

His research interests span cardiac catheterization, echocardiography, lipid and atherosclerosis research, genetics, artificial intelligence, nanomedicine, nanosensors, and point-of-care testing. His research integrates cardiovascular medicine with emerging diagnostic and digital technologies, with particular emphasis on translational applications that improve cardiovascular risk assessment, diagnosis, and patient care.

Prof. Liu has made significant contributions to cardiovascular research, including lipid and atherosclerosis management, cardio-oncology, artificial intelligence-assisted cardiovascular diagnosis, and point-of-care biosensing technologies. His recent work includes studies on cardioprotection in patients receiving cancer therapy, AI-based cardiovascular imaging, and portable diagnostic platforms. He has published extensively in leading international journals and holds patents related to atherosclerosis risk assessment and cardiovascular disease therapeutics.



Speaker

Name Che-Mai Chang
Job Title Assistant Professor
Department Master Program in Clinical Genomics and Proteomics
Organization Taipei Medical University

A brief biographical sketch

Dr. Chang is an Assistant Professor in the Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University (TMU). He received his BSc in Biotechnology from Kaohsiung Medical University, MSc in Molecular Biotechnology from the University of Birmingham, and PhD in Medical Biotechnology from TMU. During his doctoral training, he developed and optimized next-generation sequencing (NGS)-based adaptive immune receptor repertoire (AIRR) sequencing platforms and applied them to characterize T-cell receptor (TCR) and B-cell receptor (BCR) repertoires across diverse human diseases, including infectious diseases, kidney disorders, autoimmune diseases, and cancers.

After completing his PhD, he served as a postdoctoral researcher at Taipei Medical University-Shuang Ho Hospital, where he continued AIRR research and immune-cell atlas profiling of human kidney diseases. He subsequently joined the Genomics Research Center at Academia Sinica and later the National Health Research Institutes as a postdoctoral researcher, expanding his expertise to long-read sequencing, human pangenome analysis, and complex genomic variation. A representative achievement from this work was the comprehensive characterization of genetic variation and evolutionary divergence in the C-type lectin domain family 18 (CLEC18), using long-read whole-genome and transcriptome sequencing together with pangenome resources to resolve paralog-specific variation and identify a novel CLEC18A segmental duplication.

His current research focuses on immunogenomics and immunopharmacogenomics, aiming to elucidate the mechanisms underlying human disease and the inter-individual variability in responses to drugs and vaccines. His representative studies include AIRR analyses in rheumatoid arthritis (RA), coronavirus disease (COVID-19), primary mucosal melanoma, aldosterone-producing adenoma (APA), and immunoglobulin A nephropathy (IgAN). He aims to develop scalable high-throughput AIRR sequencing platforms and analytical frameworks to discover disease-associated immune biomarkers and signatures for precision diagnostics and therapeutics.

Speaking Topic(s)

Decoding the Adaptive Immune Receptor Repertoire in Human Infectious Diseases

Session Abstract

This presentation will introduce the concept of the adaptive immune receptor repertoire (AIRR) and its role in shaping adaptive immune responses. It will describe how AIRR sequencing can be used to characterize T-cell receptor repertoires and investigate their associations with human diseases. Finally, the presentation will highlight our research on identifying TCR features and signatures associated with infectious disease severity, demonstrating their potential as biomarkers for disease monitoring, risk stratification, and clinical assessment.



Moderator

Name Chun-Yu Lin
Job Title Associate Professor
Department Division of Infectious Disease
Organization Department of Internal Medicine



Speaker

Name Yu-Te, Tsai
Job Title Director
Department Infectious Disease
Organization Kaohsiung Medical University Gangshan Hospital

A brief biographical sketch

- Current employer and work place:
  - Attending Physician
  - Division of Infectious Diseases, Department of Internal Medicine
  - Department of Infection Control
  - Institution: Kaohsiung Medical University Gangshan Hospital
- Educational background:

  2025/9-present: Ph.D. Program, Graduate Institute of Medicine, Kaohsiung Medical University

  2020/9-2024/1 M.Sc: Tropical Medicine, Graduate Institute of Medicine ,Kaohsiung University, Kaohsiung, Taiwan

  2008/9-2014/6 M.D: School of Medicine, Kaohsiung University, Kaohsiung, Taiwan
- Professional experience: infectious disease, internal medicine, HIV disease
- Research interest: arboviral diseases, viral disease, immunology

Speaking Topic(s)

Dengue Unveiled: Current Insights into Pathogenesis, Clinical Advances, and AI Integrations

Session Abstract

Dengue virus (DENV) remained a global public health challenge, driven by expanding vector habitats and complex host-pathogen interactions.

We examine updated mechanisms of dengue pathogenesis, vascular leakage and severe immunopathology, particularly host inflammatory responses and cross-reactive immunity.

In clinical management, we highlight progress in early diagnostic biomarkers, host-directed therapies, and novel vaccine platforms designed to mitigate antibody-dependent enhancement. Furthermore, we explore the emerging role of artificial intelligence in predicting disease severity, therapeutic target discovery, and optimizing epidemiological surveillance.



Moderator

Name Tzong-Shiann Ho
Job Title Superintendent
Organization National Cheng Kung University Hospital Dou-Liou Branch

A brief biographical sketch


Tzong-Shiann Ho, MD, MSc, PhD, is Superintendent of National Cheng Kung University (NCKU) Hospital Dou-Liou Branch, Taiwan, and Associate Professor of Pediatrics at NCKU. A pediatric infectious disease specialist, he is also an attending physician at NCKU Hospitals. Dr. Ho holds a BS in Biology and an MSc in Microbiology and Immunology from NCKU, an MD from Kaohsiung Medical University, and a PhD from the NCKU Institute of Clinical Medicine. After pediatric residency and an infectious diseases fellowship at NCKU Hospital, he practiced emergency medicine there (2009– 2021). From 2013 to 2014, he was a visiting scholar at the Johns Hopkins Bloomberg School of Public Health. He later directed the Departments of Pediatrics and Emergency Medicine at Tainan Hospital, Ministry of Health and Welfare. He then served as Deputy Superintendent of the Dou-Liou Branch before becoming its Superintendent. His research focuses on dengue virus infection: how the disease causes damage, biomarkers of severe disease, and tools for early diagnosis and severity prediction. His team has developed rapid diagnostic tests, flavivirus and SARS-CoV-2 protein microarrays, and machine-learning models for dengue. It has also contributed to dengue vaccine development. He also studies immunity to enteroviruses, influenza, and SARS-CoV-2 in high-risk populations. Dr. Ho has published 68 peer-reviewed papers and holds 17 patents granted in five countries. His honors include two National Innovation Awards (2022, 2024), the NSTC FutureTech Award (2023), and the NSTC Best Performance Award (2024). He has also received the NCKU Best Teacher Award five times.

October 17 | **B2 Conference Room** | **16:50-18:30**

Practices of Smart Healthcare and Sustainable Transformation

C5-智慧健康醫療與永續轉型實踐

Time	Speaker	Moderator
16:50–17:15	Simon J. A. Buczacki	Chia-Yen Dai 戴嘉言
17:15–17:40	David Jhuang 莊景榮	Jhi-Joung Wang 王志中
17:40–18:05	Cheng-Wei Lu 陸正威	Kwong-Leung Yu 余廣亮
18:05–18:30	I-Cheng Lu 盧奕丞	Kwong-Leung Yu 余廣亮



Speaker

Name Simon J.A. Buczacki
Job Title Richard Blackwell Professor of Colorectal Surgery
Department Nuffield Department of Surgical Sciences
Organization University of Oxford

A brief biographical sketch

Professor Simon Buczacki MA MB BChir PhD FRCS is the Richard Blackwell Pharsalia Professor of Colorectal Surgery at the University of Oxford. He is Associate Head of the Nuffield Department of Surgical Sciences, leads the NIHR Oxford Biomedical Research Centre Surgical Theme, and is Director of Graduate Studies for the Oxford Cancer PhD Programme.

He studied medicine at Gonville and Caius College, Cambridge, before completing a Cancer Research UK funded PhD in colorectal cancer biology. His clinical practice focuses on colorectal cancer and small intestinal neuroendocrine tumour surgery, while his translational research investigates cancer cell identity, differentiation and tumour evolution using patient derived models and contemporary genetic approaches.

His research has received substantial competitive funding, including Cancer Research UK Clinician Scientist and Advanced Clinician Scientist Fellowships and a £1.5 million CRUK Programme Foundation Award. He has published widely in cancer biology and surgery, including in Nature, Nature Genetics and Science, alongside clinical research in perioperative weight loss and surgical quality.

His awards include a National Clinical Impact Award, the John Nicholls Lecture and the British Journal of Surgery Prize. Outside medicine, he enjoys running, mountain sports, country pursuits and photography.

Speaking Topic(s)

Creation and validation of an AI-driven classifier for precision immuno-oncology in colorectal cancer

Session Abstract

Immune checkpoint therapy has transformed the treatment of mismatch repair deficient colon cancer, but mutational burden alone incompletely captures tumour immunogenicity and most patients remain unlikely to benefit. We developed the Immunogenicity Classification of Colon Cancer Subtypes (ICS), a multidimensional multiomic classification of tumour immunogenicity that identifies five biologically distinct immune states, including an immunogenic non hypermutated subgroup, and have validated these subtypes across independent external cohorts. A supervised machine learning classifier enables ICS subtype assignment directly from de novo transcriptomic data, providing a scalable framework for prospective biological and clinical application. Interrogation and functional validation of the determinants underlying these immune states identified ZFHX4 mutation and IHH expression as candidate predictors of tumour immunogenicity, providing potential biomarkers and mechanistic targets for extending immunotherapy beyond conventionally defined immune responsive colon cancer.



Moderator

Name Chia-Yen Dai
Job Title Vice Superintendent
Department Division of Hepatobiliary and Pancreatic Medicine
Organization Kaohsiung Medical University Chung-Ho Memorial

A brief biographical sketch

Chia-Yen Dai, M.D., Ph.D., is Vice Superintendent of Kaohsiung Medical University Hospital, Distinguished Professor at the College of Medicine, Kaohsiung Medical University, and Attending Physician in the Hepatobiliary Division, Department of Internal Medicine. He received his M.D. from Kaohsiung Medical University and subsequently earned both his Master's and Ph.D. degrees in Medical Science from the Institute of Medical Science at Kaohsiung Medical University.

Dr. Dai is a hepatologist whose clinical and research interests focus on the epidemiology and treatment of hepatitis B and C, liver cirrhosis, and the extrahepatic manifestations of chronic hepatitis C. His research also encompasses steatosis and metabolic liver diseases, as well as the natural course, treatment, and molecular biology of hepatocellular carcinoma (HCC).

Dr. Dai has authored or co-authored more than 480 SCI-indexed manuscripts, including more than 70 as first author. In recognition of his dedication and contributions to healthcare and medicine, he was honored with the 33rd Medical Contribution Award presented by the Health, Welfare and Environment Foundation.

He is also actively engaged in professional societies and organizations, serving as Executive Director of the Taiwan Liver Cancer Association; Director of the Gastroenterological Society of Taiwan, Taiwan Academy of Tumor Ablation, and Taiwan Society of Health Promoting Hospitals; and Medical Director of the Taiwan Liver Research Foundation.



Speaker

Name David Jhuang
Job Title Senior Data Scientist
Department B Business Group
Organization Foxconn (Hon Hai Technology Group)

A brief biographical sketch

Dr. David Jhuang is a Senior Data Scientist in the B Business Group at Hon Hai Technology Group (Foxconn). Leveraging a Ph.D. in Epidemiology and Preventive Medicine from National Taiwan University and a background in AI engineering, he bridges clinical science, data architecture, and regulatory compliance. At Foxconn, Dr. Jhuang leads the smart endoscope ecosystem initiative in close collaboration with Kaohsiung Medical University (KMU), NVIDIA, YuanYu, and YUAN. By combining Foxconn's technology architecture with KMU's clinical excellence, he drives the development of AI-driven colonoscopy solutions toward SaMD regulatory approval—transforming clinical collaboration into scalable, high-impact smart healthcare.

Speaking Topic(s)

AI-Enabled Colonoscopy for Precision Screening: Shaping the Next Generation of Smart Endoscopic Care

Session Abstract

This presentation explores the paradigm shift toward AI-enabled colonoscopy for precision diagnosis. By integrating real-time computer vision into endoscopic technology, this system assists clinicians in identifying subtle colorectal polyps and early-stage lesions, minimizing missed diagnoses while significantly enhancing diagnostic efficiency.

Central to this session is the strategic collaboration among Foxconn, KMU Hospital, YuanYu, and YUAN. By pairing Foxconn's scalable technology architecture with KMU's clinical excellence, this joint initiative demonstrates how medical AI transitions from R&D into frontline clinical suites to address critical healthcare needs and deliver tangible value.

Ultimately, the session shows how AI reshapes colonoscopy—evolving from instant image analysis to comprehensive clinical decision support. By bridging engineering innovation with rigorous clinical practice, this ecosystem showcases a scalable model for the next generation of smart endoscopic care that is accurate, proactive, efficient, and patient-centered.



Moderator

Name Jhi-Joung Wang
Job Title Senior Research Professor
Department Department of Medical Research
Organization Chi Mei Medical Center

A brief biographical sketch

CURRICULUM VITAE

Jhi-Joung Wang, M.D., Ph.D.

Professor of Anesthesiology

Education

National Defense Medical Center, Taiwan 1981-M.B., (M.D.)

National Defense Medical Center, Taiwan, 1992-D.M.Sc. (Ph.D.)

Current Position

1. Senior research professor, department of medical research, Chi Mei Medical Center, Tainan, Taiwan
2. External expert committee member of the Advisory Team for Controlled drugs, Taiwan FDA
3. Jointly appointed professor of the College of Photonics, National Yang Ming Chiao Tung University, Tainan, Taiwan
4. Jointly appointed professor of National Defense Medical Center, Tainan, Taiwan
5. Adjunct professor of several Medical Universities and Universities of Science & Technology in Taiwan

Experience

1. 7th Chairman of the Taiwan Pain Society (2001-2003,)
2. 22nd Chairman of the Taiwan Society of Anesthesiologists (2002-2004)
3. Chair of Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan (2000-2007)
4. Chair of Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan (2000-2021)
5. Deputy Superintendent of Education, Chi Mei Medical Center, Tainan, Taiwan (2007-2021)
6. Board member of the Chi Mei Hospital Board of Directors, Tainan, Taiwan
7. Chair professor of the Chi Mei Hospital Steering Committee

Research Focus and Achievements

- Opioid agents, AI big data analytics, novel medical device R&D with AI technologies, AI robots
- With more than 150 SCI publications and recognition with more than 10 National Innovation Awards in the recent 5 years.



Speaker

Name Cheng-Wei Lu
Job Title Director
Department Department of Anesthesiology
Organization Far Eastern Memorial Hospital

A brief biographical sketch

Dr. Cheng-Wei Lu is Director of the Department of Anesthesiology at Far Eastern Memorial Hospital, New Taipei City, Taiwan, and a joint-appointment professor in the Department of Mechanical Engineering at Yuan Ze University. He also holds an adjunct faculty position in the Department of Anesthesiology, College of Medicine, National Taiwan University.

Education:
He received his MD from National Taiwan University (1992–1999), a Master's from the Graduate Institute of Biomedical Sciences at Fu Jen Catholic University (2006–2008), and a PhD in Mechanical Engineering from Yuan Ze University (2009–2013).

Professional experience:
Following residency at National Taiwan University Hospital (1999–2003), Dr. Lu joined Far Eastern Memorial Hospital as an attending physician in 2003, where he has practiced continuously since. He has held faculty appointments at both National Taiwan University College of Medicine and Yuan Ze University, and has served in leadership roles at the Taiwan Society of Cardiothoracic and Vascular Anesthesiologists, including Secretary-General (2021–2024) and current executive board member.

Research interests:
His work spans cardiac and geriatric anesthesia, perioperative pain control, and physiological signal analysis (EEG-based depth-of-anesthesia monitoring, intracranial pressure complexity), alongside a substantial line of synaptosome-based research on how natural compounds and anesthetic/analgesic agents modulate glutamate release and neuroprotection. He is also engaged in perioperative environmental sustainability, including carbon-footprint analysis of surgical and anesthetic practice.

Representative achievements:
Dr. Lu has authored well over 100 peer-reviewed publications in journals including Brain, British Journal of Anaesthesia, Anesthesiology, and Journal of Thoracic and Cardiovascular Surgery, and has led or co-led more than a dozen national research grants on neuroprotection and perioperative monitoring. His honors include the Taiwan Society of Anesthesiologists' Young Investigator Award, the Yu-Hsiang Hsu Memorial Foundation Distinguished Professor Award, and the Excellence Lecture Award from the Taiwan Society of Cardiothoracic and Vascular Anesthesiologists.

Speaking Topic(s)

No More Hot Air, No More Cold Feet: Implementing a Green Anesthesia Framework in a Tertiary Medical Center

Session Abstract

This presentation explores how a tertiary medical center can translate the principles of green anesthesia into practical and sustainable clinical practice. It will introduce a structured framework focusing on anesthetic gas optimization, resource and waste reduction, environmental impact assessment, education, and patient safety. Beyond carbon emissions, the presentation will address emerging concerns such as life-cycle environmental impacts, pharmaceutical waste, and ecotoxicity. Finally, real-world implementation strategies will illustrate how environmental sustainability can be integrated with quality, safety, efficiency, and value-based perioperative care.



Moderator

Name Kwong-Leung Yu
Job Title CEO
Department PTCH Board
Organization Pingtung Christian Hospital

A brief biographical sketch

Dr. Kwong-Leung Joseph Yu (余廣亮) is an Associate Professor of Anesthesiology at Kaohsiung Medical University (KMU) and currently serves as the CEO of Pingtung Christian Hospital Board. A distinguished clinical medical alumnus and PhD of KMU, Dr. Yu has dedicated his career to bridging advanced clinical practices—including anesthesia, intensive care, pain management, and palliative care—with pioneering international health programs in developing nations.

He served as the Chief of the Taiwan Medical Mission to Malawi from 2003 to 2008, and has acted as the Director of the International Cooperation Department for Luke International since 2008. A recipient of the prestigious ICMDA HIV/AIDS Initiative Dignity and Right to Health Award in 2010, Dr. Yu's extensive work in international development and pandemic containment exemplifies Taiwan's vital and active role as an essential partner in global health cooperation In his submitted oral presentation, he can elegantly tie his background to the study's conclusions:

- The Palliative/Intensive Care Connection: His experience in managing severe cases (intensive care) and quality of life in developing nations (such as his research on palliative cancer care in Northern Malawi) highlights why optimizing vaccine distribution to prevent severe disease is so critically vital in resourceconstrained environments.
- The Pandemic Programs Legacy: His leadership during the HIV/AIDS pandemic in Malawi provides the perfect historical foundation for why he established the research partnership with the Public Health Institute of Malawi (PHIM) to build the digital infrastructure and epidemiological datasets needed for this SARSCoV- 2 study



Speaker

Name I-Cheng Lu
Job Title Associate Professor
Department Anesthesiology
Organization Kaohsiung Medical University

A brief biographical sketch

Biographical Sketch: Dr. I-Cheng Lu

Current Position

Dr. I-Cheng Lu, MD, PhD, currently serves as an **Associate Professor in the Department of Anesthesiology** at the College of Medicine, Kaohsiung Medical University. Clinically, he holds the position of **Chief of the Division of Cardiothoracic Anesthesiology** at the Kaohsiung Medical University Hospital and concurrently acts as the Director of the Department of Anesthesiology at Kaohsiung Medical University Hospital.

Educational Background

Dr. Lu completed his entire medical and academic training at Kaohsiung Medical University, where he received his Bachelor of Medicine (MD) in 2000. Driven by a passion for advanced medical research, he later earned his Master's degree in 2005 and successfully obtained his **PhD in Medicine** in 2016.

Professional Experience

With over two decades of clinical experience in anesthesiology, Dr. Lu has established himself as a leading specialist in Taiwan. Beyond his roles within the KMU healthcare system, he is highly active in professional societies. He serves for the Taiwan Society of Cardiothoracic and Vascular Anesthesia and the Taiwan Society of Airway Management.

Research Interests

Dr. Lu's primary research interests lie at the intersection of clinical anesthesiology, patient safety, and medical monitoring technology. His focal areas include: Advanced **intraoperative neuromonitoring** during thyroid surgery; Multimodal analgesia and Enhanced Recovery After Surgery (ERAS) & Airway management and patient safety.

Representative Achievements

Dr. Lu has published numerous high-impact SCI papers in leading international journals. One of his most notable achievements is his pioneering work in translational research involving **anesthesia and neural monitoring models**. His doctoral research established robust experimental frameworks that successfully translated into clinical workflows, specifically improving the safety of thyroid surgeries by safeguarding vocal cord nerves through optimized anesthetic techniques.

Speaking Topic(s)

From Standardization to Sustainability: Leveraging ERAS & Encare as Innovation Engines for Perioperative Leadership

Session Abstract

Enhanced Recovery After Surgery (ERAS) has evolved from an evidence-based clinical initiative into a standardized model of perioperative care, reshaping the role of anesthesiologists beyond the operating room. This presentation will explore how the ERAS® Interactive Audit System (EIAS) and ERAS® Implementation Program support structured implementation, continuous audit, international benchmarking, and certification. It will also examine how the ERAS era is redefining anesthesiologists' professional identity, talent development, and leadership responsibilities within multidisciplinary perioperative teams. Finally, the presentation will discuss how anesthesiologists can leverage ERAS as a platform to cultivate future talent and lead sustainable transformation in perioperative care.

October 18 Hall A | 10:20-12:00

Precision Medicine and Global Developments in Innovative Clinical Technologies

A6-精準醫療與國際臨床新技術發展

Time	Speaker	Moderator
10:20–10:45	Yi-Lwun Ho 何奕倫	Zhih-Cherng Chen / Chao-Ming Hung 陳志成／洪朝明
10:45–11:10	Kai-Wen Huang 黃凱文	Zhih-Cherng Chen / Chao-Ming Hung 陳志成／洪朝明
11:10–11:35	Chin-Chen Pan 潘競成	Tai-Lung Cha / Jin-Shuen Chen 查岱龍／陳金順
11:35–12:00	Wei-Ming Li 李威明	Tai-Lung Cha / Jin-Shuen Chen 查岱龍／陳金順



Speaker

Name Yi-Lwun Ho
Job Title Vice Superintendent/Director
Department Superintendent office/Telehealth Center
Organization National Taiwan University Hospital

A brief biographical sketch

Yi-Lwun Ho is the Vice Superintendent of National Taiwan University hospital (NTUH). At the same time, he is also the Director of the Telehealth Center of NTUH. He had been Associate Dean and Director of Branch Office of Academic Affairs in the of College of Medicine, National Taiwan University (NTUCM), Director of the Department of Internal Medicine in NTUH, Director of the Smart Health Technology R&D Center in NTU, and Professor of the Department of Internal Medicine in NTU School of Medicine. He is also Professor (joint appointment) of Graduate Institute of Clinical Medicine, Graduate Institute of Medical Genomics and Proteomics, Graduate Institute of Medical Devices and Imaging in NTUCM, and Department of Computer Science and Information Engineering in College of Electrical Engineering and Computer Science, NTU.

Dr. Ho began his medical studies in 1983 at the NTU School of Medicine, receiving his MD in 1990. He then completed residency training in the Department of Internal Medicine of NTUH (1990-1993), and chose to specialize in cardiology, fulfilling his fellowship training in the Section of Cardiology, Department of Internal Medicine, NTUH (1993-1995). In 1998, Dr. Ho commenced doctoral studies at the Graduate Institute of Clinical Medicine,NTUCM; his PhD was conferred in 2003. He also completed an Executive MBA (EMBA) at the Graduate Institute of Information Management, NTU College of Management (2010-2012).

His academic positions include Clinical Assistant Professor (since 2001) at NTU School of Medicine, and Assistant Professor at the Graduate Institute of Clinical Medicine, NTUCM (since 2006). He is also Director of the Heart Failure Center of NTUH, a position he has held since 2008. Dr. Ho previously served as Secretary of the Taiwan Society of Atherosclerosis and Cardiovascular Disease from 2001 to 2010. He served as Director of the Information Management Division of NTUCM from 2016 to 2019.

Since his first publication in 1994, Dr. Ho has authored or co-authored more than 150 articles in peer-reviewed journals, most recently with a focus on telehealth programs and their application to modern medical practice.

Speaking Topic(s)

The ABCDEFG Roadmap of AI Empowered Telehealth

Session Abstract

The roadmap of AI empowered telehealth included algorithm, big data, cloud computing, device, edge computing, FinTech, and generative AI. Through the platform which integrating measurable home data (from wearable apparatus), voice texture (from conversation between patients and case managers), and health medical records (from hospital), precision tele- care could be performed in patient centric medical home.



Moderator

Name Zhih-Cherng Chen
Job Title CEO, Medical Education Allinance
Department Superintendent's Office
Organization Chi Mei Medical Center

A brief biographical sketch

Dr. Chen was born in Kaohsiung and completed his education in Taipei. From 1989 to 1994, he underwent residency and fellowship training in internal medicine and cardiology at the National Cheng Kung University Hospital. In 1994, he moved to Chi Mei Medical Center, where he served as an attending physician in cardiology, Director of the Division of Cardiology, Director of the Teaching Center, and Deputy Superintendent for Medical Education. He also attained the rank of Ministry-certified Professor while teaching at the Department of Pharmacy, Chia Nan University of Pharmacy and Science.



Moderator

Name Chao-Ming Hung
Job Title Superintendent
Department General Surgery
Organization E-Da Cancer Hospital

A brief biographical sketch

Current Position:

E-Da Cancer Hospital, Superintendent
I-SHOU UNIVERSITY, School of Medicine, Professor
Ministry of Education, Professor

Educational background:

2014.09 – 2019.08 National Kaohsiung Normal University, PhD
2009.09 – 2011.09 National Sun Yat-sen University, M.D
1985.09 – 1992.06 China Medical University, Taiwan

Professional experience:

General Surgeon、Breast Surgery、Surgical Oncology、Thyroid Surgery



Speaker

Name Chin-Chen Pan
Job Title Director, Professor
Department Department of Pathology and Laboratory Medicine
Organization Taipei Veterans General Hospital

A brief biographical sketch

Department Director 2022.11-present

Department of Pathology, Taipei Veterans General Hospital Professor 2004-present, National Yang Ming University

International councilor Asia. International Society of Urologic Pathology, 2015-2019

M.D. 1982-1989 National Yang-Ming University

Research Fellowship in Kidney-Urologic Pathology , Johns-Hopkins University, School of Medicine,1998 – 1999

Speaking Topic(s)

Implementing precision medicine in a Medical Center-Taipei Veterans General Hospital Experience

Session Abstract

We will share our experience implementing multidisciplinary precision medicine at a medical center, covering germline diseases, somatic mutations in cancer, gut microbiota, and pharmacogenomics. Real-world cases will be presented to demonstrate the value of precision medicine in diagnosis, treatment, and prevention.



Moderator

Name Tai-Lung, Cha
Job Title Distinguished Investigator and Director
Department National Institute of Cancer Research
Organization National Health Research Institutes

A brief biographical sketch

Dr. Cha is the Distinguished Investigator and Director of the National Institute of Cancer Research, National Health Research Institute, Professor of the Division of Urology, Department of Surgery, TSGH, NDMC, as well as Jointly Appointed Professor of Genomics Research Center, Academia Sinica.

Dr. Cha received his MD degree from the School of Medicine, National Defense Medical Center in 1990. He got his PhD degree from GSBS, The University of Texas, MD Anderson Cancer Center in 2005. Upon his return to Taiwan, he served as a surgeon-scientist dedicated to cancer diagnosis and treatment, along with his active participation in international anti-cancer drug development clinical trials worldwide, which has afforded him a profound understanding of the entire spectrum of cancer research. During his tenure as the full professor of the National Defense Medical Center, he was invited to be the convener of the Department of Nephrology, Urology, and Metabolism at the National Science Council, he possesses a comprehensive understanding of the nation's scientific research direction and key points that would contribute to the advancement and connection of the basic and clinical research.

Dr. Cha has played numerous leadership roles in medicine and research. He served the Presidentship in NDMC and is a member of the Taiwan Medical Education Evaluation Committee, he strives to align Taiwan's medical education with international standards collaboratively. Additionally, his involvement in the Medical Policy Council, directorship and supervision of the Health Policy Council, and roles in the National Innovation Award's academic research and corporate innovation committees. He has served as the director of the Acer Foundation and the Revitalization Hospitals. He received the 2021 National Excellent Teacher Award from the Ministry of Education and was listed in the World’s Top 2% Scientists 2021.

Dr. Cha’s research interests concentrated on unraveling the mechanisms of cancer metastasis and progression and discovering innovative cancer treatments. His lab uncovered a novel cancer mitochondrial regulatory mechanism and identified a drug combination targeting this mechanism. This study was transferred to a biotechnology

company. After completing pre-clinical animal toxicity testing, this new drug combination obtained IND approval in Taiwan and the United States. Dr. Cha initiated and completed a Phase I clinical trial to assess the drug's safety and preliminary efficacy for patients with advanced kidney cancer and other cancers resistant to multiple drug treatments. The biotechnology company collaborated with six medical centers in Australia for Phase I and Phase IIa clinical trials, leading to the prestigious 13th National Innovation Award.

Over the past decade, Dr. Cha's Lab identified a novel G protein-coupled receptor, mediating the evolution of cancer metastasis in various cancer types. Dr. Cha elucidated the fundamental molecular mechanisms governing the transition of cancer cells from paracrine to autocrine signaling regulation through the novel GPCR pathway.



Moderator

Name Jin-Shuen Chen
Job Title Superintendent
Department Nephrology
Organization Kaohsiung Veterans General Hospital

A brief biographical sketch

Jin-Shuen Chen, M.D., Ph.D., currently serves as Superintendent of Kaohsiung Veterans General Hospital, one of Taiwan's leading tertiary medical centers, and holds a professorship in the Department of Internal Medicine at National Defense Medical Center. A nationally recognized nephrologist and clinician-scientist, he has served as President of the Taiwan Society of Nephrology since December 2025, where he helps shape national standards of kidney care. Concurrently, he serves as Chairman of the Kaohsiung City Medical Association (since April 2025), extending his influence into regional healthcare policy, physician advocacy, and medical governance.

Dr. Chen earned his Ph.D. from the Graduate Institute of Clinical Medicine at National Defense Medical Center, where he was trained in both laboratory science and evidence-based clinical practice, and he subsequently completed an Executive MBA with a concentration in Accounting and Management. This dual academic foundation bridges clinical scholarship with institutional leadership, allowing him to combine scientific rigor with financial and strategic management in the running of a large public hospital.

Dr. Chen's professional experience spans internal medicine, nephrology, clinical research, medical education, and hospital administration. Before assuming his present role, he served as Deputy Superintendent of Kaohsiung Veterans General Hospital from March 2021 to January 2024, taking on hospital-wide responsibility for clinical services, quality management, and research development. As Superintendent he now leads the institution's operations and long-term strategic planning. He remains actively engaged in professional societies and teaching, with a sustained commitment to advancing nephrology care, strengthening chronic kidney disease programs, and training the next generation of specialists in Taiwan.

Dr. Chen specializes in internal medicine and nephrology, with research focusing on the pathophysiology and translational study of kidney diseases. His laboratory uses animal models to investigate membranous nephropathy and diabetic nephropathy, focusing on the mechanistic roles of plasminogen and the discovery of novel disease biomarkers for earlier diagnosis and risk stratification. He also leads initiatives to establish and analyze

comprehensive biobanks for end-stage renal disease (ESRD), linking clinical, laboratory, and molecular data in order to advance precision nephrology. Also, his career reflects a sustained record of clinical excellence, academic leadership, and institutional innovation.

A committed advocate of Smart Healthcare and ESG-based sustainable governance, he led the hospital in developing the "FHIR Commander" system, recognized by Taiwan's SMART 50 Awards, and in achieving prestigious placements in Newsweek's 2026 rankings—2nd in Taiwan and 116th globally among the World's Best Smart Hospitals, and 13th in Taiwan among the World's Best Hospitals. Throughout his career, Dr. Chen has received numerous honors, including Outstanding Military Physician, Best Teacher at National Defense Medical Center and Tri-Service General Hospital, the National Quality Control Circle Outstanding Award, and Clinical Teaching Excellence Awards, underscoring his dedication to medical talent cultivation and pedagogical innovation.

Moreover, in the past decades, he has published more than 100 articles in nephrology and other areas of medicine, and he continues to mentor younger physicians and researchers, contributing to the international exchange of knowledge in kidney health.



Speaker

Name Wei-Ming Li
Job Title Director
Department Urology
Organization Kaohsiung Medical University Gangshan Hospital

A brief biographical sketch

Position and Affiliation:

2024-presen Director, Department of Urology, Kaohsiung Medical University Gangshan Hospital, Kaohsiung, Taiwan

2009-present Attending Urologist, Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

2022-present Professor, Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Education

1995-2002 M.D., School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

2006-2008 M.S., Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

2010-2017 Ph.D., Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Research Focus:

Uro-oncology, cancer biology, cancer metastasis

Speaking Topic(s)

Recent Advances in Molecular Diagnostics and Intelligent Minimally Invasive Treatment for Urothelial Carcinoma

Session Abstract

This presentation will review recent advances in molecular diagnostics for urothelial carcinoma, focusing on molecular subtyping, urinary biomarkers, circulating tumor DNA and molecular residual disease, with emphasis on their emerging roles in risk stratification and treatment selection. It will then explore the evolution of intelligent, minimally invasive treatment, including AI-assisted tumor detection, digital pathology, precision TURBT, robotic-assisted radical cystectomy, and kidney-sparing approaches for upper tract urothelial carcinoma. The presentation will highlight the integration of molecular data, advanced imaging, and artificial intelligence to improve diagnosis, treatment selection, and surveillance, while discussing the future of personalized precision uro-oncology.

October 18 Hall B | 10:20-12:00

Technological Innovation in Home Healthcare and Swallowing Care: A Taiwan-Japan Perspective

B6-產學及金屬工業中心

Time	Speaker	Moderator
10:10–10:50	Kazunari Ogura 小倉和也	Lan-Yuen Guo / Sang-Ju Yu / Te-jen Chu 郭藍遠／余尚儒／朱得仁
10:50–11:20	Haruka Tohara 戸原玄	Ming-Chu Feng 馮明珠
11:20–12:10	Chen-Cheng Yang 楊鎮誠	Chun-Hung Chen / Sang-Ju Yu 陳俊鴻／余尚儒



Speaker

Name Kazunari Ogura
Job Title Director/President
Organization Hachinohe Family Clinic/Japan Network for Inclusive Communities

A brief biographical sketch


Dr. Kazunari Ogura is a family physician and Director of Hachinohe Family Clinic in Aomori, Japan. He serves as President of Japan Network for Inclusive Communities, and President of NPO Reconnect. His work focuses on home care medicine, multidisciplinary collaboration, advance care planning, and the use of ICT, telemedicine, and IoT to support community-based care. He has led several national and international initiatives promoting Hybrid Care and integrated care models in aging societies.

Speaking Topic(s)

Innovations in Home-Based Care and Community Integration in Japan

Session Abstract

Japan's aging and declining population is driving innovations in home-based care and community integration. This presentation introduces connect 8, a community care team established by NPO Reconnect in Hachinohe, which promotes multidisciplinary collaboration through shared learning and ICT-based information sharing. It explores how these community networks can support pandemic and disaster responses, improve coordination with emergency services, and respect individual wishes through Advance Care Planning. It also considers how this approach can contribute to an inclusive society that supports older adults, people with disabilities, children, and foreign residents.



Moderator

Name Sang Ju Yu
Job Title Honorary president
Organization Taiwan society of home health care

A brief biographical sketch

Dr. Yu Sang-Ju is a distinguished physician from Kaohsiung, Taiwan, specializing in family medicine, hospice, and palliative care. He holds an M.D. from Kaohsiung Medical University and an M.Sc. in Public Health from National Cheng-Kung University. He is the founder and president of the Taiwan Society of Home Health Care (TSOHHC) and the chief director of Home Clinic Dulan. Dr. Yu's work is focused on advancing an ecological system for home care medicine, especially in rural and remote areas, through innovative hospital-at-home services and hybrid care models. He was a key figure in establishing the National Health Insurance's Home Acute Care pilot program and assisted the National Science and Technology Council in promoting a national project on "Home Medical Technology." He also serves as the vice-chair of the NHI home care medicine committee, and chair of that since 2025, and played the Co-chair of the first Asia-Pacific Hospital at Home congress held in Taipei 2026. His enthusiasm of promoting home care in Asia, and extensive research and publications on home healthcare, palliative care, and telemedicine underscore his commitment to multidisciplinary care and improving patient well-being.



Speaker

Name Haruka Tohara
Job Title Professor
Department Department of Dysphagia Rehabilitation
Organization Institute of Science Tokyo

A brief biographical sketch

Haruka Tohara, DDS, PhD, is a Professor in the Department of Dysphagia Rehabilitation at the Institute of Science Tokyo, Japan. He graduated from the School of Dentistry at Tokyo Medical and Dental University in 1997 and completed his graduate studies in Geriatric Dentistry. He also conducted research training in Rehabilitation Medicine at Fujita Health University and Johns Hopkins University School of Medicine.

He has extensive clinical and academic experience in geriatric dentistry and dysphagia rehabilitation. He has held academic and clinical positions at Tokyo Medical and Dental University and Nihon University School of Dentistry, and has served as a clinician in both hospital and home-care settings. His clinical practice includes home dental care for older adults, with a particular focus on dysphagia and oral health.

From 2008 to 2013, he served as Associate Professor at Nihon University School of Dentistry, followed by an Associate Professor position at Tokyo Medical and Dental University from 2013 to 2019. He became Professor of Dysphagia Rehabilitation at Tokyo Medical and Dental University in 2020 and has been Professor at the Institute of Science Tokyo since 2024.

His research interests include dysphagia rehabilitation, geriatric dentistry, swallowing function, and oral health in older adults. He has received several academic and professional awards, including awards from the Japanese Society of Dysphagia Rehabilitation, the Japanese Society of Gerodontology, and Tokyo Medical and Dental University. He serves in leadership and committee positions in several professional societies, including the Japanese Society of Gerodontology and the Japanese Society of Dysphagia Rehabilitation. He is a certified professional of the Japanese Society of Dysphagia Rehabilitation and holds certifications as a specialist and supervising specialist from the Japanese Society of Gerodontology.

Speaking Topic(s)

The Future of Dysphagia Rehabilitation: From Research to Clinical Practice

Session Abstract

Dysphagia rehabilitation involves more than swallowing tests and exercises, as the causes and severity of swallowing dysfunction vary among individuals. This presentation will introduce recent research conducted by our group, including perspectives on chewing, texture-modified diets, and rehabilitation approaches in institutional and home-care settings, and discuss how these findings may be applied in clinical practice. Although some of these findings are still preliminary, they may offer new perspectives for the future of dysphagia rehabilitation. The presentation aims to provide clinicians with perspectives that may help broaden the way they assess and manage patients with dysphagia.



Moderator

Name Ming-Chu Feng
Job Title Vice Superintendent
Department Superintendent Office
Organization Kaohsiung Municipal Siaogang Hospital

A brief biographical sketch

Educational

- Master of Science in Nursing, Graduate Institute of Nursing, National Cheng Kung University, Tainan, Taiwan.
- Master of Business Administration and Executive Master of Law and Business Administration, National University of Kaohsiung, Kaohsiung, Taiwan.

Professional

- Vice Superintendent, Kaohsiung Municipal Siaogang Hospital, August 2023 – Present
- Chief Executive Officer, Department of Multidisciplinary Swallowing Center, Kaohsiung Municipal Siaogang Hospital, August 2020 – Present
- Mastication and Deglutition Functional Restoration Center Fooyin University, Associate professor, August 2020 – Present

Representative achievements

- 2026 Asia-Pacific Sustainability Action Awards-Outstanding Chief Sustainability Officer Award
- 2024 TCSA(Taiwan Corporate Sustainability Awards)-Social Inclusion Leadership Award



Speaker

Name Chen-Cheng Yang

Job Title

Department

Organization

A brief biographical sketch

Chen-Cheng Yang is Director of the Department of Occupational Medicine at Kaohsiung Municipal Siaogang Hospital and Assistant Professor at Kaohsiung Medical University, Taiwan. He also serves as Director of the International Committee of the Taiwan Society of Home Health Care. He received his MD, MPH, and PhD from Kaohsiung Medical University and has been a Visiting Researcher at the University of Tokyo.

His clinical and research interests include **occupational injury rehabilitation, return to work**, **workplace mental health, healthy aging, and home healthcare**. His work focuses on integrating medical treatment, functional rehabilitation, home- and community-based care, and return-to-work support to improve continuity of care for injured workers. He is also actively involved in research on Hospital at Home, artificial intelligence in healthcare, frailty, and sustainable healthcare.

Speaking Topic(s)

The Journey Home: Rehabilitation and Home-Based Care for Patients with Traumatic Brain Injury

Session Abstract

Traumatic brain injury (TBI) resulting from occupational accidents can lead to persistent physical, cognitive, behavioral, and psychosocial consequences. For working-age patients, recovery extends beyond acute treatment and hospital discharge and involves rebuilding independence, family and social participation, and, whenever feasible, returning to work.

This presentation introduces an integrated care pathway for occupational TBI developed from the experience of occupational injury management at Kaohsiung Municipal Siaogang Hospital. The model connects acute medical treatment with functional assessment, multidisciplinary rehabilitation, occupational injury case management, home-based care, workplace assessment, and return-to-work planning. Functional recovery is evaluated not only through neurological outcomes but also through activities of daily living (ADL), instrumental activities of daily living (IADL), mobility, communication, and participation. Our previous occupational injury cohort research has demonstrated an association between short-term improvements in ADL/IADL and subsequent return to work, highlighting the importance of early functional recovery.

For patients with complex disability, the home becomes an extension of the rehabilitation environment, where caregiver needs, environmental barriers, safety, and meaningful daily activities can be addressed. Effective recovery therefore requires coordination across hospital, home, community, and workplace settings.

Rather than viewing discharge as the endpoint, this integrated approach considers returning home as the beginning of the next stage of recovery, with the ultimate goals of functional independence, social participation, and sustainable return to work.

October 18 | **B2 Conference Room** | **10:20-12:00**

Orthopedic Regenerative Medicine: Innovations and Clinical Applications

C6-醫療科技與政策研究中心

Time	Speaker	Moderator
10:20–10:50	Masato Sato 佐藤正人	Yin-Chih Fu 傅尹志
10:55–11:25	Mel S. Lee 李炫昇	Chung-Hwan Chen 陳崇桓
11:30–12:00	Chung-Hwan Chen 陳崇桓	Mel S. Lee 李炫昇



Speaker

Name Masato Sato
Job Title Professor & Director
Department Orthopaedic Surgery
Organization Tokai University

A brief biographical sketch

Masato Sato, M.D., Ph.D.

Professor & Chair, Department of Orthopaedic Surgery, Tokai University School of Medicine Director, Center for Musculoskeletal Innovative Research and Advancement (C-MiRA) 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. Tel +81-463-93-1121 (ext. 2320) sato-m@tokai.ac.j

PROFILE

Dr. Masato Sato is an orthopaedic surgeon and translational scientist who has spent over two decades turning cartilage regeneration from laboratory concept into approved clinical therapy. A pioneer of chondrocyte cell sheet transplantation for knee osteoarthritis, he led its first-in-human application and its approval as Advanced Medical Care in Japan; the technique has since been successfully applied to more than 65 patients in Taiwan. Exploiting the immune privilege of cartilage, he developed allogeneic chondrocyte sheets from polydactyly donor tissue and launched industry-partnered clinical trials, opening a scalable, off-the-shelf pathway for joint preservation. His program uniquely integrates surgery, automated cell sheet manufacturing, small RNA and extracellular vesicle biology, photoacoustic cartilage diagnostics, and regulatory science.

CLINICAL & RESEARCH ACTIVITIES

2023–present Principal Investigator, large-scale multi-center clinical study of platelet-rich plasma for knee osteoarthritis (JSRM–JOA joint initiative), and AMED supported Clinical Trial
2019–present Principal Investigator, Advanced Medical Care and clinical studies of autologous chondrocyte sheets for osteoarthritis
2014–present Principal Investigator, Clinical studies of allogeneic chondrocyte sheets for osteoarthritis
2010–2018 Leeder, Non-invasive cartilage diagnosis using laser-induced photoacoustic measurement
2004–2018 Principal Investigator, Clinical studies of autologous chondrocyte sheets for joint repair

APPOINTMENTS

2003–present Tokai University School of Medicine — Assistant Professor (2003), Associate Professor (2007), Professor (2013); Head, Department of Orthopaedic Surgery, Tokai University Hospital (2019); Director, C-MiRA (2020)
2001–2003 Chief, Department of Orthopaedic Surgery, Self-Defense Force Hospital Yokosuka
2001–2003 Resident and Senior Resident, National Defense Medical College and Self-Defense Force Hospitals

EDUCATION

Ph.D. in Medicinal Sciences, National Institution for Academic Degrees, 2001 (Graduate study: National Defense Medical College, 1997–2001)
M.D., National Defense Medical College, Japan, 1991

LEADERSHIP & PROFESSIONAL SERVICE

A s Director of the Japanese Society for Regenerative Medicine, he chairs its committees for institutional accreditation and appropriate evaluation of regenerative medicine and helped shape the Yokohama Declaration promoting evidence-based, exploratory therapies over unverified out-of-pocket treatments. He chairs the MHLW Working Group for Review of Regenerative Medicine and serves as an expert member for AMED, PMDA, and JSPS..

President & Director, Japanese Society of Cartilage Metabolism, Delegate, Japanese Orthopaedic Association, Fellow, International Cartilage Regeneration & Joint Preservation Society and International Orthopaedic Research Society, Associate Editor, Regenerative Therapy and Journal of Orthopaedic Science.

Speaking Topic(s)

Polydactyly-Derived Allogeneic Chondrocyte Cell-Sheet Transplantation Combined with High Tibial Osteotomy: A Scalable Regenerative Therapy for Knee Osteoarthritis

Session Abstract

This lecture presents a translational program integrating high tibial osteotomy (HTO) with chondrocyte cell-sheet transplantation as a joint-preserving regenerative therapy for knee osteoarthritis. Building on our first-in-human autologous experience, the presentation will focus on allogeneic chondrocyte cell sheets fabricated from juvenile polydactyly-derived cartilage (PD sheets), covering their preclinical validation and a clinical series of ten patients treated with open-wedge HTO combined with PD-sheet transplantation. Clinical outcomes, photoacoustic assessment of cartilage viscoelasticity, histological evidence of hyaline-like repair, and gene-expression markers predictive of therapeutic response will be discussed. Finally, I will briefly introduce our next-generation NACS platform for automated cell-sheet manufacturing, which aims to make allogeneic regenerative therapy scalable and widely accessible.



Moderator

Name Yin-Chih Fu
Job Title Superintendent
Department Office of the Superintendent
Organization Kaohsiung Show Chwan Memorial Hospital

A brief biographical sketch

Professor Yin-Chih Fu, M.D., Ph.D., is Superintendent of Kaohsiung Show Chwan Memorial Hospital, Professor in the Ph.D. Program in Biomedical Engineering at Kaohsiung Medical University, and an attending orthopedic surgeon at Kaohsiung Medical University Hospital. As a clinician-scientist and hospital leader, his expertise encompasses hand surgery, microsurgery, trauma surgery, regenerative medicine, biomaterials, and biomedical translation.

His research focuses on translating clinical needs into innovative medical devices and regenerative strategies. In recent years, he has directed preclinical studies on kidney regeneration and transplantation using supercritical carbon dioxide-decellularized whole-kidney extracellular matrix scaffolds in New Zealand White rabbit and Lanyu mini-pig models. These studies investigate host-cell recruitment, vascular and tissue remodeling, renal-lineage repopulation, and partial functional recovery following transplantation.

He has also contributed to patented innovations in minimally invasive surgery, bone fixation and positioning systems, controlled-release technologies, and additive manufacturing. Notably, technologies he co-developed—including a minimally invasive surgical instrument for carpal tunnel syndrome, controlled-release pharmaceutical technology, and a PTH-based treatment for early-stage osteoarthritis—have successfully progressed to technology transfer.



Speaker / Moderator

Name Mel S. Lee
Job Title Superintendent
Department Orthopedic Surgery
Organization Pao-Chien Hospital

A brief biographical sketch

Prof. Mel S Lee graduated with a Doctor of Medicine from Taipei Medical University and a PhD from the Graduate Institute of Clinical Medicine, Chang Gung University, Taiwan. From 1999-2000, he was a Visiting Assistant Professor to Stanford Medical Center, USA. He is now the superintendent of Pao-Chein Hospital, Taiwan.

Prof. Lee is specialized in joint reconstruction and was the president of Taiwan Joint Reconstruction Society, the editor in chief of the Formosan Journal of Musculoskeletal Disorders, and independent reviewer for peer-reviewed journals such as JOR, JBJS, CORR, J Rheumatology, J Biomechanics, JOSR, etc. He has published more than 250 peer-reviewed articles and 100 symposium papers in the field of joint reconstruction. As a renowned surgeon in his country, he has delivered more than 100 invited speeches and lectures domestically and internationally.

Speaking Topic(s)

Osteonecrosis of the femoral head, from C2B

Session Abstract

Osteonecrosis of the femoral head commonly affects young adults and is the leading cause for the hip joint replacements in many Asian countries including Taiwan. The ultimate goal is to preserve the involved hip. However, this is often challenging since early diagnosis is difficult, etiologies are miscellaneous, pathogenesis is unclear, and successful treatment is undetermined. As a consequence, this disease remains to be well-known but unresolved. This talk is to discuss the progress from the clinical studies to the bench works on the natural history, risk factors, genetic predilections, diagnosis, staging, and miscellaneous therapeutic modalities.



Speaker / Moderator

Name Chung-Hwan Chen

Job Title Present CEO/ Regenerative Medicine and Cell Therapy Research Centre
Present Director/ Orthopaedic Research Center

Organization Kaohsiung Medical University

A brief biographical sketch

Dr. Chung-Hwan Chen is the Chief Executive Officer of the Regenerative Medicine and Cell Therapy Research Centre at Kaohsiung Medical University (KMU), Taiwan, a position he has held since August 2025. He is also a Professor at KMU, Director of the Orthopaedic Research Center, Attending Physician in the Department of Orthopaedics at Kaohsiung Medical University Hospital, Jointly Appointed Professor at National Sun Yat-sen University, and President of the Taiwanese Osteoporosis Association.

Dr. Chen received his Doctor of Medicine (M.D.) from Kaohsiung Medical University in 1994 and completed his Ph.D. at the same institution in 2013. Following his residency training in orthopaedic surgery, he has devoted more than two decades to clinical practice, academic research, and medical education in orthopaedics and regenerative medicine. Throughout his career, he has held numerous leadership positions, including Director of the Department of Orthopaedics at Kaohsiung Municipal Ta-Tung Hospital, President of the Taiwan Orthopedic Research Society, General Secretary of the Taiwan Osteoporosis Association, and Deputy General Secretary of the Taiwan Orthopedic Association.

His research focuses on regenerative medicine, orthopaedic surgery, musculoskeletal tissue engineering, cartilage and bone regeneration, biomaterials, additive manufacturing, osteoporosis, and innovative therapies for degenerative musculoskeletal diseases. He is particularly interested in translating basic scientific discoveries into clinically applicable regenerative treatments through interdisciplinary collaboration integrating stem cell biology, biomaterials, and tissue engineering.

Dr. Chen has received multiple prestigious awards recognizing his contributions to biomedical innovation. In 2024, he received the 21st National Innovation Award for his work on thrombomodulin- and miRNA-based strategies for the prevention and treatment of osteoarthritis. In 2020, he was honored with the 17th National Innovation Award for innovative additive manufacturing technologies for bioceramic applications. Earlier, he received the First Prize for Best Abstract at The Acelity Surgical Wound Forum in 2018. These achievements reflect his longstanding commitment to advancing translational research and developing innovative regenerative therapies that improve patient care.

Today, Dr. Chen continues to lead multidisciplinary research programs in regenerative medicine and cell therapy while fostering international collaborations, promoting translational research, and advancing innovations in musculoskeletal health and regenerative medicine.

Speaking Topic(s)

The study of exosomes in musculoskeletal system in Kaohsiung Medical University

Session Abstract

Application of exosomes from stem cells in musculoskeletal regeneration

Chung-Hwan Chen

1Department of Orthopedic Surgery, Kaohsiung Medical University Hospital, Taiwan

hwan@kmu.edu.tw

Musculoskeletal disorders, including osteoarthritis, cartilage and bone defects, tendinopathies, and ligament and severe skeletal muscle injuries, represent a profound global health burden that frequently leads to chronic pain and impaired mobility. Stem cell-based therapies—particularly those utilizing mesenchymal stem cells (MSCs)—have shown significant regenerative promise, their clinical translation is often hindered by challenges such as low cell survival rates post-transplantation, potential immune rejection, and the risk of tumorigenesis. Recently, stem cell-derived exosomes have emerged as a groundbreaking, "cell-free" alternative, overcoming these limitations while retaining the regenerative efficacy of their parent cells. Exosomes are nanoscale extracellular vesicles (30–150 nm in diameter) uniquely enriched with bioactive cargoes, including lipids, functional proteins, and nucleic acids such as microRNAs (miRNAs). As crucial mediators of intercellular communication, they execute their regenerative functions primarily through paracrine signaling. Upon internalization by target cells in the musculoskeletal system, stem cell-derived exosomes deliver their therapeutic payloads to modulate local microenvironments, suppress inflammation, promote angiogenesis, and inhibit cellular apoptosis. As a cell-free therapeutic platform, stem cell-derived exosomes offer distinct advantages over whole-cell therapies, including higher biological stability, negligible immunogenicity, and simplified logistics for storage and transport. Moreover, they can be bioengineered to carry specific pharmacological agents or targeted to specific tissues. In this study, we demonstrate exosome from bone marrow mesenchymal stem cells (BMSCs) and adipose tissue-derived stem cells (ADSCs), umbilical cord MSCs (UCMSCs) and induced pluripotent stem cells (iPSCs) facilitate the regeneration bone, cartilage, muscle and ligament and also ameliorate osteoarthritis.

Keywords : *Adipose tissue-derived stem cells (ADSCs), bone marrow mesenchymal stem cells (BMSCs), exosome, induced pluripotent stem cells (iPSCs)*



Speaker

Name Li-Huei Tsai
Job Title Picower Professor of Neuroscience
Department Brain and Cognitive Sciences
Organization Massachusetts Institute of Technology

A brief biographical sketch

Professor Li-Huei Tsai is the Picower Professor of Neuroscience at the Department of Brain and Cognitive Sciences and an Investigator at the Picower Institute for Learning and Memory at MIT. Prof Tsai uses multi-omic approach to decipher the pathophysiology of Alzheimer's dementia (AD). Her team pioneered the use of patient-derived induced pluripotent stem cells (iPSCs) to produce various brain cell types and a novel 3D brain tissue model of AD pathology. She also pioneered the use of non-invasive sensory stimulation to treat AD and other neurological disorders. Tsai is a Fellow of the American Association for the Advancement of Science, a Fellow of the National Academy of Inventors, a Member of the National Academy of Medicine, an Academician of the Academia Sinica in Taiwan, and a Member of the American Academy of Arts and Sciences. She is a recipient of the Mika Salpeter Lifetime Achievement Award, the 2018 Hans Wigzell Research Foundation Science Prize for her research on Alzheimer's disease, and 2025 Distinguished Lecturer for Parkinson's Disease Research, Diana Helis Henry and Adrienne Helis Malvin Medical Research Foundations. In 2022 she was named a Visiting Professor of the Vallee Foundation.

Speaking Topic(s)

Frequency Matters: Gamma Sensory Stimulation Activates Neuromodulatory Pathways to Elicit Neuroprotection

Session Abstract

Rhythmic neural activity in the gamma range (30–80 Hz) plays a crucial role in cognitive function and is disrupted in several neurological conditions, including Alzheimer's disease (AD). We developed a method termed Gamma ENtrainment Using Sensory stimuli (GENUS), which uses patterned light and sound stimulation at 40 Hz in AD model mice to assess the effects of enhancing gamma oscillations. Our findings demonstrate that GENUS increases gamma power across multiple brain regions. Moreover, daily application significantly mitigates neuronal and synaptic degeneration, AD related pathology and improves cognitive function.

In addition, GENUS induces morphological and gene expression changes in glial cells and the vasculature. It also enhances cerebrospinal fluid influx and facilitates glial-mediated and lymphatic-like brain waste clearance, known as glymphatic clearance, through a hierarchical neuromodulatory system including the cholinergic signaling and neuropeptides. I will present our latest work elucidating the interplay between neuropeptides and neurotransmitters in mediating the neuroprotective effects of GENUS.



Speaker

Name Sara Mangsbo
Job Title Professor in Biologics and Vice Dean of Collaboration
Department Department of Pharmacy
Organization Domain Medicine and Pharmacy, Uppsala University

A brief biographical sketch

Professor Sara Mangsbo is a researcher, entrepreneur and translational immunologist working at the interface of antibody/peptide design, cancer immunotherapy and targeted drug delivery. She is Professor of Biologics at Uppsala University and has broad experience spanning academic research, therapeutic concept development and biotech innovation.

She holds a PhD in clinical immunology and has built her career around understanding and harnessing immune mechanisms for cancer treatment. Her research has included local immune modulation, therapeutic cancer vaccines, checkpoint-targeted strategies and agonistic immunotherapies, with particular focus on CD40-directed activation of antigen-presenting cells and anti-tumor T-cell responses.

Professor Mangsbo's current interests centre on the development of multifunctional biologics and precision delivery technologies. Her work combines antibody and bispecific-antibody engineering with peptide conjugates and functionalized lipid nanoparticles to enable selective delivery of therapeutic payloads, including siRNA and mRNA, to relevant cell populations. A central aim is to translate molecular targeting into safer, more effective and scalable treatments, including approaches for in-vivo immune-cell programming.

Her representative achievements include contributions to the development of CD40-targeted immunotherapies and peptide vaccine platforms, advances in antibody-based targeted delivery, and the establishment of translational biotech ventures. She has published widely in immunology, oncology and drug-delivery research, and continues to contribute to the development of next-generation immunotherapies.

Speaking Topic(s)

Title suggestion: "From Immune Checkpoint Blockade to Targeted Immune Programming: Antibody Agonists, Bispecifics and Precision Drug Delivery"

Session Abstract

Antibody therapeutics have evolved from selectively blocking pathogenic signals to actively programming immune responses and directing therapeutic activity with increasing precision. This keynote will focus on translational milestones from antagonistic checkpoint inhibitors to agonistic antibodies targeting co-stimulatory pathways such as CD40, and onward to bispecific formats that integrate tumour targeting, immune engagement and controlled receptor activation. Drawing on examples from our work in CD40-directed immunotherapy, peptide-based cancer vaccination and antibody engineering, the presentation will illustrate the opportunities and challenges in developing multifunctional therapeutics. Finally, it will explore how affinity-based targeting can be used to functionalize lipid nanoparticles, enabling cell-selective RNA delivery.



Speaker

Name Xiang Qian

Job Title Stanford Medicine Endowed Director; Clinical Professor of Anesthesiology, Perioperative and Pain Medicine; Clinical Professor (by courtesy) of Neurosurgery; Medical Director of International Medical Services in Stanford Health Care

Department Anesthesiology, Perioperative and Pain Medicine

Organization Stanford University School of Medicine / Stanford Health Care

A brief biographical sketch

Xiang Qian, MD, PhD, is the inaugural Stanford Medicine Endowed Director and Clinical Professor of Anesthesiology, Perioperative and Pain Medicine at Stanford University, with a courtesy appointment as Clinical Professor of Neurosurgery. He received his PhD in Physiology and Biophysics from the University of Miami Miller School of Medicine and completed postdoctoral training in neuroscience at the University of California, San Francisco, supported by an HHMI postdoctoral fellowship. He completed his anesthesiology residency and pain medicine fellowship at Stanford, and is board certified by the American Board of Anesthesiology in both anesthesiology and pain medicine.

Dr. Qian is internationally recognized for developing novel therapies for chronic pain, with particular expertise in migraine and headache, trigeminal and glossopharyngeal neuralgia, hemifacial spasm, atypical facial pain, cancer pain, and neuropathic pain. He leads Stanford's CT-guided interventional pain program and co-directs the Stanford Facial Pain Program, where he has pioneered minimally invasive, awake CT-guided procedures for facial pain and hemifacial spasm. He also serves as Co-Faculty Director of the Stanford Wearable Electronics Initiative (eWEAR), collaborating with engineering colleagues on wirelessly powered miniature implantable nerve stimulators. His research interests further include AI-based diagnosis and management, optogenetics, ion channel biology, and the mechanisms of neuropathic pain.

Since 2016, Dr. Qian has served as Medical Director of Stanford International Medical Services, advancing care for international patients and global academic collaboration. He is also the founder of the Chinese American Physicians' Society, which now has more than 800 physician members across 50 states and over 40 subspecialties. His honors include the Stanford Medicine Translational and Clinical Innovation Award (2017), the Fok Ying-Tung Medal from WACD (2019), and a Stanford Faculty Teaching Award (2021). A member of the Wu Tsai Neurosciences Institute, he has published widely in journals including Nature, PNAS, Neuron, and the Journal of Neurosurgery.

Speaking Topic(s)

Seeing the future of health

Session Abstract

The United States spends $5.3 trillion a year on healthcare, yet heart attacks and lung cancer are still too often caught too late, and roughly nine out of ten drug candidates never make it to approval. The Health World Model was built to address exactly this: it brings medical history, labs, imaging, genomics, medications, and physiological signals together into a single evolving health state that updates with every new observation, and from there simulates the trajectories a patient may follow under different treatment decisions. In our latest validation work, cancer-risk prediction reaches 74% sensitivity at 99% specificity, treatment-response prediction reaches an AUROC of up to 0.963, and adverse-event prediction across 12 organ systems reaches up to 0.877; we can also draw on roughly 2 million real-world U.S. patients and a 300,000-patient KMUH cohort to validate trial designs and endpoints before a single patient is enrolled. What we ultimately want is not just to see the future, but to create more opportunities to change it — earlier intervention and prevention, better-informed treatment, and a meaningful improvement in human health.

KISQALI® 擊癌利®
ribociclib 200毫克膜衣錠

早期乳癌適應症：
與芳香環轉化酶抑制劑併用，可做為治療荷爾蒙受體(HR)陽性、第二型人類表皮生長因子受體(HER2)陰性，高復發風險的第二期及第三期早期乳癌成人病人之輔助治療。



DO MORE

把握早期治療，守護長遠未來

什麼是擊癌利(KISQALI®)，為何醫師會開立處方給我？

擊癌利是乳癌治療計畫中的一個藥物，其長期目標為治療乳癌並預防復發[1,2]。擊癌利是標靶治療被設計為只阻止癌細胞的生長，不像化學療法會同時攻擊正常細胞與癌細胞[1]。擊癌利應與荷爾蒙治療 (例如芳香環轉化酶抑制劑)併用[1,3]。

擊癌利(KISQALI®)適用於哪些病人？

擊癌利適用於確診為早期乳癌(第二期或第三期沒有轉移至乳腺以外的器官)且已接受過手術或其他初始治療(例如放射治療和／或化學療法)的病人[4-6]。

1.Tripathy D et al. Clin Cancer Res. 2017;23(13):3251-3262. 2. Cancer.net. Breast Cancer: Types of Treatment, https://www.cancer.net/cancer-types/breast-cancer/types-treatment. Accessed November 2023. 3. Gennari A et al. 2021. Ann Oncol. 2021;32(12):1475-1495. 4. Ann Oncol. 2025 Feb;36(2):149-157. 5. American Cancer Society (ACS). Breast Cancer Facts & Figures 2022-2024, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2022-2024-breast-cancer-fact-figures-acs.pdf. Accessed November 2023. 6. Cancer Research UK. About breast cancer staging and grades, https://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-grades. Accessed November 2023.

擊癌利200毫克膜衣錠 KISQALI® 200mg Film-Coated Tablets 衛部藥輸字 第027320號

禁忌: KISQALI禁用於對活性物質或任何賦形劑過敏的病人。警語: QT間期延長。與Tamoxifen併用提高了QT期間延長。肝膽毒性。嗜中性白血球減少。胚胎-胎兒毒性。嚴重皮膚反應。間質性肺病(ILD)/肺炎。 副作用: 早期乳癌最常見 (≥ 20%)：淋巴球降低、白血球計數降低、嗜中性白血球計數降低、血紅素降低、丙胺酸轉胺酶增加、天冬胺酸轉胺酶增加、感染、肌酐增加、血小板降低、頭痛、噁心、倦怠。晚期乳癌最常見(≥ 20%)：白血球計數降低、嗜中性白血球計數降低、血紅素降低、淋巴球降低、天冬胺酸轉胺酶增加、丙麩胺醯轉移酶增加、丙胺酸轉胺酶增加、感染、噁心、肌酸酐增加、倦怠、血小板降低、腹瀉、嘔吐、頭痛、便秘、掉髮、咳嗽、皮疹、背痛、血清葡萄糖下降。

詳細資訊請掃QR code參閱完整仿單

FA-11644078_20260409-20280409

NOVARTIS 台灣諾華股份有限公司
10480 台北市中山區民生東路三段2號8樓
諾華網站：www.novartis.com.tw
電話：(02) 2322-7777
傳真：(02) 2322-7328

使用前請詳閱產品說明書之警語及注意事項，詳細處方資料備索

北市衛藥廣字第 115080181 號

FA-11747934_20260723-20280723

KISQALI® 擊癌利®
ribociclib 200毫克膜衣錠

僅限醫療專業人員參閱

A4廣告頁1.pdf 1 2026/9/30 下午 04:42:39

BIOTRONIC

精準建立氣道，效率升級

Precise Airway Management. Greater Efficiency

亞仕丹企業有限公司



The Voice of Biotronic

這個產品從線條，
重量，長度，配重，功能...
是台灣醫師與亞仕丹
一刀一刀雕刻出來
謝謝你們讓它變得更好
安全，創新，進步
獻給所有麻醉醫師

用電保全溫控新趨勢





首創雙加溫套管系統



高流量輸液加溫系統



■ 影像式插管/軟鏡 系列



◇ 新生兒



◇ 兒童/成人



骨科醫師的定心丸

有效有感 病患感恩





為關節照護而生
效果突破 實證有感

獨家成分
Sheaflex75
活關素75



為骨本提升而設
醫師驚艷 實證有效

專利獨特
ACC
非晶鈣



★ 數百場workshop 認證/肯定/共鳴 ★

醫學中心進院選用・口碑廣傳

UIC GROUP
天義企業股份有限公司
台北市復興南路一段129號5樓
總公司電話：(02)2752-3235

耀瑄科技 × 健康台灣深耕計畫

以科技為橋樑，以信任為根基——從智慧醫療、社會責任到人才培育，耀瑄攜手院方共同打造永續的智慧醫療生態。

深耕計畫首選夥伴

我們不只擁有技術，更擁有深厚且成功的實戰經驗。

聯手 20 多家 指標醫院、精準對應 四大範疇 的全線產品矩陣，以實戰經驗助您全方位制霸數位醫療先機！

40+
關鍵落地實績

範疇一 | 優化醫療工作條件 / 範疇三 | 導入智慧科技醫療



INFINITT PACS
醫療影像管理系統
為 INFINITT 代理商，整合影像資訊，提升診療效率。 代理商授權

eEMR 2.0
電子病歷管理系統
智慧記錄，安心醫療，讓每一份病歷更高效！

eMCS
數位憑證管理系統
安全掌握，隨行無憂，行動憑證，守護信任！

eReport
檢查報告系統
Web 化彈性表單，打造全院無紙化智能檢查報告系統！

eCDMS
慢性病個案管理系統
支援多疾病擴充，申報格式自動產製，精準掌握個案狀況。

eForm
電子表單管理系統
智慧表單管理，高效流暢運行！

eCIS
生理量測管理系統
CIS 數位量測平台，化繁為簡，照護更省力。

eRTS
呼吸照護管理系統
照護有感，效率翻倍，呼吸治療資訊一手掌握。

範疇四 | 社會責任醫療永續



UWB
智慧精準定位服務方案
結合高精度定位技術，實現資產管理、醫療照護多種應用。

eForm
同意書管理系統
推進全院無紙化永續減碳，友善簽署流程，守護醫病權益與信任。

範疇二 | 規劃多元人才培育



eEPO
數位學習暨臨床教育訓練管理系統
專為醫療機構打造的全員訓練合規管理平台，串連臨床實習歷程、專科醫師年度繼續教育、與全院職訓課程，讓「訓練規劃、執行、評核、追蹤」在單一系統中完成。

攜手推進，智慧醫療的每一步

我們深知智慧醫療的實踐不只仰賴技術，更來自對臨床需求的理解與現場的信任。

更多智慧醫療應用，敬請參閱耀瑄科技官方網站！

查看官網

聯絡我們

itovebi®
inavolisib癌妥飛®

精準第一步 啟動新篇幅

AGAINST *PIK3CA*mut in 1L Endocrine Resistance HR+/HER2- mBC[1]

- 顯著降低 33%死亡風險[2]
- 延長超過 2 倍之中位疾病無惡化存活期(mPFS)[1]
- 延後後續化療時間近3年[2]
- Itovebi 相關不良事件多為輕度至中度(1-2級)[1,2]
- 因任何不良反應導致的永久停藥率僅 6.8%[2]

適應症 與palbociclib和fulvestrant併用，適用於治療患有*PIK3CA*突變、荷爾蒙受體(HR)陽性、第二型人類表皮生長因子受體(HER2)陰性，對內分泌治療具抗藥性(endocrine resistance)，於輔助治療期間或輔助治療後疾病復發的局部晚期或轉移性乳癌成人病人。



1L:first line; HER2-:human epidermal growth factor receptor 2-negative; HR+:hormone receptor-positive; mBC=metastatic breast cancer; mut, mutation; *PIK3CA*=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

References: **1.** Turner NC, Im S-A, Saura C, et al. N Engl J Med. 2024;391(17):1584-1596. **2.** Jhaveri K, Im S-A, Saura C, et al. N Engl J Med. 2025 (ePub ahead of print)

福妥飛3, 9毫克膜衣錠
itovebi 3mg, 9 mg film-coated tablets 衛部藥輸字 第 028944 號 第 028945 號

適應症：與palbociclib和fulvestrant併用，適用於治療患有 *PIK3CA* 突變、荷爾蒙受體(HR)陽性、第二型人類表皮生長因子受體(HER2)陰性，對內分泌治療具抗藥性(endocrine resistance)，於輔助治療期間或輔助治療後疾病復發的局部晚期或轉移性乳癌成人病人。

用法用量：開始治療前：在開始itovebi治療前，應確認 *PIK3CA* 突變狀態。HR 陽性、HER2 陰性、局部晚期或轉移性乳癌病人接續效之檢驗確認存在一或多個 *PIK3CA* 突變後，方可展開接受 itovebi 治療。開始使用itovebi治療前，應檢測空腹血葡萄糖(fasting plasma glucose; FPG)/空腹血糖(fasting blood glucose; FBG)和 HbA_{1c} 數值，且所有病人的空腹血糖值均應達到最佳化再開始服藥。**建議劑量：** itovebi的建議劑量為9 mg，每日口服一次，可與食物併服或空腹服用。itovebi藥錠應整顆吞服，吞服前請勿咀嚼、壓碎或剝半。itovebi應與palbociclib和荷爾蒙治療併用。Palbociclib的建議劑量為每日口服一次125 mg，連續治療21天後停止治療7天，以28天為一個完整的週期。所用的荷爾蒙治療應依據處方資訊中的建議劑量投予。停經前/停經前後(pre/perimenopausal)婦女使用itovebi治療，也應依據當地臨床常規合併給予黃體生成素釋放素(luteinizing hormone-releasing hormone; LHRH)致效劑。針對男性病人，考慮依據當地臨床常規使用LHRH致效劑治療。**治療期間：** 建議病人應持續使用itovebi治療，直到疾病惡化或出現無法接受的毒性為止。延遲或遺漏劑量：建議病人每天大約相同的時間服藥。當忘記服用itovebi時，在平時服藥時間的9小時內可直接服藥。如果超過9小時，應跳過當天的劑量，隔天再於平時服藥時間服用itovebi。如果病人在服用itovebi後發生嘔吐，吐出已服用的藥錠，當天不應再服用額外的劑量，隔天於平時的服藥時間再繼續用藥。劑量調整：不良反應的處置可能需要暫時中斷用藥、降低劑量或停止itovebi治療。起始劑量：每日9mg/ 第一次降低劑量：每日6mg/ 第二次降低劑量：每日3mg/ 如果病人無法耐受3 mg的每日劑量，應永久停用itovebi。根據主治醫師對於病人的臨床評估，itovebi劑量可能再次調升至每日最高劑量9 mg。**警語/注意事項：** **高血糖症：** 使用itovebi治療的病人中曾有高血糖症的嚴重案例通報，包括危及生命的酮酸中毒等併發症。將未研究itovebi對於第一型糖尿病或需要持續接受全身性治療的第二型糖尿病病人的安全性。有第二型糖尿病病史且控制良好的病人，可能需要視臨床指示加強降血糖藥物治療和密切監測空腹血糖。高血糖症可以降血糖藥物處置[請參閱臨床重要副作用/不良反應(8.1)]。開始使用itovebi治療前，應檢測空腹血糖(FPG或FBG)和 HbA_{1c} 數值，且所有病人的空腹血糖值均應達到最佳。也應告知病人高血糖症的徵兆及症狀(如：極度口渴、排尿頻率變高、視力模糊、精神遲鈍、呼吸困難或食慾增加而體重減輕)，以及如果發生這些症狀應立即尋格醫護人員。在有高血糖症風險因子的病人中，包括但不限於：糖尿病(前期)、HbA_{1c} ≥ 5.7%、BMI ≥ 30 kg/m^2、年齡≥ 45歲、妊娠期糖尿病的病史和糖尿病的家族病史，應視臨床指示更頻繁地監測或自我監測空腹血糖值。應視需要開始使用或調整降血糖藥物治療[請參閱用法用量(3.1)]。NAVO120試驗中建議針對有高血糖症風險因子的病人給予metformin預防治療。如果病人在開始接受itovebi治療後發生高血糖症，應視臨床指示更密切監測空腹血糖。使用降血糖藥物治療期間，應至少每週監測一次空腹血糖持續8週，之後每2週一次，以及視臨床指示進行。針對有高血糖症風險因子或發生高血糖症的病人，應考慮進行居家空腹血糖監測。根據高血糖症的嚴重程度，可能需要中斷、調降劑量或停用itovebi。如表2所述[請參閱用法用量(3.1)]。應指導所有病人改變生活型態(如：飲食調整、體能活動)。**口腔炎** 接受itovebi治療的病人中曾有口腔炎的表例通報[請參閱臨床重要副作用/不良反應(8.1)]。根據口腔炎的嚴重程度，可能會中斷、調降或永久停用itovebi(見表3)。臨床試驗建議所有病人使用浸質鹽膠漱口水來預防口腔炎的第一個徵象時開始使用不含酒精的浸質鹽膠漱口水，並避免使用含酒精或過氧化物的漱口水。因為可能會加重病情[請參閱臨床重要副作用/不良反應(8.1)]。應考慮調整飲食習慣(如：避免辛辣食物)。**腹瀉** 接受itovebi治療的病人，可能會發生嚴重腹瀉，症狀包括脫水和急性腎損傷、電解病人腹瀉的徵象與症狀，病人在服用 itovebi 期間出現腹瀉的第一個徵象時，建議病人增加口服液體攝取量並開始給予止瀉治療。根據腹瀉的嚴重程度，暫停、減少劑量或永久停用 itovebi。**胚胎-胎兒毒性** 根據動物試驗和inavolisib的藥理特性，預期itovebi用於懷孕女性可能對胚胎或胎兒造成傷害[請參閱臨床前安全性資料(10.3)]。應告知懷孕女性對胎兒的潛在風險。應建議有生育能力的女性和男性病人，在itovebi治療期間和最後一劑itovebi劑量後2個內週使用有效的避孕措施[請參閱有生育能力的女性與男性(8.3)]。**臨床重要副作用/不良反應：** **高血糖症：** 在試驗BYNAVO120中，接受itovebi/常用palbociclib和fulvestrant治療中通報任何等級高血糖症的病人有99.9%；分別有38.3%和5.6%的病人通報第2級和第3級事件，且無第4級事件的通報(根據CTCAE第5.0版)。發生高血糖症新發作率在治療的前2個月最高(範圍：1至32個月)，首次發生的時間中位數為7天(範圍：2至955天)。**口腔炎：** 接受itovebi併用palbociclib和fulvestrant治療中通報口腔炎的病人有51.2%；有32.1%的病人通報第1級事件、13.8%的病人通報第2級事件，以及5.6%的病人通報第3級事件，並無第4級口腔炎事件的通報。首次發生的時間中位數為13天(範圍：1至610天)。**腹瀉：** 接受itovebi併用palbociclib和fulvestrant治療中通報腹瀉的病人有48.1%；有27.8%的病人通報第1級事件，16.7%的病人通報第2級事件，以及3.7%的病人通報第3級事件。並無第4級腹瀉事件的通報。首次發生的時間中位數為15天(範圍：2至602天)。**禁忌：** itovebi禁止使用於已知對inavolisib或任何賦型劑過敏之病人。

產品詳細資訊，請參考完整仿單。
羅氏大藥廠股份有限公司 臺北市南港區經貿一路170號10樓、10樓之1至之3、10樓之5至之8

M-TW-00007850

北市衛藥廣字第 114110024 號

Roche

以優質醫療保健豐富人們的生活



DKSH Taiwan Healthcare 台灣大昌華嘉醫療保健事業單位專精於藥品、非處方用藥、消費保健品、醫療器材、和病患支持服務。經銷通路包括醫院、診所、醫師、藥局、藥妝店、牙醫診所、眼科等。以提供民眾優質醫療保健為使命，堅守對國際品質標準的承諾和企業法規遵從。

擁有亞洲最大醫藥智能倉儲物流中心、受衛福部國際醫藥品稽查協約組織西藥優良運銷 (PIC/S GDP) 認證、ESG物流永續獎肯定的醫療自動化儲存和檢索系統 (ASRS) 設施，及 ISO、PIC/S、GMP 等關鍵認證。為您提供物流、倉管、藥品醫材加工、行銷與通路管理、銷售、醫院之醫材庫存管理、SAP 資訊系統、財務與人力管理的全方位服務。



讓我們成為您的最佳夥伴！

歡迎造訪 DKSH 官網 www.dksh.com
或掃描 QR Code 與我們聯繫！

DKSH

Delivering Growth – in Asia and Beyond.

SIEMENS Healthineers

Built on FHIR
Ready for the Future

Open APIs
Limitless Innovation

Interoperability
Without Barriers

ARIA CORE

ARIA API/FHIR Interface Engine

Demographics | Workflow | Documents | Diagnosis | Vitals | Providers | Billing | RT Summary

Oncology Management Solution
Multidisciplinary workflow management

Oncology Planning and Coordination
Radiation Therapy, Interventional, Radiopharmaceuticals

Therapy Selection
Decision Support, Genomics

Patient Engagement
Symptom monitoring, ePROs, Remote monitoring

Analytics and Insights
Actionable insights with KPI's, dashboards and reports

Advanced Capabilities
AI, Mobile Access



QR700039746



INCONVENIENCE IS A BARRIER, ALONG WITH SHAME AND LACK OF DISCRETION[1]

溶解親密關係的障礙[1,2]

VIAGRA® ODF
(sildenafil citrate)

DISSOLVES IN SECONDS

傳奇性的[4] VIAGRA®
現在有快速溶解的口溶膜[3,5,6]

VIAGRA 口溶膜讓男性能夠以私密且便利的方式管理勃起功能障礙[2,6,7,8]

References

1. Rodler S, von Büren J, Buchner A, et al. Epidemiology and treatment barriers of patients with erectile dysfunction using an online prescription platform:A cross-sectional study. Sex Med. 2020;8(3):370–377.
2. Jannini EA, Droupy S. Needs and expectations of patients with erectile dysfunction: An update on pharmacological innovations in phosphodiesterase type 5 inhibition with focus on sildenafil. Sex Med. 2019;7(1):1–10.
3. Shaw A, Lawrence TE, Yan T, et al. Bioequivalence studies of sildenafil citrate orodispersible film administered with and without water vs VIAGRA® film-coated tablets in healthy male volunteers. Curr Ther Res Clin Exp. 2023;99:100708
4. Tiefer L. The VIAGRA® Phenomenon. Sexualities. 2006;9(3):273-294.
5. Karki S, Kim H, Na SJ, et al. Thin films as an emerging platform for drug delivery. Asian J Pharm Sci. 2016;11(5):559–574.
6. 威而鋼口溶膜 50 毫克中文仿單
7. Shimoyama H, Sasaki H, Ogushi Y, et al. Clinical analysis on the pharmaceutical formulation of VIAGRA OD Film. J Sex Med. 2022;19(5):S190 .
8. Irfan M, Rabel S, Bukhtar Q, et al. Orally disintegrating films: A modern expansion in drug delivery system. Saudi Pharm J. 2016;24(5):537-546.


僅供專業醫護人員使用　北市衛藥廣字第 113120162 號　衛部藥輸字第 028643 號　TW-VIAG-2024-00021-202412

請掃描 QR code
取得仿單詳細資訊

VIATRIS

LEADING INNOVATIVE TRENDS

金屬工業研究發展中心
METAL INDUSTRIES RESEARCH & DEVELOPMENT CENTRE



聚焦產業

金屬材料及製品產業

- 低碳材料及製品
- 輕量化材料及構件
- 高值化金屬製品

醫療器材及照護產業

- 功能性植入式醫材
- 智慧監測診斷
- 智慧治療
- 智慧健康照護

高值精微製品產業

- 高值模具產業
- 半導體設備業
- 馬達產業

高值設備產業

- 表面製程設備
- 服務型機器人
- 減碳製程設備

綠能產業

- 創能
- 節能
- 儲能
- 氫能
- 低(碳)燃料

加入社群、會員廠商，看更多科技產業最新動態！

金屬中心

MIRDC Taiwan

YouTube
MIRDC Channel

LINE
產業淨零服務中心

MEET TECH
遇見科技–數位展示室

官網
會員廠商

檢測驗證網



www.mirdc.org.tw 金屬中心廣告

Sponsorship

Agilent Trusted Answers

AstraZeneca

BIO-CANDO

Biomedica Simple & Precise

亞仕丹企業有限公司 BIOTRONIC INSTRUMENT ENTERPRISE LTC

Boehringer Ingelheim

中華系統整合 CHUNGHWA SYSTEM INTEGRATION

DKSH

Eisai

ejoy2 捷懿企業股份有限公司

eXentric

J&H 博克科技 J&H TECHNOLOGY CO., LTD.

LEADGENE 偉基生醫

level Discovering new boundaries

MacroInsight Innovation

MIRDC 金屬工業研究發展中心 METAL INDUSTRIES RESEARCH & DEVELOPMENT CENTRE

超微醫學科技股份有限公司 MicroInstruments Medical Technology Co., Ltd.

NOVARTIS Reimagining medicine, together.

Pfizer

PharmiGENE 世基生物醫學股份有限公司

Roche

SIEMENS Healthineers varian

天義企業集團 UIC GROUP

元佑實業 YUAN YU INDUSTRY CO., LTD.

湛盧科技有限公司 Zhan-Lu Technology Co., Ltd.





控糖護腎力 救心保生命

forxiga®
(dapagliflozin)
福 適 佳®

預防心血管事件 (用於第二型糖尿病)
降低心衰竭住院 (HR 0.73；p<0.001)

預防腎臟病 (用於第二型糖尿病)
降低CKD新發生或惡化風險 (HR 0.53；p<0.001)

降低慢性腎臟病風險
降低ESKD (HR 0.64；P=0.0004)
降低總死亡 (HR 0.69，p=0.0035)

降低心衰竭風險
心臟重塑，對心血管死亡和心衰竭事件的治療效果在不同LVEF範圍(≧40; <40)一致

Reference: 1. FORXIGA 仿單 (2024/04)。

北市衛藥廣字第 113070243 號

福適佳 膜衣錠 5 毫克、10 毫克 Forxiga (Dapagliflozin) Film-coated Tablets 5 mg , 10 mg

【適應症】1. 第二型糖尿病：血糖控制：配合飲食和運動，改善第二型糖尿病成人病人的血糖控制。預防心血管事件：用於具第二型糖尿病且已有心血管疾病 (CVD) 或多重心血管風險因子的成人病人時，可降低心衰竭住院的風險。預防腎臟病：降低慢性腎臟病 (CKD) 新發生或惡化的風險。2. 慢性腎臟病：用於治療有惡化風險之慢性腎臟病的成人病人時，可降低持續性腎絲球過濾率 (eGFR) 下降、末期腎病 (ESKD)、心衰竭住院和心血管死亡的風險。3. 心衰竭：用於心衰竭的成人病人時，可降低心血管死亡、心衰竭住院和心衰竭緊急就醫的風險。【使用限制】不建議 Forxiga 用於第一型糖尿病病人，其可能增加這群病人糖尿病酮酸中毒之風險。不建議使用 Forxiga 作為 eGFR 低於 45 mL/min/1.73 m² 的第二型糖尿病病人的血糖控制。Forxiga 基於其作用機制，在此情況下可能無效。不建議使用 Forxiga 用於治療多囊性腎臟病病人、或慢性腎臟病病人其病情需要或近期曾接受免疫抑制療法治療。Forxiga 預計不會對這些病人族群有效。【用法用量】在開始 Forxiga 治療前應評估腎功能，之後依臨床需要進行評估。對於血容量不足的病人，應於在開始 Forxiga 治療前應評估血容量狀態，必要時應矯正血容量不足的情形。建議劑量：1. eGFR 45 或以上：為改善血糖控制，Forxiga 的建議起始劑量是 5 毫克每天口服 1 次。在耐受 Forxiga 5 毫克每天 1 次的病人，需要對於額外血糖控制時，劑量可增至 10 毫克每天口服 1 次。對於所有其他適應症的建議起始劑量是每天口服 1 次 10 毫克。2. eGFR 25 至小於 45：每天口服 1 次 10 毫克。3. eGFR 小於 25：針對此類病人不建議開始治療，然而 Forxiga 治療後，eGFR 降低至小於 25 的病人，可持續使用以降低 eGFR 下降、ESKD、心血管死亡和心衰竭住院的風險。【禁忌】對 Forxiga 嚴重過敏反應病史，如過敏反應或血管性水腫。【警語和注意事項】於糖尿病病人的酮酸中毒：使用 Forxiga 治療的病人，若出現嚴重代謝性酸中毒的症狀，無論血糖值為何，皆應評估是否發生酮酸中毒。當懷疑是酮酸中毒時，應停用 Forxiga，並評估病人狀況立即採取適當的治療。在開始使用 Forxiga 前，應考慮病人病史中可能容易產生酮酸中毒的因素，包括任何原因所導致的胰島素不足、熱量限制及酗酒。預計接受非緊急、選擇性手術的病人，應考慮至少 3 天前暫時中斷 Forxiga。血容量不足：Forxiga 可導致血管內容積減少，有時可能引起症狀性低血壓或肌酸酐急性短暫變化。腎功能不全的病人、老年病人或使用環利尿劑的病人，發生血容量不足或低血壓的風險可能增加。尿路敗血症和腎盂腎炎：接受 SGLT2 抑制劑 (包括 Forxiga) 的病人，有發生因嚴重泌尿道感染，包括尿路敗血症和腎盂腎炎，而需要住院的通報案例。與胰島素和胰島素分泌促進劑同時使用伴隨的低血糖：當與胰島素或胰島素分泌促進劑併用，Forxiga 可能會增加低血糖風險，會降低壞死性筋膜炎 (弗尼羅氏壞疽)：對於接受 Forxiga 治療如有出現生殖器或會陰區域疼痛或壓痛、紅斑或腫脹並伴隨發燒或身體不適的病人，皆應評估是否發生壞死性筋膜炎。生殖器黴菌感染：Forxiga 會增加生殖器黴菌感染風險，【不良反應】於糖尿病病人的酮酸中毒、血容量不足、尿路敗血症和腎盂腎炎、與胰島素和胰島素分泌促進劑同時使用伴隨的低血糖、會陰部壞死性筋膜炎 (弗尼爾氏壞疽)、生殖器黴菌感染。

本簡易仿單版本修訂日期：2024-4-09
節錄自完整仿單：2024 年 4 月 02 日 (版本修訂日期)

【使用前詳閱說明書警語及注意事項，詳細仿單資料備索。】
【僅限醫藥專業人員參考，處方藥物請參考衛生福利部核准仿單說明書。】

AstraZeneca 臺灣阿斯特捷利康股份有限公司 台北市敦化南路二段207號21樓
電話：(02) 2378-2390 傳真：(02) 2377-0914 http://www.astrazeneca.com.tw

TW-29814_FOR_16/10/2025



Breakthroughs that change patients' lives

逾175年來，
輝瑞研發的新藥已經挽救數百萬人的性命。
我們協助人們在生命中的各個階段預防或對抗疾病，
享受更好的生活品質。

在人道關懷及醫療經濟上，
持續擴大影響力並做出貢獻。

Pfizer 輝瑞大藥廠

Pfizer Taiwan
更多健康資訊與企業訊息，
歡迎追蹤台灣輝瑞官方臉書

LENVIMA®
(lenvatinib) capsules

RESPONSE THAT MATTERS

The first-line therapy for your uHCC patients.

在一項與 Sorafenib 對照的大型跨國第三期臨床試驗中，Lenvatinib 達到主要試驗指標，首度發現下列結果[1]：

統計證實整體存活期 (OS) 中位數不劣於 Sorafenib

Lenvatinib 13.6 個月 (95%信賴區間: 12.1-14.9) vs Sorafenib 12.3個月 (95%信賴區間: 10.4-13.9)；風險比: 0.92, (95%信賴區間: 0.79-1.06) , 試驗主持人依 mRECIST 評估

2倍 PFS

無惡化存活期 (PFS) 相較於 Sorafenib 治療組具有顯著統計意義之優勢

Lenvatinib 7.4個月 (95%信賴區間: 6.9-8.8) vs Sorafenib 3.7個月 (95% 信賴區間: 3.6-4.6)；風險比: 0.66 (95%信賴區間: 0.57-0.77)；P值<0.0001；試驗主持人依 mRECIST 評估

3倍 ORR

客觀反應率 (ORR) 相較於 Sorafenib 治療組具有顯著統計意義之優勢

Lenvatinib 40.6% vs Sorafenib 12.4%；P值<0.0001；依據 mRECIST by IIR 評估

LENVIMA®(lenvatinib); uHCC, unresectable hepatocellular carcinoma; OS, overall survival; PFS, progression free survival; ORR, objective response rate; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; mRECIST, modified Response Evaluation Criteria in Solid Tumors; IIR, Independent Imaging Review

Reference: 1. Kudo M et al. *Lancet*. 2018 Mar 24; 391(10126) : 1163–1173.

試驗設計：在一項隨機分配、開放性多中心之臨床試驗(REFLECT)中，以屬患無法手術切除之肝細胞癌且先前未接受過治療的病人為對象，評估 LENVIMA 治療肝細胞癌之療效。總計 954 位病人中，其中 478 位被隨機分配至 LENVIMA 治療組，而 476 位被隨機分配至 sorafenib 治療組。該試驗受試者之納入條件為：罹患肝細胞癌分級為 Child-Pugh A 及巴塞羅納臨床肝癌 (BCLC) 分期 C 或 B 之成人、ECOG PS 為 0 或 1、病人未曾接受過肝細胞癌之全身性治療，且根據 mRECIST，病人至少有 1 個可測量的標靶病灶。病人被隨機分配至接受 LENVIMA 每日口服一次（基期體重 ≥ 60kg 者服用 12mg；基期體重 < 60kg 者服用 8mg），或 sorafenib 400 mg 每日口服二次之治療，直到放射診斷結果顯示疾病惡化或發生無法接受之毒性則停藥。主要療效指標為整體存活期(OS)。REFLECT 試驗設計為足以偵測 LENVIMA 治療組之整體存活期 (OS) 不劣於 sorafenib 治療組。
其它療效指標是依 mRECIST, modified response evaluation criteria in solid tumors 判定（實質腫瘤立放射影像檢查）之無惡化存活期 (PFS) 及客觀反應率(ORR)。
安全性資訊摘錄：LENVIMA 無相關禁忌症。肝細胞癌臨床研究最常見之不良反應（≥ 20%）為高血壓、疲倦、腹瀉、食慾減退、關節痛/肌肉疼痛、體重減輕、腹部疼痛、肢端紅腫症、蛋白尿、發聲困難、出血事件、甲狀腺功能低下和嘔吐。
「處方 LENVIMA 之前，請詳閱藥品全文仿單說明書。」

Lenvima® 樂衛瑪® 膠囊 4毫克、10毫克 處方資訊摘要

產品名稱：樂衛瑪膠囊 4 毫克 產品名稱：樂衛瑪膠囊 10 毫克 主成分：Lenvatinib mesilate 適應症：分化型甲狀腺癌 (Differentiated thyroid cancer, DTC)：適用於放射性碘治療無效之進行性，且為局部晚期或轉移性之分化型甲狀腺癌之成人病人。腎細胞癌 (Renal Cell Carcinoma, RCC)：與pembrolizumab 併用，做為晚期腎細胞癌病人的第一線治療藥物。與everolimus併用，做為曾經接受過一種抗血管新生療法的晚期腎細胞癌病人的治療藥物。肝細胞癌 (Hepatocellular Carcinoma, HCC)：適用於無法手術切除且不適合局部治療之晚期肝細胞癌病人。子宮內膜癌 (Endometrial Carcinoma, EC)：與pembrolizumab併用適用於曾經以任何形式接受過全身性治療後疾病惡化，且不適合根治手術或放射治療之晚期子宮內膜癌病人，類別：須由腫瘤處方使用。用法及用量：腎臟或肝臟功能不全之病人應降低劑量。每日服用一次，可隨餐或空腹使用。如果忘記服藥並且未能在12小時內服用，應略過該次劑量並且於原定服藥時間投予下一次劑量。分化型甲狀腺癌 (DTC)：建議劑量為 24 mg，每日口服一次直到疾病惡化或發生無法接受之毒性。腎細胞癌 (RCC)：併用 pembrolizumab，用於晚期腎細胞癌(RCC)的第一線治療。建議劑量為每日口服一次20 mg，併用每3週靜脈輸注一次 pembrolizumab 200 mg，每次輸注時間超過 30 分鐘，直到疾病惡化或發生無法接受之毒性。併用 everolimus，用於先前曾經接受過治療的晚期腎細胞癌(RCC)。建議劑量為 18 mg，併用 5 mg everolimus，每日口服一次直到疾病惡化或發生無法接受之毒性。肝細胞癌 (HCC)：建議劑量是根據病人的實際體重：體重大於或等於60公斤(kg)的病人為 12 mg，或體重小於60公斤(kg)的病人為 8 mg，每日口服一次直到疾病惡化或發生無法接受之毒性。子宮內膜癌 (EC)：建議劑量為每日口服一次20 mg，併用每3週靜脈輸注一次 pembrolizumab 200 mg，每次輸注時間超過30分鐘，直到疾病惡化或發生無法接受之毒性。禁忌：無相關禁忌。警語及注意事項：使用 Lenvima® 可能會有下列風險與注意事項，視嚴重程度，暫停使用、減不良反應至對控制時，再降低劑量繼續治療，或是永久停用。使用前請詳閱衛福部核可之仿單：高血壓、心臟功能障礙、　動脈血管栓塞、肝毒性、腎衰竭或腎功能不全、蛋白尿、腹瀉、傷口癒合功能受損、顎骨壞死、下列為臨床試驗經驗，其發生率不能直接與其他藥物臨床試驗中的不良反應發生率相比，且不能代表實際服藥之不良反應發生率。Lenvima® 治療組之 DTC 病人中，最常見之嚴重不良反應(≥2%)為肺炎(4%)、高血壓(3%)和脫水(3%)。Lenvima® 併用 pembrolizumab治療組之 RCC 病人中，發生在≥2%病人中的嚴重不良反應為出血事件(5%)、腹瀉(4%)、高血壓(3%)、心肌梗塞(3%)、肺炎(pneumonitis)(3%)、嘔吐(3%)、急性腎損傷(2%)、腎上腺機能不全(2%)、呼吸困難(2%)和肺炎(pneumonia)(2%)。Lenvima® 併用 everolimus 治療組之 RCC 病人中，最常見之嚴重不良反應(≥ 5%)為腎衰竭(11%)、脫水(10%)、貧血(6%)、血小板低下(5%)、腹瀉(5%)、嘔吐(5%)和呼吸困難(5%)。Lenvima® 治療組之 HCC 病人中，最常見之嚴重不良反應(≥ 2%)為肝性腦病變(5%)、肝衰竭(3%)、腹水(3%)和食慾減退(2%)。Lenvima® 併用 pembrolizumab 治療組之 EC 病人中，發生在≥3%病人中的嚴重不良反應為高血壓(4.2%)和泌尿道感染(3.2%)。 藥商名稱：衛采製藥股份有限公司

TW-LV-ET-25I-05

衛部藥輸字第 026933、026934 號 北市衛藥廣字第 114100067 號

Eisai

MSD
INVENTING FOR LIFE

metalyse®
tenecteplase 25mg

全新世代血栓溶解劑

10秒1針 拯救人生



單次 5-10 秒的 IV推注注射[1-4]

確保給予完整劑量，讓溶栓不中斷[5]

無須輸注幫浦和不佔用 IV 管路[1,3,6]

1. Metalyse® 5000 units (25 mg) European Summary of Product Characteristics. Boehringer Ingelheim International GmbH. June 2025. 2. Alamowitch S., et al. Eur Stroke J. 2023; 8(1): 8–54. 3. Tsivgoulis G, et al. Lancet Neurol. 2023; 22: 418–429. 4. Warach SJ and Saver JL. JAMA Neurol. 2020; 77(10): 1203-1204. 5. Putaala J., et al. Stroke. 2021; 52:3075–80 6. Gerschenfeld G., et al. Eur Stroke J. 2022; 7.(4): 358–64. 7.Warach SJ., et al. Stroke. 2022; 53: 3583–93.

掃我查看使用方式 ▶

METALYSE, 栓體溶 凍晶乾燥注射劑 25 毫克

(詳細資料請參閱完整仿單)

適應症： 急性缺血性中風成人患者，在排除顱內出血後作為血栓溶解治療。

用法及用量： 應於中風發作 3 小時內盡早開始治療，並排除顱內出血後施用。治療效果與時間有關；盡早治療會增加有利結果的可能性。應根據體重施用 Metalyse，完成配製溶液應立即以靜脈給藥方式使用。所需劑量應以單次靜脈推注方式於 5 至10 秒鐘注射完畢。**禁忌：** 對任一成分或gentamicin (製造過程中微量殘留物) 過敏者禁用。禁用於以下情況：6個月內有重大出血性疾病；正接受凝血劑治療；懷疑有顱內出血或有病史；蛛網膜下腔出血；頭部或顱部創傷；已知出血傾向；2 個月內有重大手術、實質器官活檢或重大創傷；有活動性出血的胃腸道潰瘍；動脈瘤或動脈/靜脈畸形；伴隨出血風險增加的腫瘤；48 小時內使用 heparin，且凝血酶原時間超出檢測值正常上限；血小板少於 100,000/mm^3 ；中樞神經系統損傷病史；嚴重且未控制的動脈高血壓；嚴重中風(如 NIHSS >25)；無致殘性神經功能缺損或注射前症狀已迅速改善；細菌性心內膜炎、心包炎；急性胰臟炎；嚴重肝功能障礙；三個月內中風；處置後收縮壓 > 185 mg 或舒張壓 > 110 mmHg；處置後血糖仍 < 50 或 > 400 mg/dL。**常見不良反應：** 發生率 >1% 副作用包括: 出血(如顱內出血、鼻衄血、腸胃道、泌尿生殖器或注射部位出血等)，如發生嚴重而持久的出血，可考慮替代治療。

藥商 台灣百靈佳殷格翰股份有限公司　台北市中山區民生東路三段2號12樓
製造廠 Boehringer Ingelheim Pharma GmbH & Co. KG
(Birkendorfer Strasse 65, 88397, Biberach an der Riss, Germany)

北市衛藥廣字第 115070151 號
PC-TW-108875-26-June-2026

Boehringer Ingelheim

Jardiance® 恩排糖®
(empagliflozin)

護腎不限
全能守心



SGLT2i 中唯一不受腎功能限制
顯降 25% CV 死亡風險

Reference:
1. Herrington WG, et al. N Engl J Med. 2023;388(2):117-127.; 2. Herrington WG, et al. N Engl J Med (DOI: 10.1056/NEJMoa2409183).

恩排糖® 膜衣錠 10 毫克 Jardiance® 10 mg Film-Coated Tablets　衛部藥輸字第 026406 號
1. 適應症與用法：1.1 第二型糖尿病 1.1.1 血糖控制：用於成人及 10 歲以上小兒之第二型糖尿病病人 1.1.2 預防心血管事件：用於具第二型糖尿病且已有心血管疾病的成人病人時，可降低心血管原因死亡的風險。1.2 心臟衰竭 JARDIANCE 10 mg 用於紐約心臟學會 (NYHA) 第二級至第四級的心臟衰竭成年病人，可：• 降低心血管死亡和心臟衰竭住院風險。• 減緩預估腎絲球過濾率 (eGFR) 下降。1.3 慢性腎臟病：適用於患有慢性腎臟病的成人病人，以降低以下風險：• 腎臟疾病惡化（預估腎絲球過濾率 (eGFR) 持續降低、末期腎臟疾病或腎臟死亡）或心血管死亡 • 全因性住院。1.4 使用上的限制 JARDIANCE 不建議用於第一型糖尿病病人，其可能會增加這類病人酮酸中毒的風險。對於 eGFR 低於 30 mL/min/1.73m² 的第二型糖尿病成人病人，不建議使用JARDIANCE 改善其血糖控制。根據其作用機制，JARDIANCE 在此情況下可能無療效。2 用法用量：本藥須由醫師處方使用 2.1 開始使用 JARDIANCE 之前：請在開始使用 JARDIANCE 治療前及治療中認為有必要時，應行腎功能評估。針對體液容量減少的病人，開始服用 JARDIANCE 前先矯治此一狀況。2.2 第二型糖尿病：JARDIANCE 可單獨使用亦可與 metformin、metformin 併用 sulfonylurea、pioglitazone (併用或不併用 metformin)、胰島素 (併用或不併用 metformin 及 / 或 sulfonylurea) 合併使用，作為附加於飲食控制及運動之外的治療藥物，藉以改善第二型糖尿病病人的血糖控制 效果。JARDIANCE 的建議劑量為每天早上一次、每次 10 mg，可與食物一起服用，亦可空腹服用。當耐受性良好 且病人 eGFR≥30 mL/min/1.73m²，需要進一步的血糖控制時，可將劑量提升至 25 mg。2.3 心臟衰竭 :JARDIANCE 的建議劑量為每天早上一次、每次 10 mg，可與食物一起服用，亦可空腹服用。2.4 慢性腎臟病 :JARDIANCE 的建議劑量為每天一次、每次 10 mg。2.5 間於漏服劑量的建議：如果漏服劑量，請指示病人盡快服用該劑量。告知病人勿加倍服用下個劑量。2.6 小兒族群 : 第二型糖尿病 : JARDIANCE 的建議劑量為每天 10 mg。當耐受性良好，需要進一步的血糖控制時，可將劑量提升至每天 25 mg。2.7 腎功能不全者 : 不論腎功能如何，皆可使用 Empagliflozin 10 mg。由於經驗有限，針對透析病人，不建議使用 Jardiance作為起始治療。若 eGFR 低於 30 mL/min/1.73m²，則 empagliflozin 建議劑量限於 10 mg，且如有需要，應考慮額外的降血糖治療 3 禁忌：對 empagliflozin 或 JARDIANCE 中其他賦形劑產生嚴重過 敏反應。例如首發生血管性水腫。4 不良反應：酮酸中毒、體液容量減少、泌尿生殖系統感染，包括尿路敗血症、腎盂腎炎、會陰部壞死性筋膜炎（奧尼爾氏壞疽）及生殖器微菌感、使用胰島素與胰島素促分泌物質時發生的低血糖、過敏反應、低密度脂蛋白膽固醇 (LDL-C) 上升。
修正日期 : 2025 年 12 月　核定日期 : 2026 年 05 月

Boehringer Ingelheim
台灣百靈佳殷格翰股份有限公司
台北市民生東路三段2號12樓
電話：(02)2503-2636

PC-TW-108690-04-May-2026

Jardiance® 恩排糖®
(empagliflozin)



Jardiance® 提供「糖、心、腎」全方位保護力

T2D

用於成人及 10 歲以上小兒之 T2D 病人的**血糖控制**

用於 T2D 且已有心血管疾病的成人病人時，可**降低心血管原因死亡的風險**

HF

用於 NYHA 第二級至第四級的心臟衰竭成年病人，**可降低心血管死亡**和**心臟衰竭住院風險**，並**減緩 eGFR 的下降**

CKD

降低腎臟疾病惡化
(eGFR 持續降低、末期腎臟疾病或腎臟死亡) 或**心血管死亡風險**

降低全因性住院風險

不論 T2D、HF、CKD 病人

Jardiance® 10 mg
一天一錠，不論腎功能皆能持續使用



由於經驗有限，針對透析病人，不建議使用 Jardiance® 作為起始治療。

Abbreviation: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; HF = heart failure; T2D = type 2 diabetes mellitus.
References: Jardiance® 10 mg 仿單。

恩排糖® 膜衣錠 10 毫克 Jardiance® 10 mg Film Coated Tablets 衛部藥輸字第 026406 號

1. 適應症與用法：1.1 第二型糖尿病 1.1.1 血糖控制：用於成人及 10 歲以上小兒之第二型糖尿病病人 1.1.2 預防心血管事件：用於具第二型糖尿病且已有心血管疾病的成人病人時，可降低心血管原因死亡的風險。1.2 心臟衰竭 JARDIANCE 10 mg 用於紐約心臟學會 (NYHA) 第二級至第四級的心臟衰竭成年病人，可：• 降低心血管死亡和心臟衰竭住院風險。• 減緩預估腎絲球過濾率 (eGFR) 下降。1.3 慢性腎臟病：適用於患有慢性腎臟病的成人病人，以降低以下風險：• 腎臟疾病惡化（預估腎絲球過濾率 (eGFR) 持續降低、末期腎臟疾病或腎臟死亡）或心血管死亡，全因性住院。1.4 使用上的限制 JARDIANCE 不建議用於第一型糖尿病病人，其可能會增加這類病人酮酸中毒的風險。對於 eGFR 低於 30 mL/min/1.73m² 的第二型糖尿病成人病人，不建議使用 JARDIANCE 改善其血糖控制。根據其作用機制，JARDIANCE 在此情況下可能無療效。2 用法用量：本藥須由醫師處方使用 2.1 開始使用 JARDIANCE 之前：請在開始使用 JARDIANCE 治療前及治療中認為有必要時，進行腎功能評估。針對體液容量減少的病人，開始服用 JARDIANCE 前先矯治此一狀況。2.2 第二型糖尿病：JARDIANCE 可單獨使用亦可與 metformin、metformin 併用 sulfonylurea、pioglitazone (併用或不併用 metformin)、胰島素 (併用或不併用 metformin 及 / 或 sulfonylurea) 合併使用，作為附加於飲食控制及運動之外的治療藥物，藉以改善第二型糖尿病病人的血糖控制效果。JARDIANCE 的建議劑量為每天早上一次、每次 10 mg，可與食物一起服用，亦可空腹服用。當耐受性良好且病人 eGFR ≥30 mL/min/1.73m²，需要進一步的血糖控制時，可將劑量提升至 25 mg。2.3 心臟衰竭：JARDIANCE 的建議劑量為每天早上一次、每次 10 mg，可與食物一起服用，亦可空腹服用。2.4 慢性腎臟病：JARDIANCE 的建議劑量為每天一次、每次 10 mg。2.5 關於漏服劑量的建議：如果漏服劑量，請指示病人盡快服用該劑量。告知病人勿加倍服用下個劑量。2.6 小兒族群：第二型糖尿病：JARDIANCE 的建議劑量為每天 10 mg。當耐受性良好，需要進一步的血糖控制時，可將劑量提升至每天 25 mg。2.7 腎功能不全者：不論腎功能如何，皆可使用 Empagliflozin 10 mg。由於經驗有限，針對透析病人，不建議使用 Jardiance 作為起始治療。若 eGFR 低於 30 mL/min/1.73m²，則 empagliflozin 建議劑量限於 10 mg，且如有需要，應考慮額外的降血糖治療 3 禁忌：對 empagliflozin 或 JARDIANCE 中其他賦形劑產生嚴重過敏反應，例如曾發生血管性水腫。4 不良反應：酮酸中毒、體液容量減少、泌尿生殖系統感染，包括尿路敗血症、腎盂腎炎、會陰部壞死性筋膜炎（弗尼爾氏壞疽）及生殖器黴菌感、併用胰島素與胰島素促分泌物質時發生的低血糖、過敏反應、低密度脂蛋白膽固醇 (LDL-C) 上升。

修正日期 :2025 年 12 月　核定日期 :2026 年 05 月

Boehringer Ingelheim
台灣百靈佳殷格翰股份有限公司
台北市民生東路三段2號12樓
電話：(02)2503-2636

北市衛藥廣字第 115100073 號　PC-TW-107226-29-Jan-2026